US20020035264A1 - Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug - Google Patents
Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drugDownload PDFInfo
- Publication number
- US20020035264A1 US20020035264A1US09/904,098US90409801AUS2002035264A1US 20020035264 A1US20020035264 A1US 20020035264A1US 90409801 AUS90409801 AUS 90409801AUS 2002035264 A1US2002035264 A1US 2002035264A1
- Authority
- US
- United States
- Prior art keywords
- composition
- eye
- drug
- pat
- selective cox
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0Cc1*cc(*[Y]c2ccc(S(C)(=O)=O)cc2)cc1.I[V]IChemical compoundCc1*cc(*[Y]c2ccc(S(C)(=O)=O)cc2)cc1.I[V]I0.000description3
- LNPDTQAFDNKSHK-UHFFFAOYSA-NCC1=C(C2=CC=C(S(N)(=O)=O)C=C2)C(C2=CC=CC=C2)=NO1Chemical compoundCC1=C(C2=CC=C(S(N)(=O)=O)C=C2)C(C2=CC=CC=C2)=NO1LNPDTQAFDNKSHK-UHFFFAOYSA-N0.000description1
- RZEKVGVHFLEQIL-UHFFFAOYSA-NCC1=CC=C(C2=CC(C(F)(F)F)=NN2C2=CC=C(S(N)(=O)=O)C=C2)C=C1Chemical compoundCC1=CC=C(C2=CC(C(F)(F)F)=NN2C2=CC=C(S(N)(=O)=O)C=C2)C=C1RZEKVGVHFLEQIL-UHFFFAOYSA-N0.000description1
- QXDHHFKMACUDAM-UHFFFAOYSA-MCC1=CC=C(C2=NC=C(Cl)C=C2C2=CC=C(S(C)(=O)=O)C=C2)C=N1.[V]IChemical compoundCC1=CC=C(C2=NC=C(Cl)C=C2C2=CC=C(S(C)(=O)=O)C=C2)C=N1.[V]IQXDHHFKMACUDAM-UHFFFAOYSA-M0.000description1
- NIZNSMGBKDNIJL-UHFFFAOYSA-MCCC(=O)NS(=O)(=O)C1=CC=C(C2=C(C)ON=C2C2=CC=CC=C2)C=C1.[V]IChemical compoundCCC(=O)NS(=O)(=O)C1=CC=C(C2=C(C)ON=C2C2=CC=CC=C2)C=C1.[V]INIZNSMGBKDNIJL-UHFFFAOYSA-M0.000description1
- COOKFSQLRKNOCA-UHFFFAOYSA-NCOC1=CC=C(C2=CC(C(F)F)=NN2C2=CC=C(S(N)(=O)=O)C=C2)C=C1F.IIChemical compoundCOC1=CC=C(C2=CC(C(F)F)=NN2C2=CC=C(S(N)(=O)=O)C=C2)C=C1F.IICOOKFSQLRKNOCA-UHFFFAOYSA-N0.000description1
- QLVXJYJEJAJTGA-UHFFFAOYSA-NCS(=O)(=O)C1=CC=C(C2=C(C3=CC=CC=C3)C(=O)OC2)C=C1.[V]Chemical compoundCS(=O)(=O)C1=CC=C(C2=C(C3=CC=CC=C3)C(=O)OC2)C=C1.[V]QLVXJYJEJAJTGA-UHFFFAOYSA-N0.000description1
- XNHGEYVIJGFSSD-UHFFFAOYSA-LI[V]I.O=C(O)C1=CC2=C(OC1C(F)(F)F)C(Cl)=CC(Cl)=C2Chemical compoundI[V]I.O=C(O)C1=CC2=C(OC1C(F)(F)F)C(Cl)=CC(Cl)=C2XNHGEYVIJGFSSD-UHFFFAOYSA-L0.000description1
Images
Classifications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
Definitions
- the present inventionrelates to a pharmaceutical composition containing a drug of low water solubility and which is useful for topical application to an eye for treatment or prevention of an ophthalmic disease or disorder.
- the present inventionrelates to an ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug that can be applied to the eye for treatment or prevention of a cyclooxygenase-2 mediated ophthalmic disease or disorder.
- the field of the present inventionalso includes therapeutic or prophylactic use of such a composition, and use of such a composition in preparation of a medicament.
- deracoxibhas the structure shown in formula (II):
- Parecoxibis described in U.S. Pat. No. 5,932,598 to Talley et al. as one of a class of water-soluble prodrugs of selective COX-2 inhibitory drugs. Parecoxib, which has the structure shown in formula (IV) below, rapidly converts to the substantially water-insoluble selective COX-2 inhibitory drug valdecoxib following administration to a subject.
- U.S. Pat. No. 5,981,576 to Belley et al.discloses additional(methylsulfonyl)phenyl furanones said to be useful as selective cyclooxygenase-2 inhibitory drugs, including 3-(1-cyclopropylmethoxy)-5,5-dimethyl-4-[4-(methylsulfonyl)phenyl]-5H-furan-2-one and 3-(1-cyclopropylethoxy)-5,5-dimethyl-4-[4-(methylsulfonyl)phenyl]-5H-furan-2-one.
- U.S. Pat. No. 5,861,419 to Dube et al.discloses substituted pyridines said to be useful as selective cyclooxygenase-2 inhibitory drugs including, for example, 5-chloro-3-(4-methylsulfonyl)phenyl-2-(2-methyl-5-pyridinyl)pyridine, hereinafter referred to as “etoricoxib”, which has the structure shown in formula (VI )
- European Patent Application No. 0 863 134discloses 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-1-one as a compound said to be useful as a selective cyclooxygenase-2 inhibitory drug.
- U.S. Pat. No. 6,034,256 to Carter et al.discloses a series of benzopyrans said to be useful as selective COX-2 inhibitory drugs, including the compound (S)-6,8-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid (VII).
- NSAIDsnonsteroidal anti-inflammatories
- a racemic mixture of R(+) and S( ⁇ ) ketorolac tromethamineis formulated commercially as a sterile isotonic 0.5% aqueous solution in the product Acular® of Allergan, Inc., which is indicated for temporary relief of ocular itching due to seasonal allergic conjunctivitis, and for treatment of postoperative inflammation following cataract surgery. See Physicians' Desk Reference, 54th Edition (2000), pp. 491-492.
- U.S. Pat. No. 4,474,751 to Haslam et al.discloses liquid aqueous ophthalmic compositions comprising a drug, preferably a water-soluble drug, together with 10% to 50% by weight of a thermosetting polymer that forms a gel at a human body temperature. Upon placement of such a liquid composition in an eye, a gel is formed thereby retarding loss of the drug from the eye by lacrimal drainage.
- U.S. Pat. No. 4,861,760 to Mazuel & Friteyrediscloses a liquid in situ gelling composition said to be suitable for ophthalmic use.
- the compositioncontains in aqueous solution a polysaccharide that undergoes liquid-gel phase transition in response to ionic strength of tear fluid.
- a suitable polysaccharideis gellan gum, which can be used in a concentration of 0.1% to 2% by weight of the composition.
- U.S. Pat. No. 5,587,175 to Viegas et al.discloses further liquid in situ gelling compositions said to be suitable for ophthalmic use.
- These compositionscontain an ionic polysaccharide, for example gellan gum, alginate gum or chitosan, and a film-forming agent, for example hydroxypropyl methylcellulose, carboxymethylcellulose, sodium chondroitin sulfate, sodium hyaluronate, polyvinylpyrrolidone, etc.
- the compositionsare pH buffered to match pH of tear fluid. Gelling is said to occur upon contact with calcium ions.
- U.S. Pat. No. 6,174,524 to Bawa et al.discloses in situ gelling compositions, comprising xanthan gum for ophthalmic use.
- the gellingis said to be due, at least in part, to an interaction with the lysozyme component of tear fluid.
- U.S. Pat. No. 5,192,535 to Davis et al.discloses liquid compositions said to be suitable for use as eye drops, utilizing a different in situ gelling mechanism.
- These compositionscontain a lightly cross-linked carboxyl-containing polymer such as polycarbophil and have a pH of about 3.0 to about 6.5.
- lacrimal fluidhaving a pH of about 7.2 to about 7.4 is said to result in gelling and consequent increase of residence time in the eye, permitting sustained release of a drug contained in the composition.
- Drugs for which such a composition is said to be usefulinclude anti-inflammatories such as ibuprofen, flurbiprofen and naproxen and esters thereof; also ketorolac and suprofen.
- U.S. Pat. No. 5,876,744 to Della Valle et al.discloses bioadhesive and mucoadhesive compositions, including some said to be useful as ophthalmic compositions, comprising mixtures of synthetic polymers such as polycarbophil and polyvinyl alcohol and biopolymers such as alginic acid, hyaluronic acid and dermatan sulfate. Such compositions are said to be capable of increasing contact time with a treated eye of specific drugs, for example anti-inflammatories.
- U.S. Pat. No. 5,814,655 to Patel et al.discloses topical ophthalmic formulations of an NSAID such as diclofenac, suprofen or flurbiprofen wherein pH and concentration of the NSAID are such that a therapeutic amount of the NSAID is present in suspension and a therapeutic amount of the NSAID is present in solution.
- an NSAIDsuch as diclofenac, suprofen or flurbiprofen
- the applicationdescribes examples of application of 1-4 drops of a solution or suspension, or a comparable amount of an ointment, gel or other solid or semisolid composition, 1-4 times a day, wherein the composition contains such an anti-inflammatory agent in a concentration of about 0.01% to about 1% by weight.
- WO 00/18387 and WO 00/25771 cited abovedo not address the problems of formulating an ophthalmically acceptable composition comprising a selective cyclooxygenase-2 inhibitory drug.
- Such problemsare particularly acute for selective cyclooxygenase-2 inhibitory drugs of low water solubility, including celecoxib, deracoxib, valdecoxib, rofecoxib, etoricoxib and 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-1-one.
- the compositionmust generally be formulated in a way that provides continuous delivery of the drug to an eye in order to be therapeutically effective against a cyclooxygenase-2 mediated disorder of the eye.
- COX-2cyclooxygenase-2
- COX-1COX-1
- the present inventionprovides a pharmaceutical composition suitable for topical administration to an eye, the composition comprising nanoparticles of a drug of low water solubility in a concentration effective for treatment and/or prophylaxis of a disorder in the eye, and at least one ophthalmically acceptable excipient ingredient that preferably reduce the rate of removal of the composition from the eye by lacrimation such that the composition has an effective residence time in an eye of about 2 to about 24 hours, after being applied thereto.
- the present inventionalso provides a pharmaceutical composition suitable for topical administration to an eye, the composition comprising a selective COX-2 inhibitory drug in a concentration effective for treatment and/or prophylaxis of a COX-2 mediated disorder in the eye, and one or more ophthalmically acceptable excipient ingredients that preferably reduce rate of removal of the composition from the eye by lacrimation such that the composition has an effective residence time in the eye of about 2 to about 24 hours.
- lacrimationrefers to the production of tear fluid. Matter is typically removed from eyes by external wash-out, by lacrimal drainage into the nasopharyngeal cavity via the nasolacrimal ducts, or by a combination of the two means.
- effective residence timeherein is meant a period of time following application of the composition to the eye during which a substantial portion of the applied composition remains in situ even in the presence of lacrimation and/or external wash-out, and during which the drug is released therefrom in a therapeutically or prophylactically effective amount to tissues of the eye and/or to fluids secreted thereby.
- the compositiontherefore provides sustained release at an effective concentration over a period of at least about 2 hours.
- a portion of the selective COX-2 inhibitory drugcan be present in the composition in immediate-release form so that the composition provides a combination of immediate and sustained release (herein referred to as “dual release”) of the drug.
- the inventionalso provides a method of preparing a medicament for treating or preventing a COX-2 mediated disorder in an eye, using a composition as described above.
- the present inventionprovides a method of treating or preventing a disorder in an eye, the method comprising application of a composition as described above in a therapeutically or prophylactically effective dose.
- Also embraced by the present inventionis a method of treating or preventing a COX-2 mediated disorder in an eye, the method comprising application to the eye of a composition as described above in a therapeutically or prophylactically effective dose.
- COX-2 mediated disorders of the eye for which the method is usefulinclude without limitation inflammatory disorders such as endophthalmitis, episcleritis, retinitis, iriditis, cyclitis, choroiditis, keratitis, conjunctivitis and blepharitis, including inflammation of more than one part of the eye, e.g., retinochoroiditis, iridocyclitis, iridocyclochoroiditis (also known as uveitis), keratoconjunctivitis, blepharoconjunctivitis, etc.; other COX-2 mediated retinopathies including diabetic retinopathy; ocular tumors; ocular photophobia; acute trauma of any tissue of the eye including postsurgical trauma, e.g., following cataract or corneal transplant surgery; postsurgical ocular inflammation; intraoperative miosis; corneal graft rejection; ocular, for example retinal, neovascularization including that
- COX-2 mediated disorders of the eyeare disorders of surface tissues such as the conjunctiva, and that topical application of a selective COX-2 inhibitory drug to the eye, therefore, results in delivery of the drug directly to its site of action in the case of such disorders.
- Other COX-2 mediated disorders of the eyeare disorders of internal tissues such as the retina, in which case the drug has to move from the locus of administration to the targeted tissue.
- Administration of a composition of the invention to the eyegenerally results in direct contact of the drug with the cornea, through which at least a portion of the administered drug passes.
- topicalas applied herein to ocular administration of a composition of the invention will be understood to embrace administration followed by corneal absorption as well as administration directly to a targeted surface tissue of the eye such as open tissues in connection with eye surgery or postsurgical treatment.
- a concentration effective for treatment and/or prophylaxis of a COX-2 mediated disorderdepends, among other factors, on the particular drug being administered; the residence time provided by the particular formulation of the drug; the species, age and body weight of the subject; the particular ophthalmic condition for which treatment or prophylaxis is sought; and the severity of the condition.
- an effective concentration in a composition of the invention for topical administration to an eyewill generally be found in the range from about 0.1% to about 50% weight/volume.
- an appropriate concentration rangeis one that is therapeutically equivalent to the celecoxib concentration range indicated above.
- a composition of the inventionis preferably formulated as an in situ gellable aqueous liquid, and can be administered as eye drops.
- each drop of the compositiongenerated by a conventional dispensing means, has a volume of about 15 to about 40 ⁇ l. From 1 to about 6 such drops typically provides a suitable dose of the selective COX-2 inhibitory drug.
- an equivalent doseis provided. Such a dose can be administered as needed, but typically administration to the eye 1 to about 4 times per day, in most cases 1 or 2 times a day, provides adequate continuing relief or prevention of the ophthalmic disorder indicated.
- ophthalmically acceptablewith respect to a formulation, composition or ingredient herein means having no persistent detrimental effect on the treated eye or the functioning thereof, or on the general health of the subject being treated. It will be recognized that transient effects such as minor irritation or a “stinging” sensation are common with topical ophthalmic administration of drugs and the existence of such transient effects is not inconsistent with the formulation, composition or ingredient in question being “ophthalmically acceptable” as herein defined. However, preferred formulations, compositions and ingredients are those that cause no substantial detrimental effect, even of a transient nature.
- the method of the present inventionis particularly suitable where conventional NSAIDs are contraindicated, for example in patients with peptic ulcers, gastritis, regional enteritis, ulcerative colitis or diverticulitis, patients with a recurrent history of gastrointestinal lesions, patients with gastrointestinal bleeding, coagulation disorders including anemia such as hypothrombinemia, hemophilia and other bleeding problems, or kidney disease, patients prior to surgery, or patients taking anticoagulants.
- a particular advantage over conventional NSAIDs for topical application to eyesis the lack of effect on baseline COX-1 mediated physiological functions including wound healing following eye surgery, and intraocular pressure control.
- ophthalmic compositions containing a selective COX-2 inhibitory drughave not been specified to be resistant to removal from a treated eye by lacrimation, and in particular an effective residence time of at least about 2 hours has not been specified.
- a residence timeis believed to be critical in the case of at least the great majority of selective COX-2 inhibitory drugs. Without being bound by theory, it is believed that the criticality of a sufficiently long residence time arises at least in part from the following factors.
- a first factoris the extremely low solubility in water of most selective COX-2 inhibitory drugs, including for example celecoxib, deracoxib, valdecoxib, rofecoxib, etoricoxib, 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-1-one and 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3-(2H)-pyridazinone.
- COX-2 inhibitory drugsincluding for example celecoxib, deracoxib, valdecoxib, rofecoxib, etoricoxib, 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-1-one and 2-(3,4-difluoropheny
- a second factoris the need for sustained COX-2 inhibitory action.
- a selective COX-2 inhibitory drugWhen administered orally, it is absorbed in the alimentary tract into the bloodstream and becomes systemically distributed throughout the body.
- a drughas a relatively long half-life in the bloodstream and repeat administration is generally not necessary for about 12 to about 24 hours or more.
- the dosageis generally insufficient to lead to a therapeutically or prophylactically effective blood serum concentration and sustained effectiveness is therefore dependent on a depot of the drug remaining in situ at the locus of application.
- composition and method of the inventionby comparison with normal orally administered doses of selective COX-2 inhibitory drugs, is a further advantage of the invention.
- Formulations of the inventionare contemplated to be useful for any drug, of low water solubility, for which ophthalmic administration is desired.
- FIG. 1is a graph illustrating the pharmacokinetic results of ocular versus oral delivery for the concentration of valdecoxib in the conjunctiva plotted against time;
- FIG. 2is a graph illustrating the valdecoxib concentration in the conjunctiva, cornea, aqueous humor and plasma four hours after oral administration of the drug.
- FIG. 3is a graph illustrating the valdecoxib concentration in the conjunctiva, cornea, aqueous humor and plasma four hours after ocular administration of the drug.
- the inventionprovides a pharmaceutical composition suitable for topical administration to an eye.
- the compositioncomprises a selective COX-2 inhibitory drug or a salt or prodrug thereof in a concentration effective for treatment and/or prophylaxis of a COX-2 mediated disorder in the eye, and one or more ophthalmically acceptable excipient ingredients that reduce rate of removal of the composition from the eye by lacrimation, such reduction in rate of removal including rendering the composition resistant to removal from the eye by lacrimation.
- the compositionhas an effective residence time in the eye of about 2 to about 24 hours.
- the selective COX-2 inhibitory drugis of low water solubility.
- Low water solubilityherein is defined as water solubility of not more than about 10 mg/ml, preferably not more than about 5 mg/ml, for example not more than about 1 mg/ml.
- the selective COX-2 inhibitory drugcan be any such drug known in the art, including, without limitation, compounds disclosed in the patents and publications listed below, each of which is individually incorporated herein by reference.
- compositions of the inventionare especially useful for compounds having the formula (VII):
- R 3is a methyl or amino group
- R 4is hydrogen or a C 1-4 alkyl or alkoxy group
- Xis N or CR 5 where R 5 is hydrogen or halogen
- Y and Zare independently carbon or nitrogen atoms defining adjacent atoms of a five- to six-membered ring that is unsubstituted or substituted at one or more positions with oxo, halo, methyl or halomethyl groups.
- Preferred such five- to six-membered ringsare cyclopentenone, furanone, methylpyrazole, isoxazole and pyridine rings substituted at no more than one position.
- prodrugsthat provide such selective COX-2 inhibitory compounds upon administration, for example parecoxib, which is a prodrug of valdecoxib.
- Selective COX-2 inhibitory drugs used in the method and composition of the inventioncan be prepared by a process known per se, in the case of celecoxib, for example, by processes described in U.S. Pat. No. 5,466,863 to Talley et al. or in U.S. Pat. No. 5,892,053 to Zhi & Newaz, both incorporated herein by reference.
- Other selective COX-2 inhibitory drugscan be prepared by processes known per se, including processes set forth in patent publications disclosing such drugs; for example in the case of valdecoxib in above-cited U.S. Pat. No. 5,633,272, and in the case of rofecoxib in above-cited U.S. Pat. No. 5,474,995.
- the compositionhas an effective residence time in the eye of about 3 to about 24 hours, more preferably about 4 to about 24 hours and most preferably about 6 to about 24 hours.
- a composition of the inventioncan illustratively take the form of a liquid wherein the drug is present in solution, in suspension or both.
- solution/suspensionherein refers to a liquid composition wherein a first portion of the drug is present in solution and a second portion of the drug is present in particulate form, in suspension in a liquid matrix.
- a liquid compositionherein includes a gel.
- the liquid compositionis aqueous.
- the compositioncan take the form of an ointment.
- the composition of the present inventioncan also be delivered by electrophoresis, electroporation or iontophoresis.
- the compositioncan take the form of a solid article that can be inserted between the eye and eyelid or in the conjunctival sac, where it releases the drug as described, for example, in U.S. Pat. No. 3,863,633 and U.S. Pat. No. 3,868,445, both to Ryde & Ekstedt, incorporated herein by reference. Release is to the lacrimal fluid that bathes the surface of the cornea, or directly to the cornea itself, with which the solid article is generally in intimate contact.
- Solid articles suitable for implantation in the eye in such fashionare generally composed primarily of polymers and can be biodegradable or non-biodegradable.
- suitable non-biodegradable polymersare silicone elastomers.
- the compositionis an aqueous solution, suspension or solution/suspension, which can be presented in the form of eye drops.
- a desired dosage of the drugcan be metered by administration of a known number of drops into the eye. For example, for a drop volume of 25 ⁇ l, administration of 1-6 drops will deliver 25-150 ⁇ l of the composition.
- Aqueous compositions of the inventionpreferably contain from about 0.01% to about 50%, more preferably about 0.1% to about 20%, still more preferably about 0.2% to about 10%, and most preferably about 0.5% to about 5%, weight/volume of the selective COX-2 inhibitory drug.
- a composition of the inventioncontains a concentration of the selective COX-2 inhibitory drug that is therapeutically or prophylactically equivalent to a celecoxib weight/volume concentration of about 0.1% to about 50%, preferably about 0.5% to about 20%, and most preferably about 1% to about 10%.
- a composition of the inventionhas relatively high loading of the drug and is suitable for a relatively long residence time in a treated eye.
- the weight/volume concentration of the drug in the compositionis about 1.3% to about 50%, preferably about 1.5% to about 30%, and most preferably about 2% to about 20%, for example about 2% to about 10%.
- Administration of a larger volume to the eyerisks loss of a significant portion of the applied composition by lacrimation.
- Aqueous compositions of the inventionhave ophthalmically compatible pH and osmolality.
- the selective COX-2 inhibitory drugis present predominantly in the form of nanoparticles, i.e., solid particles smaller than about 1 ⁇ m in their longest dimension.
- a benefit of this embodimentis more rapid release of the drug, and therefore more complete release during the residence time of the composition in a treated eye, than occurs with larger particle size.
- Another benefitis reduced potential for eye irritation by comparison with larger particle size. Reduced eye irritation in turn leads to a reduced tendency for loss of the composition from the treated eye by lacrimation, which is stimulated by such irritation.
- the drugpreferably has a D 90 particle size of about 0.01 to about 200 ⁇ m, wherein about 25% to 100% by weight of the particles are nanoparticles.
- D 90is defined as a linear measure of diameter having a value such that 90% by volume of particles in the composition, in the longest dimension of the particles, are smaller than that diameter. For practical purposes a determination of D 90 based on 90% by weight rather than by volume is generally suitable.
- substantially all of the drug particles in the compositionare smaller than 1 ⁇ m, i.e., the percentage by weight of nanoparticles is 100% or close to 100%.
- the selective cyclooxygenase-2 inhibitory drugcan be in crystalline or amorphous form in the nanoparticles. Processes for preparing nanoparticles that involve milling or grinding typically provide the drug in crystalline form, whereas processes that involve precipitation from solution typically provide the drug in amorphous form.
- Nanoparticlescomprising or consisting essentially of a selective COX-2 inhibitory drug of low water solubility can be prepared according to any process previously applied to preparation of other poorly water soluble drugs in form of nanoparticles. Suitable processes, without restriction, are illustratively disclosed for such other drugs in patents and publications listed below and incorporated herein by reference.
- nanoparticles of a selective COX-2 inhibitory drugare prepared by a milling process, preferably a wet milling process in presence of a surface modifying agent that inhibits aggregation and/or crystal growth of nanoparticles once created.
- nanoparticles of a selective COX-2 inhibitory drugare prepared by a precipitation process, preferably a process of precipitation in an aqueous medium from a solution of the drug in a non-aqueous solvent.
- the non-aqueous solventcan be a liquefied, e.g., supercritical, gas under pressure.
- nanoparticlesare prepared by a process comprising the steps of (a) dispersing a selective COX-2 inhibitory drug and a surface modifying agent in a liquid dispersion medium; and (b) wet milling the resulting drug dispersion in presence of grinding media to result in crystalline nanoparticles of the drug having the surface modifying agent adsorbed on the surface thereof in an amount sufficient to maintain a weight average particle size of less than about 400 nm, substantially as disclosed in above-cited U.S. Pat. No. 5,145,684.
- the surface modifying agentinhibits aggregation of the nanoparticles and can be any of various polymers, low molecular weight oligomers, natural products, surfactants, etc.
- the nanoparticles in this and related embodimentsare referred to herein as being composed of a nanocrystalline drug/surface modifier complex.
- water-soluble polymeric excipientssuch as povidone and modified celluloses, may be present in order to help prevent the occurrence of nucleation/crystallization.
- a nanocrystalline drug/surface modifier complex prepared as described abovecomprises a purified surface modifying agent, for example a purified polymeric surfactant, to prevent particle aggregation during a subsequent sterilization step, substantially as disclosed in above-cited U.S. Pat. No. 5,352,459.
- a purified surface modifying agentfor example a purified polymeric surfactant
- a nanocrystalline drug/surface modifier complex prepared as described abovecomprises as a surface modifying agent the surfactant p-isononylphenoxypoly(glycidol), substantially as disclosed in above-cited U.S. Pat. No. 5,340,564.
- a nanocrystalline drug/surface modifier complex prepared as described aboveis associated with an anionic or cationic cloud point modifier to increase the cloud point of the surface modifying agent, substantially as described in above-cited U.S. Pat. No. 5,298,262 (cationic or anionic surfactant as cloud point modifier), U.S. Pat. No. 5,336,507 (charged phospholipid as cloud point modifier), or U.S. Pat. No. 5,346,702 (non-ionic cloud point modifier).
- a nanocrystalline drug/surface modifier complex prepared as described abovefurther comprises a cryoprotectant, for example a carbohydrate or sugar alcohol, in an amount sufficient to permit the nanoparticles to be lyophilized, substantially as described in above-cited U.S. Pat. No. 5,302,401.
- a preferred cryoprotectant of this embodimentis sucrose.
- the method of making nanoparticles having a surface modifier adsorbed on the surface thereof and a cryoprotectant associated therewithcomprises contacting the nanoparticles with the cryoprotectant for a time and under conditions sufficient to permit lyophilization of the nanoparticles.
- drug nanoparticles having a surface modifying agent adsorbed on the surface thereof in an amount sufficient to maintain a weight average particle size of less than about 400 nmare prepared by a process comprising the steps of (a) dispersing the drug in a liquid dispersion medium wherein the drug is insoluble; and (b) grinding the medium (e.g., in a dispersion mill) in the presence of rigid grinding media, wherein pH of the medium is maintained within a range of about 2 to about 6, substantially as disclosed in above-cited U.S. Pat. No. 5,552,160.
- nanoparticlesare prepared by a process comprising the steps of (a) providing a selective COX-2 inhibitory drug substance; (b) depyrogenating rigid grinding media, for example in an oven at about 200° C. to about 300° C. for about 6 to about 20 hours; mixing the drug substance and grinding media together and autoclaving at about 100° C. to about 150° C.
- a surface modifying agente.g., selected from polymers, low molecular weight oligomers, natural products and surfactants
- a surface modifying agente.g., selected from polymers, low molecular weight oligomers, natural products and surfactants
- nanoparticlesare prepared by a process comprising contacting a selective COX-2 inhibitory drug with a surface modifying agent (e.g., by adding the drug to a liquid medium comprising the surface modifying agent and wet grinding in a dispersion mill) for a time and under conditions sufficient to provide and maintain a weight average particle size of less than about 400 nm, substantially as described in above-cited U.S. Pat. No. 5,429,824.
- the surface modifying agentis a nonionic liquid polymer of the alkylaryl polyether alcohol type, for example tyloxapol.
- an additional surface modifying agentcan be present.
- nanoparticlesare prepared by a process comprising the steps of (a) forming a premix of a selective COX-2 inhibitory drug and a surface modifier (e.g., selected from polymers, low molecular weight oligomers, surfactants, etc.) in a liquid dispersion medium (e.g., water, salt solution, ethanol, etc.); (b) transferring the premix to a microfluidizer having an interaction chamber capable of producing shear, impact, cavitation and attrition forces; (c) subjecting the premix to these forces at a temperature not exceeding about 40° C.
- a surface modifiere.g., selected from polymers, low molecular weight oligomers, surfactants, etc.
- a liquid dispersion mediume.g., water, salt solution, ethanol, etc.
- nanoparticlesare prepared by a process comprising the steps of (a) milling (e.g., in a dispersion mill), optionally in the presence of an oil, a selective COX-2 inhibitory drug in the presence of surface modifying agents (e.g., gelatin, casein, lecithin, polyvinylpyrrolidone, tyloxapol, poloxamers, other block polymers, etc.) substantially as disclosed in above-cited U.S. Pat. No. 5,560,931.
- the drug particleshave a non-crosslinked modifier adsorbed on the surface thereof, and are suspended in an aqueous phase which is emulsified in a continuous oil phase. Weight average particle size is less than about 1000 nm.
- the oil phasecan be oleic acid, as disclosed in above-cited U.S. Pat. No. 5,571,536.
- nanoparticlesare prepared by a process comprising the steps of (a) introducing a selective COX-2 inhibitory drug, a liquid medium, grinding media and a surface modifying agent into a grinding vessel; and (b) wet grinding to reduce the weight average particle size of the drug to less than about 1000 nm, substantially as disclosed in above-cited U.S. Pat. No. 5,565,188 (block copolymer as surface modifying agent containing one or more polyoxyethylene blocks and one or more polyoxy(higher alkylene) blocks wherein at least some of the blocks are linked together by an oxymethylene linking group) and U.S. Pat. No. 5,587,143 (block copolymer of ethylene oxide and butylene oxide as surface modifying agent).
- a compositioncomprising selective COX-2 inhibitory drug nanoparticles having a block copolymer linked to at least one anionic group as a surface modifying agent adsorbed on the surface thereof.
- the compositionis prepared by a process comprising the steps of (a) preparing the drug in particulate form, preferably at a particle size less than about 100 ⁇ m; (b) adding the drug to a liquid medium in which it is essentially insoluble to form a premix; and (c) subjecting the premix to mechanical means to reduce the average particle size in the premix to less than about 1000 nm, substantially as disclosed in above-cited U.S. Pat. No. 5,569,448.
- the surface modifying agentis present in the premix.
- nanoparticlesare prepared by a process comprising the steps of (a) adding a selective COX-2 inhibitory drug and a surface modifying agent (e.g., a steric stabilizer such as gelatin, casein, lecithin, gum acacia, cholesterol, tragacanth, sorbitan esters, polyethylene glycol, polyoxyethylene alkyl esters, polyoxyethylene stearates, etc.) to a liquid in which the drug is insoluble to form a premix, and (b) subjecting the premix to mechanical means (e.g., in a dispersion mill) to reduce average particle size to less than about 400 nm, substantially as disclosed in above-cited U.S. Pat. No. 5,573,783.
- a surface modifying agente.g., a steric stabilizer such as gelatin, casein, lecithin, gum acacia, cholesterol, tragacanth, sorbitan esters, polyethylene glycol, polyoxyethylene alkyl esters
- nanoparticlesare prepared by a process comprising the steps of (a) dispersing a selective COX-2 inhibitory drug and a surface active agent (e.g., poloxamers having a molecular weight of about 1,000 to about 15,000 daltons, polyvinyl alcohol, polyvinylpyrrolidone, hydroxypropylmethylcellulose, and polyoxyethylene sorbitan monooleate) in a liquid dispersion medium in which the drug is poorly soluble, then applying mechanical means (e.g., in a dispersion mill) to reduce drug particle size to less than about 400 nm, substantially as disclosed in above-cited U.S. Pat. No. 5,585,108.
- a surface active agente.g., poloxamers having a molecular weight of about 1,000 to about 15,000 daltons, polyvinyl alcohol, polyvinylpyrrolidone, hydroxypropylmethylcellulose, and polyoxyethylene sorbitan monooleate
- mechanical meanse.g., in a
- nanoparticlesare prepared by a process comprising the steps of (a) adding a selective COX-2 inhibitory drug and hydroxypropylcellulose as a surface modifying agent to a liquid medium in which the drug is essentially insoluble to form a premix, and employing mechanical means (e.g., in a dispersion mill) to reduce drug particle size to less than about 1000 nm, preferably less than about 400 nm, substantially as disclosed in above-cited U.S. Patent No. 5,591,456.
- nanoparticlesare prepared by a process as described herein that employs a surface modifying agent, the surface modifying agent being selected such that the resulting composition has a hydrophile-lipophile balance (HLB) of about 4 to about 9, substantially as disclosed in above-cited International Patent Publication No. WO 00/30615.
- HLBhydrophile-lipophile balance
- nanoparticlesare prepared by a process comprising the steps of (a) mixing a selective COX-2 inhibitory drug with a support material, preferably a crosslinked, water-swellable polymer; (b) grinding the resulting mixture in a grinding chamber which is saturated with a solvent vapor (e.g., water, ethanol, isopropanol, chloroform, methanol, etc.); (c) drying the ground mixture under vacuum; and (d) sieving the dried ground mixture to eliminate any aggregates formed, substantially as disclosed in above-cited U.S. Pat. No. 5,354,560.
- a solvent vapore.g., water, ethanol, isopropanol, chloroform, methanol, etc.
- nanoparticlesare prepared by a process comprising the steps of (a) forming a paste comprising (i) nanoparticles of a selective COX-2 inhibitory drug, (ii) at least one thickening or binding agent (e.g., selected from polypeptides, high molecular weight polymers, colloids, etc.) and/or extender, (iii) one or more stabilizing agents to prevent settling and/or rising to the surface of the nanoparticles, and (iv) a suitable amount of water to adjust viscosity; and (b) lyophilizing the paste, substantially as disclosed in above-cited U.S. Pat. No. 5,384,124.
- a pastecomprising (i) nanoparticles of a selective COX-2 inhibitory drug, (ii) at least one thickening or binding agent (e.g., selected from polypeptides, high molecular weight polymers, colloids, etc.) and/or extender, (iii) one or more stabilizing agents to prevent settling and
- nanoparticlesare prepared by a process comprising the steps of (a) preparing a selective COX-2 inhibitory drug in particulate form, preferably at a particle size smaller than about 100 ⁇ m; (b) adding the prepared drug to a liquid medium (preferably comprising a surface modifying agent such as a hygroscopic sugar) in which the drug is essentially insoluble to form a premix; and (c) subjecting the premix to mechanical means to reduce the average particle size in the premix to less than about 1000 nm, substantially as disclosed in above-cited U.S. Pat. No. 5,518,738.
- polyvinylpyrrolidone and/or a wetting agente.g., sodium lauryl sulfate
- a wetting agente.g., sodium lauryl sulfate
- Compositions prepared by this processpreferably have a film adsorbed on the surface of the nanoparticles comprising a polyvinylpyrrolidone, a hygroscopic sugar and sodium lauryl sulfate.
- nanoparticlesare prepared by a process comprising the steps of (a) co-solubilizing one or more polymeric constituents including, for example, a biodegradable polymer (e.g., polylactic acid, polyglycolic acid or co-polymers thereof, polyhydroxybutyric acid, polycaprolactone, polyorthoesters, etc.), a polysaccharide jellifying and/or bioadhesive polymer, and/or an amphiphilic polymer (e.g.
- a biodegradable polymere.g., polylactic acid, polyglycolic acid or co-polymers thereof, polyhydroxybutyric acid, polycaprolactone, polyorthoesters, etc.
- a polysaccharide jellifying and/or bioadhesive polymere.g.
- Nanoparticles prepared by this processpreferably have a weight average particle size of about 0.1 ⁇ m to about 150 ⁇ m.
- nanoparticlesare prepared by a process comprising the steps of (a) preparing a solution of a selective COX-2 inhibitory drug in a water-miscible organic solvent; (b) infusing an aqueous precipitating liquid (e.g., water, solution of mineral salt, or surfactant solution) into the solution to produce a suspension of precipitated, amorphous, solid drug in the form of non-aggregated particles; and (c) separating the particles from the precipitating liquid and washing in an aqueous washing liquid, substantially as disclosed in above-cited U.S. Pat. No. 4,826,689.
- aqueous precipitating liquide.g., water, solution of mineral salt, or surfactant solution
- nanoparticlesare prepared by a process comprising the steps of (a) dissolving a selective COX-2 inhibitory drug in an aqueous base (e.g., NaOH, KOH, CsOH, etc.) with stirring to form a solution; (b) adding a surface modifier (e.g., various polymers, surfactants, low molecular weight oligomers, etc.) to form a clear solution; and (c) neutralizing the clear solution with stirring and with an appropriate acid solution (e.g., HCl, HNQ 3 , HClO 4 , H 2 SO 4 , formic acid, propionic acid, acetic acid, butyric acid, etc.), substantially as disclosed in above-cited U.S. Pat. Nos. 5,560,932 and No. 5,580,579.
- an aqueous basee.g., NaOH, KOH, CsOH, etc.
- a surface modifiere.g., various polymers, surfactants, low mole
- nanoparticlesare prepared by a process comprising the steps of (a) dissolving a selective COX-2 inhibitory drug in a liquid medium base (e.g., NaOH, KOH, CsOH, trialkylamines, pyridine, etc.) comprising a non-toxic solvent in which the drug is poorly soluble to form a solution; (b) adding an aqueous solution of one or more surface modifying agents (e.g., anionic or nonionic surfactants, polymeric or oligomeric substances); and (c) neutralizing the resulting alkaline solution with an acid (e.g., HCl, HNO 3 , HC10 4 , H 2 SO 4 , formic acid, propionic acid, acetic acid, butyric acid, etc.), to form a dispersion, preferably having a Z-average particle diameter of less than about 100 nm as measured by photon correlation spectroscopy, substantially as disclosed in above-cited U.S.
- a liquid medium basee.g
- nanoparticlesare prepared by a process comprising the steps of (a) dissolving a selective COX-2 inhibitory drug and a crystal growth modifier (i.e., a compound that is substantially isostructural to the drug) in an aqueous base (e.g., NaOH, KOH, CsOH, trialkylamines, pyridine, etc.) to form a solution; (b) adding an aqueous solution of one or more surface modifying agents (e.g., a mixture of anionic surfactant, nonionic surfactant, polymeric substance and oligomeric substance); and neutralizing the resulting alkaline solution with an acid (e.g., HCl, HNO 3 , HCl0 4 , H 2 SO 4 , formic acid, propionic acid, acetic acid, butyric acid, etc.), to form a dispersion, preferably wherein the drug particles have a Z-average particle diameter of less than about 400 nm
- a crystal growth modifieri.e
- nanoparticles having a weight average particle size of less than about 400 nmare prepared from a dispersion comprising a first particle distribution of a selective COX-2 inhibitory drug together with a surface modifying agent such as polysulfated tyloxapol by a process comprising the steps of (a) placing the dispersion between a first electrode and a second electrode; and (b) removing a portion of the dispersion at a position between the first electrode and the second electrode, this portion of the dispersion having a second particle size distribution that is smaller than the first particle distribution, substantially as disclosed in above-cited U.S. Pat. No. 5,503,723.
- nanoparticles having a weight average particle size of up to about 300 nmare prepared by a process comprising the steps of (a) dissolving a selective COX-2 inhibitory drug in a solvent to form a solution; and (b) spraying the solution into a liquefied gas or supercritical fluid in presence of a surface modifying agent dispersed or dissolved in an aqueous phase, substantially as disclosed in above-cited International Patent Publication No. WO 97/14407.
- nanoparticles having a weight average particle size of up to about 300 nmare prepared by a process comprising the steps of (a) dissolving a selective COX-2 inhibitory drug in a liquefied gas or supercritical fluid to form a solution; (b) preparing an aqueous phase containing a surface modifying agent; and (c) spraying the solution into the aqueous phase, substantially as disclosed in the same above-cited International Patent Publication No. Wo 97/14407.
- Patent and other literature relating to drug nanoparticle compositionsteaches that, in general, the smaller the drug particle size, the greater is the advantage in speed of onset of therapeutic effect, or other pharmacodynamic benefit, obtained upon oral administration. For example, at least the following patents propose reduction of particle size to about 400 nm or smaller.
- a selective COX-2 inhibitory drug composition having a weight average particle size of about 450 nm to about 1000 nmexhibits onset time and bioavailability substantially equal to that of a comparative composition having a weight average particle size of about 200 to about 400 nm, as measured in vitro and in vivo.
- the sub-micron formulationrequires less milling time and energy than the formulation comprising smaller nanoparticles with a weight average particle size in the 200-400 nm range.
- a pharmaceutical compositioncomprising a selective COX-2 inhibitory drug of low water solubility in a therapeutically effective amount, wherein the drug is present in solid particles having a D 25 particle size of about 450 nm to about 1000 nm, and more preferably about 500 nm to about 900 nm, the composition providing at least a substantially similar C max and/or at most a substantially similar T max by comparison with an otherwise similar composition having a D 25 particle size of less than 400 nm, and/or providing a substantially greater C max and/or a substantially shorter T max by comparison with an otherwise similar composition having a D 25 particle size larger than 1000 nm.
- compositioncomprising a selective COX-2 inhibitory drug of low water solubility in a therapeutically effective amount, wherein the drug is present in solid particles, about 25% to 100% by weight of which have a particle size of about 450 nm to about 1000 nm, more preferably about 500 nm to about 900 nm.
- compositionscomprising a selective COX-2 inhibitory drug of low water solubility in a therapeutically effective amount, wherein the drug is present in solid particles having a weight average particle size of about 450 nm to about 1000 nm, and more preferably about 500 nm to about 900 nm, the composition providing at least a substantially similar C max and/or at most a substantially similar T max by comparison with an otherwise similar composition having a weight average particle size of less than 400 nm, and/or providing a substantially greater C max and/or a substantially shorter T max by comparison with an otherwise similar composition having a weight average particle size larger than 1000 nm.
- “weight average particle size”can be considered synonymous with D 50 particle size.
- the ophthalmic compositioncomprises an aqueous suspension of a selective COX-2 inhibitory drug of low water solubility, wherein preferably the drug is present predominantly or substantially entirely in form of nanoparticles
- a selective COX-2 inhibitory drug of low water solubilitywherein preferably the drug is present predominantly or substantially entirely in form of nanoparticles
- release of the drug from nanoparticlesis significantly faster than from a typical “micronized” composition having a D 90 particle size of, for example, about 10 ⁇ m or greater.
- An aqueous suspension composition of the inventioncan comprise a first portion of the drug in form of nanoparticles, to promote relatively rapid release, and a second portion of the drug having a D 90 particle size of about 10 ⁇ m or greater, that can provide a depot or reservoir of the drug in the treated eye for release over a period of time, for example about 2 to about 24 hours, more typically about 2 to about 12 hours, to promote sustained therapeutic effect and permit a reduced frequency of administration.
- An aqueous suspensioncan contain one or more polymers as suspending agents.
- Useful polymersinclude water-soluble polymers such as cellulosic polymers, e.g., hydroxypropyl methylcellulose, and water-insoluble polymers such as cross-linked carboxyl-containing polymers.
- the compositionis an in situ gellable aqueous solution, suspension or solution/suspension having excipients substantially as disclosed in above-cited U.S. Pat. No. 5,192,535, comprising about 0.1% to about 6.5%, preferably about 0.5% to about 4.5%, by weight, based on the total weight of the composition, of one or more cross-linked carboxyl-containing polymers.
- Such an aqueous suspensionis preferably sterile and has an osmolality of about 10 to about 400 mOsM, preferably about 100 to about 250 mOsM, a pH of about 3 to about 6.5, preferably about 4 to about 6, and an initial viscosity, when administered to the eye, of about 1000 to about 30,000 cPs, as measured at 25° C. using a Brookfield Digital LVT viscometer with #25 spindle and 13R small sample adapter at 12 rpm. More typically the initial viscosity is about 5000 to about 20,000 cPs.
- the polymer componenthas an average particle size not greater than about 50 ⁇ m, preferably not greater than about 30 ⁇ m, more preferably not greater than about 20 ⁇ m, and most preferably about 1 ⁇ m to about 5 ⁇ m, in equivalent spherical diameter, and is lightly cross-linked to a degree such that, upon contact with tear fluid in the eye, which has a typical pH of about 7.2 to about 7.4, the viscosity of the suspension rapidly increases, to form a gel. This formation of a gel enables the composition to remain in the eye for a prolonged period without loss by lacrimal drainage.
- Preferred carboxyl-containing polymers for use in this embodimentare prepared from one or more carboxyl-containing monoethylenically unsaturated monomers such as acrylic, methacrylic, ethacrylic, crotonic, angelic, tiglic, ⁇ -butylcrotonic, ⁇ -phenylacrylic, ⁇ -benzylacrylic, ⁇ -cyclohexylacrylic, cinnamic, coumaric and umbellic acids, most preferably acrylic acid.
- carboxyl-containing monoethylenically unsaturated monomerssuch as acrylic, methacrylic, ethacrylic, crotonic, angelic, tiglic, ⁇ -butylcrotonic, ⁇ -phenylacrylic, ⁇ -benzylacrylic, ⁇ -cyclohexylacrylic, cinnamic, coumaric and umbellic acids, most preferably acrylic acid.
- the polymersare cross-linked by using less than about 5%, preferably about 0.1% to about 5%, more preferably about 0.2% to about 1%, by weight of one or more polyfunctional cross-linking agents such as non-polyalkenyl polyether difunctional cross-linking monomers, e.g., divinyl glycol.
- polyfunctional cross-linking agentssuch as non-polyalkenyl polyether difunctional cross-linking monomers, e.g., divinyl glycol.
- Other suitable cross-linking agentsillustratively include 2,3-dihydroxyhexa-1,5-diene, 2,5-dimethylhexa-1,5-diene, divinylbenzene, N,N-diallylacrylamide and N,N-diallylmethacrylamide. Divinyl glycol is preferred.
- Polyacrylic acid cross-linked with divinyl glycolis called polycarbophil.
- a polymer system containing polycarbophilis commercially available under the trademark DuraSite®
- a composition of this embodimentcan be prepared by a procedure substantially as disclosed in above-cited U.S. Pat. No. 5,192,535.
- One of skill in the artwill readily modify such procedure as appropriate for incorporation of a selective COX-2 inhibitory drug in accordance with the present invention.
- the compositionis an in situ gellable aqueous solution, suspension or solution/suspension having excipients substantially as disclosed in above-cited U.S. Pat. No. 4,861,760, comprising about 0.1% to about 2% by weight of a polysaccharide that gels when it contacts an aqueous medium having the ionic strength of tear fluid.
- a preferred polysaccharideis gellan gum.
- a composition of this embodimentcan be prepared by a procedure substantially as disclosed in above-cited U.S. Pat. No. 4,861,760.
- One of skill in the artwill readily modify such procedure as appropriate for incorporation of a selective COX-2 inhibitory drug in accordance with the present invention.
- the compositionis an in situ gellable aqueous solution, suspension or solution/suspension having excipients substantially as disclosed in above-cited U.S. Pat. No. 5,587,175, comprising about 0.2% to about 3%, preferably about 0.5% to about 1%, by weight of a gelling polysaccharide, preferably selected from gellan gum, alginate gum and chitosan, and about 1% to about 50% of a water-soluble film-forming polymer, preferably selected from alkylcelluloses (e.g., methylcellulose, ethylcellulose), hydroxyalkylcelluloses (e.g., hydroxyethylcellulose, hydroxypropyl methylcellulose), hyaluronic acid and salts thereof, chondroitin sulfate and salts thereof, polymers of acrylamide, acrylic acid and polycyanoacrylates, polymers of methyl methacrylate and 2-hydroxyethyl methacrylate, polydextrose, cyclo
- compositionscan optionally contain a gel-promoting counterion such as calcium in latent form, for example encapsulated in gelatin.
- a gel-promoting counterionsuch as calcium in latent form, for example encapsulated in gelatin.
- a composition of this embodimentcan be prepared by a procedure substantially as disclosed in above-cited U.S. Pat. No. 5,587,175.
- One of skill in the artwill readily modify such procedure as appropriate for incorporation of a selective COX-2 inhibitory drug in accordance with the present invention.
- the compositionis an in situ gellable aqueous solution, suspension or solution/suspension having excipients substantially as disclosed in European Patent No. 0 424 043, comprising about 0.1% to about 5% of a carrageenan gum.
- Carrageenansare sulfated polysaccharides; in this embodiment a carrageenan having no more than 2 sulfate groups per repeating disaccharide unit is preferred, including kappa-carrageenan, having 18-25% ester sulfate by weight, iota-carrageenan, having 25-34% ester sulfate by weight, and mixtures thereof.
- a composition of this embodimentcan be prepared by a procedure substantially as disclosed in above-cited European Patent No. 0 424 043.
- One of skill in the artwill readily modify such procedure as appropriate for incorporation of a selective COX-2 inhibitory drug in accordance with the present invention.
- An exemplary formulation of the inventionis an ophthalmic suspension of nanoparticles of valdecoxib comprising from about 0.01% to about 50% of valdecoxib, more preferably from about 0.1% to about 20% of valdecoxib, for example from about 0.1% to about 5% of valdecoxib; from about 0.05% to about 10% of carrageenan, preferably from about 0.1% to about 10% of carrageenan, for example from about 0.25% to about 8% of carrageenan and from about 0.5% to about 20% of hydroxypropyl ⁇ -cyclodextrin, preferably from about 1% to about 10% g of hydroxypropyl ⁇ -cyclodextrin, for example from about 2% to about 6% of hydroxypropyl ⁇ -cyclodextrin (amounts are expressed as % by weight).
- the compositioncomprises xanthan gum substantially as disclosed in U.S. Pat. No. 6,174,524.
- the compositioncomprises an ophthalmically acceptable mucoadhesive polymer, selected for example from carboxymethylcellulose, carbomer (acrylic acid polymer), poly(methylmethacrylate), polyacrylamide, polycarbophil, acrylic acid/butyl acrylate copolymer, sodium alginate and dextran.
- an ophthalmically acceptable mucoadhesive polymerselected for example from carboxymethylcellulose, carbomer (acrylic acid polymer), poly(methylmethacrylate), polyacrylamide, polycarbophil, acrylic acid/butyl acrylate copolymer, sodium alginate and dextran.
- the selective COX-2 inhibitory drugis solubilized at least in part by an ophthalmically acceptable solubilizing agent.
- ophthalmically acceptable solubilizing agentincludes agents that result in formation of a micellar solution or a true solution of the drug.
- Certain ophthalmically acceptable nonionic surfactantsfor example polysorbate 80, can be useful as solubilizing agents, as can ophthalmically acceptable glycols, polyglycols, e.g., polyethylene glycol 400, and glycol ethers.
- a class of solubilizing agents having particular utility in solution and solution/suspension compositions of the inventionis the cyclodextrins.
- Suitable cyclodextrinscan be selected from ⁇ -cyclodextrin, ⁇ -cyclodextrin, ⁇ -cyclodextrin, alkylcyclodextrins (e.g., methyl- ⁇ -cyclodextrin, dimethyl- ⁇ -cyclodextrin, diethyl- ⁇ -cyclodextrin), hydroxyalkylcyclodextrins (e.g., hydroxyethyl- ⁇ -cyclodextrin, hydroxypropyl- ⁇ -cyclodextrin), carboxyalkylcyclodextrins (e.g., carboxymethyl- ⁇ -cyclodextrin), sulfoalkylether cyclodextrins (e.g., sulfobutylether- ⁇ -cyclo
- One or more ophthalmically acceptable pH adjusting agents and/or buffering agentscan be included in a composition of the invention, including acids such as acetic, boric, citric, lactic, phosphoric and hydrochloric acids; bases such as sodium hydroxide, sodium phosphate, sodium borate, sodium citrate, sodium acetate, sodium lactate and tris-hydroxymethylaminomethane; and buffers such as citrate/dextrose, sodium bicarbonate and ammonium chloride. Such acids, bases and buffers are included in an amount required to maintain pH of the composition in an ophthalmically acceptable range.
- acidssuch as acetic, boric, citric, lactic, phosphoric and hydrochloric acids
- basessuch as sodium hydroxide, sodium phosphate, sodium borate, sodium citrate, sodium acetate, sodium lactate and tris-hydroxymethylaminomethane
- bufferssuch as citrate/dextrose, sodium bicarbonate and ammonium chloride.
- Such acids, bases and buffersare included
- the composition of the present inventionpreferably includes at least one ophthalmically acceptable salt, sugar and/or sugar alcohol in an amount required to bring osmolality of the composition into an ophthalmically acceptable range.
- Salts suitable for use in the compositioninclude those having sodium, potassium or ammonium cations and chloride, citrate, ascorbate, borate, phosphate, bicarbonate, sulfate, thiosulfate or bisulfite anions; particularly preferred salts include sodium chloride, potassium chloride, sodium thiosulfate, sodium bisulfite and ammonium sulfate, with sodium chloride being especially preferred.
- Sugars and sugar alcohols suitable for use in the compositioninclude mannitol, dextrose and lactose, glycerol, sorbitol and mannitol; preferred sugars and sugar alcohols include mannitol and dextrose.
- compositionoptionally includes at least one ophthalmically acceptable acid having at least two dissociable hydrogen as interactive agents to retard release of the drug through inhibition of erosion of the polymer, as disclosed in above-cited International Patent Publication No. WO 95/03784.
- Acids useful as interactive agentsinclude boric, lactic, orthophosphoric, citric, oxalic, succinic, tartaric and formic glycerophosphoric acids.
- compositionoptionally includes an ophthalmically acceptable xanthine derivative such as caffeine, theobromine or theophylline, substantially as disclosed in above-cited U.S. Pat. No. 4,559,343, to reduce ocular discomfort associated with administration of the composition.
- an ophthalmically acceptable xanthine derivativesuch as caffeine, theobromine or theophylline, substantially as disclosed in above-cited U.S. Pat. No. 4,559,343, to reduce ocular discomfort associated with administration of the composition.
- one or more ophthalmically acceptable preservativesare included in the composition to inhibit microbial activity.
- Suitable preservativesinclude mercury-containing substances such as merfen and thiomersal; stabilized chlorine dioxide; and quaternary ammonium compounds such as benzalkonium chloride, cetyltrimethylammonium bromide and cetylpyridinium chloride.
- one or more ophthalmically acceptable surfactantsare included in the composition to enhance physical stability or for other purposes.
- Suitable nonionic surfactantsinclude polyoxyethylene fatty acid glycerides and vegetable oils, e.g., polyoxyethylene (60) hydrogenated castor oil; and polyoxyethylene alkylethers and alkylphenyl ethers, e.g., octoxynol 10, octoxynol 40.
- one or more antioxidantsare included in the composition to enhance chemical stability where required.
- Suitable antioxidantsinclude ascorbic acid and sodium metabisulfite.
- One or more ophthalmic lubricating agentsare optionally included in the composition to promote lacrimation or as a “dry eye” medication.
- Such agentsinclude polyvinyl alcohol, methylcellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, etc.
- compositions of the inventionare preferably used in co-therapy with one or more drugs other than selective COX-2 inhibitory drugs.
- drugs other than COX-2 inhibitory drugscan be co-administered topically to the eye together with a composition of the invention.
- a composition of the inventionpreferably further comprises, in co-formulation with a first drug that is a selective COX-2 inhibitory drug as described herein, a therapeutically and/or prophylactically effective amount of a second drug that is other than a selective COX-2 inhibitory drug.
- This second drugcooperates with the first drug in treating and/or preventing a COX-2 mediated ophthalmic condition, or it can be used to treat a related or unrelated condition simultaneously affecting the eye.
- Any drug having utility as a topical ophthalmic applicationcan be used in co-therapy, co-administration or co-formulation with a composition of the invention as described immediately above.
- Such drugsinclude without limitation demulcents; antibiotics, antivirals and other anti-infectives; steroids, NSAIDs and other anti-inflammatory agents; acetylcholine blocking agents; antiglaucoma agents including beta-adrenergic receptor blocking agents, carbonic anhydrase inhibitors and prostaglandins; antihypertensives; antihistamines; anticataract agents; and topical and regional anesthetics.
- Illustrative specific drugsinclude acebutolol, aceclidine, acetylsalicylic acid (aspirin), N 4 acetylsulfisoxazole, alclofenac, alprenolol, amfenac, amiloride, aminocaproic acid, p-aminoclonidine, aminozolamide, anisindione, apafant, atenolol, bacitracin, benoxaprofen, benoxinate, benzofenac, bepafant, betamethasone, betaxolol, bethanechol, bimatoprost brimonidine, bromfenac, bromhexine, bucloxic acid, bupivacaine, butibufen, carbachol, carprofen, cephalexin, chloramphenicol, chlordiazepoxide, chlorprocaine, chlorpropamide, chlortetracycline, cicloprofen, cinmet
- a composition of the inventionis administered in co-therapy or co-formulation with a prostaglandin capable of reducing the intraocular pressure and/or treating glaucoma.
- the prostaglandinis a derivative of native prostaglandin F 2 ⁇ modified in its omega chain to reduce side effects such a ocular irritation and hyperemia and modified in its alpha chain to improve topical delivery to the cornea.
- Useful such prostaglandinsare described in the patents listed below, each of which is individually incorporated herein by reference.
- intraocular pressure reducing prostaglandin derivativessuch as latanoprost, travoprost, isopropyl unoprostone and bimatoprost are especially useful.
- the co-therapy or co-formulationhas utility for any of the COX-2 mediated disorders outlined above, in conjunction with glaucoma and/or intraocular hypertension treatment associated with prostaglandins.
- co-therapy or co-administration of a selective cyclooxygenase-2 inhibitory drug with a prostaglandinhas use in reducing or eliminating side effects that may appear from ocular prostaglandin therapy including, but not limited to, increased iridial pigmentation, disruption of the blood aqueous barrier and cystoid macular edema.
- the co-therapy or co-administration of a selective cyclooxygenase-2 inhibitory drug and a prostaglandinis of advantage by enabling the extension of a glaucoma or intraocular hypertension prostaglandin treatment to patients suffering from a COX-2 mediated complication during which prostaglandin therapy would otherwise be set out or conducted in conjunction with steroids.
- Co-therapy or co-administration of a selective cyclooxygenase-2 inhibitory drug and a prostaglandinis also useful in surgical adjunct therapy in connection with eye surgery, e.g., cataract or corneal transplant surgery.
- eye surgerye.g., cataract or corneal transplant surgery.
- Thisenables or improves glaucoma treatment also in eyes suffering from inflammatory process or trauma, such as cataract surgery, see K Miyake et al Arch. Ophthalmol. 1999, Vol. 117, pages 34-40.
- the mentioned co-therapy or co-administrationis also useful for potentiating the delivery of selective cyclooxygenase-2 inhibitory drugs to exert their activity in the posterior parts of the eye including the region of the optical nerve head.
- Such delivery enhancing effects of prostagladinshave been reported for verapamil in U.S. Pat. No. 5,952,378.
- compositions of the present inventioncan be prepared by methods known in the art and described in patents and publications cited herein and incorporated herein by reference.
- Aqueous suspension compositions of the inventioncan be packaged in single-dose non-reclosable containers. Such containers can maintain the composition in a sterile condition and thereby eliminate need for preservatives such as mercury-containing preservatives, which can sometimes cause irritation and sensitization of the eye. Alternatively, multiple-dose reclosable containers can be used, in which case it is preferred to include a preservative in the composition.
- Formulations of the inventionare contemplated to be useful for any drug, of low water solubility, for which ophthalmic administration is desired.
- nanoparticle compositions, of any drug of low water solubilitycan be formulated substantially as described for selective cyclooxygenase-2 inhibitory drugs herein above.
- the present inventionprovides a pharmaceutical composition suitable for topical administration to an eye, the composition comprising nanoparticles of a drug of low water solubility in a concentration effective for treatment and/or prophylaxis of a disorder in the eye, and one or more ophthalmically acceptable excipients that reduce rate of removal of the composition from the eye by lacrimation such that the composition has an effective residence time in the eye of about 2 to about 24 hours.
- valdecoxib nanoparticleswere prepared.
- the oral nanoparticle suspension formulationcontained unlabeled valdecoxib in a concentration of 0.5 mg/g and 2% povidone and 0.15% sodium dodecyl sulfate as vehicle components.
- the ophthalmic oral nanoparticle suspension formulationcontained labeled [ 13 C 6 ] valdecoxib in a concentration of 2.15 mg/g and 1.2% glycerin, 0.8% EDTA.2Na.2H 2 O, 4.0% hydroxypropyl ⁇ -cyclodextrin (HPBCD), 0.4% carrageenan (GelcarinTM GP-379NF,FMC Biopolymer, USA), 0.21% carrageenan (SeaSpenTM PF, FMC Biopolymer, USA) and 0.8% povidone.
- the formulationsare shown in Table 1 below.
- the two carrageenan excipientsare both ⁇ -carrageenans with slightly different chemical and physical properties.
- a first lot of rabbitswas sacrificed 0.5 hours after the administration of the oral and ophthalmic formulations of the valdecoxib, a second lot of rabbits was sacrificed two hours after the drug administration and a third lot of rabbits was sacrificed four hours after the drug administration.
- Selected eye tissues, aqueous humor, bulbar conjunctiva, cornea, eyelids, vitreous humor and sclerawere excised at the time of sacrifice, weighed directly into tared vials, solubilized and/or diluted as necessary, and analyzed by HPLC-MS.
- a blood samplewas collected from the ear central artery via a syringe, placed into a K 2 -EDTA vacutainer, mixed gently and stored on ice up to one hour prior to centrifuging to separate the plasma.
- the plasmawas stored at ⁇ 10° C. or colder until analysis.
- FIG. 1is a graph illustrating the pharmacokinetic results of ocular and oral delivery of the valdecoxib formulations plotted as the concentration of the drug in the conjunctiva versus time. As illustrated in FIG. 1, the ocular delivery of the drug achieved a much higher initial concentration of valdecoxib and maintained this higher concentration over time.
- FIG. 2is a graph illustrating the valdecoxib concentration in the conjunctiva, cornea, aqueous humor and plasma four hours after oral administration
- FIG. 3is a graph illustrating the valdecoxib concentration in the conjunctiva, cornea, aqueous humor and plasma four hours after ocular administration of valdecoxib.
- ocular administration of the valdecoxibis much more effective in delivering the drug to the eye than oral administration and yet avoids the high systemic (plasma) concentration of the drug that accompanies oral delivery.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrane Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
- This application claims the priority of U.S. Provisional Patent Application Ser. No. 60/218 101, filed Jul. 13, 2000, Ser. No. 60/279 285, filed on Mar. 28, 2001, Ser. No. 60/294 838, filed May 31, 2001 and Ser. No. 60/296 388, filed Jun. 6, 2001.[0001]
- The present invention relates to a pharmaceutical composition containing a drug of low water solubility and which is useful for topical application to an eye for treatment or prevention of an ophthalmic disease or disorder. In particular, the present invention relates to an ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug that can be applied to the eye for treatment or prevention of a cyclooxygenase-2 mediated ophthalmic disease or disorder. The field of the present invention also includes therapeutic or prophylactic use of such a composition, and use of such a composition in preparation of a medicament.[0002]
- Numerous compounds have been reported having therapeutically and/or prophylactically useful selective cyclooxygenase-2 inhibitory effect, and have been disclosed as having utility in treatment or prevention of specific cyclooxygenase-2 mediated disorders or of such disorders in general. Among such compounds are a large number of substituted pyrazolyl benzenesulfonamides as reported in U.S. Pat. No. 5,466,823 to Talley et al., including for example 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide, referred to herein as “celecoxib”, and 4-[5-(3-fluoro-4-methoxyphenyl)-3-difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide, referred to herein as “deracoxib”. Celecoxib has the structure shown in formula (I):[0003]
- Other compounds reported to have therapeutically and/or prophylactically useful selective cyclooxygenase-2 inhibitory effect are substituted isoxazolyl benzenesulfonamides (see, e.g., U.S. Pat. No. 5,633,272 to Talley et al.) including, for example, 4-[5-methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, also referred to herein as “valdecoxib”, which has the structure shown in formula (III):[0005]
- Parecoxib, is described in U.S. Pat. No. 5,932,598 to Talley et al. as one of a class of water-soluble prodrugs of selective COX-2 inhibitory drugs. Parecoxib, which has the structure shown in formula (IV) below, rapidly converts to the substantially water-insoluble selective COX-2 inhibitory drug valdecoxib following administration to a subject.[0006]
- Still other compounds reported to have therapeutically and/or prophylactically useful selective cyclooxygenase-2 inhibitory effect are substituted (methylsulfonyl)-phenyl furanones (see, e.g., U.S. Pat. No. 5,474,995 to Ducharme et al.) including, for example, the compound 3-phenyl-4-[4-(methylsulfonyl)phenyl]-5H-furan-2-one, referred to herein as “rofecoxib”, which has the structure shown in formula (V):[0007]
- U.S. Pat. No. 5,981,576 to Belley et al. discloses additional(methylsulfonyl)phenyl furanones said to be useful as selective cyclooxygenase-2 inhibitory drugs, including 3-(1-cyclopropylmethoxy)-5,5-dimethyl-4-[4-(methylsulfonyl)phenyl]-5H-furan-2-one and 3-(1-cyclopropylethoxy)-5,5-dimethyl-4-[4-(methylsulfonyl)phenyl]-5H-furan-2-one.[0008]
- U.S. Pat. No. 5,861,419 to Dube et al. discloses substituted pyridines said to be useful as selective cyclooxygenase-2 inhibitory drugs including, for example, 5-chloro-3-(4-methylsulfonyl)phenyl-2-(2-methyl-5-pyridinyl)pyridine, hereinafter referred to as “etoricoxib”, which has the structure shown in formula (VI )[0009]
- European Patent Application No. 0 863 134 discloses 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-1-one as a compound said to be useful as a selective cyclooxygenase-2 inhibitory drug.[0010]
- International Patent Publication No.[0012]
WO 00/24719 filed by Abbott Laboratories discloses substituted pyridazinones said to be useful as selective COX-2 inhibitory drugs, including the compound 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3-(2H)-pyridazinone. - Many patents relating to selective cyclooxygenase-2 inhibitory compounds, including those cited above, disclose utility of such compounds for relief of inflammation and inflammation-associated disorders. For example, above-cited U.S. Pat. Nos. 5,633,272 and 5,760,068 suggest that the subject compounds of these patents would be useful in treating inflammation in a long list of diseases, including conjunctivitis.[0013]
- Masferrer & Kulkarni (1997), in[0014]Survey of Ophthalmology41,
Supplement 2, S35-S40, further teach utility of selective cyclooxygenase-2 inhibitory drugs in treating ocular inflammation, and suggest oral use of such drugs for this purpose. - International Patent Publication No.[0015]
WO 00/32189 discloses orally deliverable compositions of celecoxib having utility in treatment of ophthalmic diseases such as retinitis, conjunctivitis, retinopathies, uveitis and ocular photophobia, and of acute injury to eye tissue. It is further disclosed therein that the subject orally deliverable compositions are useful for treatment of corneal graft rejection, ocular neovascularization, retinal neovascularization including that following injury or infection, diabetic retinopathy, macular degeneration, retrolental fibroplasia and neovascular glaucoma. - Formulations of nonsteroidal anti-inflammatories (hereinafter, “NSAIDs”) designed for topical application to the eye for relief of inflammation are known in the art. For example, a racemic mixture of R(+) and S(−) ketorolac tromethamine is formulated commercially as a sterile isotonic 0.5% aqueous solution in the product Acular® of Allergan, Inc., which is indicated for temporary relief of ocular itching due to seasonal allergic conjunctivitis, and for treatment of postoperative inflammation following cataract surgery. See[0016]Physicians' Desk Reference,54th Edition (2000), pp. 491-492.
- U.S. Pat. No. 4,474,751 to Haslam et al., incorporated herein by reference, discloses liquid aqueous ophthalmic compositions comprising a drug, preferably a water-soluble drug, together with 10% to 50% by weight of a thermosetting polymer that forms a gel at a human body temperature. Upon placement of such a liquid composition in an eye, a gel is formed thereby retarding loss of the drug from the eye by lacrimal drainage.[0017]
- U.S. Pat. No. 4,861,760 to Mazuel & Friteyre, incorporated herein by reference, discloses a liquid in situ gelling composition said to be suitable for ophthalmic use. The composition contains in aqueous solution a polysaccharide that undergoes liquid-gel phase transition in response to ionic strength of tear fluid. A suitable polysaccharide is gellan gum, which can be used in a concentration of 0.1% to 2% by weight of the composition.[0018]
- U.S. Pat. No. 5,587,175 to Viegas et al., incorporated herein by reference, discloses further liquid in situ gelling compositions said to be suitable for ophthalmic use. These compositions contain an ionic polysaccharide, for example gellan gum, alginate gum or chitosan, and a film-forming agent, for example hydroxypropyl methylcellulose, carboxymethylcellulose, sodium chondroitin sulfate, sodium hyaluronate, polyvinylpyrrolidone, etc. The compositions are pH buffered to match pH of tear fluid. Gelling is said to occur upon contact with calcium ions.[0019]
- U.S. Pat. No. 6,174,524 to Bawa et al., incorporated herein by reference, discloses in situ gelling compositions, comprising xanthan gum for ophthalmic use. The gelling is said to be due, at least in part, to an interaction with the lysozyme component of tear fluid.[0020]
- Each of the above cited U.S. Pat. No. 4,474,751, No. 4,861,760 and No. 5,587,175 suggests that the disclosed in situ gelling compositions can be used for ophthalmic delivery of anti-inflammatories such as indomethacin or sulindac.[0021]
- U.S. Pat. No. 5,192,535 to Davis et al., incorporated herein by reference, discloses liquid compositions said to be suitable for use as eye drops, utilizing a different in situ gelling mechanism. These compositions contain a lightly cross-linked carboxyl-containing polymer such as polycarbophil and have a pH of about 3.0 to about 6.5. Upon placement of such a composition in an eye, contact with lacrimal fluid having a pH of about 7.2 to about 7.4 is said to result in gelling and consequent increase of residence time in the eye, permitting sustained release of a drug contained in the composition. Drugs for which such a composition is said to be useful include anti-inflammatories such as ibuprofen, flurbiprofen and naproxen and esters thereof; also ketorolac and suprofen.[0022]
- U.S. Pat. No. 5,876,744 to Della Valle et al., incorporated herein by reference, discloses bioadhesive and mucoadhesive compositions, including some said to be useful as ophthalmic compositions, comprising mixtures of synthetic polymers such as polycarbophil and polyvinyl alcohol and biopolymers such as alginic acid, hyaluronic acid and dermatan sulfate. Such compositions are said to be capable of increasing contact time with a treated eye of specific drugs, for example anti-inflammatories.[0023]
- U.S. Pat. No. 5,814,655 to Patel et al., incorporated herein by reference, discloses topical ophthalmic formulations of an NSAID such as diclofenac, suprofen or flurbiprofen wherein pH and concentration of the NSAID are such that a therapeutic amount of the NSAID is present in suspension and a therapeutic amount of the NSAID is present in solution.[0024]
- Disclosure of topical ophthalmic formulations of an NSAID, for example diclofenac, ibuprofen, flurbiprofen, naproxen, ketorolac or suprofen, is also found individually in the references cited immediately below, which are incorporated herein by reference.[0025]
- U.S. Pat. No. 4,559,343 to Han et al.[0026]
- U.S. Pat. No. 4,960,799 to Nagy.[0027]
- U.S. Pat. No. 4,829,083 to Doulakas.[0028]
- U.S. Pat. No. 4,829,088 to Doulakas.[0029]
- U.S. Pat. No. 5,110,493 to Cherng-Chyi et al.[0030]
- International Patent Publication No. WO 95/03784.[0031]
- International Patent Publication No. WO 95/18604.[0032]
- International Patent Publication No. WO 95/31968.[0033]
- Vulovic et al. (1989)[0034]Int. J. Pharmaceut.55, 123-128.
- Weisweiler et al. (1988)[0035]J. Clin. Res. Drug Development2(4), 233-239.
- International Patent Publication No. WO 99/59634, incorporated herein by reference, discloses eye drops containing a selective cyclooxygenase-2 inhibitory drug selected from etodolac, N-(2-(cyclohexyloxy)-4-nitrophenyl)-methanesulfonamide and meloxicam.[0036]
- International Patent Publication No. WO 00/18387 filed by Alcon Laboratories, Inc, incorporated herein by reference, discloses ophthalmic compositions comprising an oxazolidinone antimicrobial agent and an anti-inflammatory agent. It is indicated that the anti-inflammatory agent can be any of a very broad list of agents, including selective cyclooxygenase-2 inhibitory drugs such as celecoxib. The anti-inflammatory agent is said to be present in such a composition in a concentration “sufficient to reduce inflammation” following topical application to the targeted tissues. The application describes examples of application of 1-4 drops of a solution or suspension, or a comparable amount of an ointment, gel or other solid or semisolid composition, 1-4 times a day, wherein the composition contains such an anti-inflammatory agent in a concentration of about 0.01% to about 1% by weight.[0037]
- International Patent Publication No. WO 00/25771 for an application by Synphora AB, incorporated herein by reference, discloses ophthalmic compositions comprising a prostaglandin analog such as latanoprost and an anti-inflammatory agent. The anti-inflammatory agent is said to reduce iridial pigmentation during topical prostaglandin therapy for glaucoma. The anti-inflammatory agent can be any of a broad list of agents, including celecoxib and rofecoxib.[0038]
- WO 00/18387 and WO 00/25771 cited above do not address the problems of formulating an ophthalmically acceptable composition comprising a selective cyclooxygenase-2 inhibitory drug. Such problems are particularly acute for selective cyclooxygenase-2 inhibitory drugs of low water solubility, including celecoxib, deracoxib, valdecoxib, rofecoxib, etoricoxib and 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-1-one. Furthermore, the composition must generally be formulated in a way that provides continuous delivery of the drug to an eye in order to be therapeutically effective against a cyclooxygenase-2 mediated disorder of the eye.[0039]
- A need therefore remains for a method of topically treating and/or preventing cyclooxygenase-2 mediated disorders of the eye. A special need exists for such a method having its therapeutic and/or prophylactic effect through selective inhibition of cyclooxygenase-2 (COX-2), without the undesirable side-effects associated with inhibition of cyclooxygenase-1 (COX-1) that can occur with conventional NSAIDs. A particular need exists for an ophthalmically acceptable formulation of a selective COX-2 inhibitory drug, particularly one of low water solubility, that is therapeutically and/or prophylactically effective when administered topically to the eye. A further particular need exists for such a formulation that delivers the drug continuously to the eye over a prolonged period of time, for example over at least about 2 hours, preferably longer.[0040]
- These and other needs will be seen to be met by the invention now described.[0041]
- The present invention provides a pharmaceutical composition suitable for topical administration to an eye, the composition comprising nanoparticles of a drug of low water solubility in a concentration effective for treatment and/or prophylaxis of a disorder in the eye, and at least one ophthalmically acceptable excipient ingredient that preferably reduce the rate of removal of the composition from the eye by lacrimation such that the composition has an effective residence time in an eye of about 2 to about 24 hours, after being applied thereto.[0042]
- The present invention also provides a pharmaceutical composition suitable for topical administration to an eye, the composition comprising a selective COX-2 inhibitory drug in a concentration effective for treatment and/or prophylaxis of a COX-2 mediated disorder in the eye, and one or more ophthalmically acceptable excipient ingredients that preferably reduce rate of removal of the composition from the eye by lacrimation such that the composition has an effective residence time in the eye of about 2 to about 24 hours.[0043]
- As used herein, the term “lacrimation” refers to the production of tear fluid. Matter is typically removed from eyes by external wash-out, by lacrimal drainage into the nasopharyngeal cavity via the nasolacrimal ducts, or by a combination of the two means. By “effective residence time” herein is meant a period of time following application of the composition to the eye during which a substantial portion of the applied composition remains in situ even in the presence of lacrimation and/or external wash-out, and during which the drug is released therefrom in a therapeutically or prophylactically effective amount to tissues of the eye and/or to fluids secreted thereby.[0044]
- The composition, therefore provides sustained release at an effective concentration over a period of at least about 2 hours. Optionally, a portion of the selective COX-2 inhibitory drug can be present in the composition in immediate-release form so that the composition provides a combination of immediate and sustained release (herein referred to as “dual release”) of the drug.[0045]
- The invention also provides a method of preparing a medicament for treating or preventing a COX-2 mediated disorder in an eye, using a composition as described above.[0046]
- The present invention provides a method of treating or preventing a disorder in an eye, the method comprising application of a composition as described above in a therapeutically or prophylactically effective dose.[0047]
- Also embraced by the present invention is a method of treating or preventing a COX-2 mediated disorder in an eye, the method comprising application to the eye of a composition as described above in a therapeutically or prophylactically effective dose.[0048]
- COX-2 mediated disorders of the eye for which the method is useful include without limitation inflammatory disorders such as endophthalmitis, episcleritis, retinitis, iriditis, cyclitis, choroiditis, keratitis, conjunctivitis and blepharitis, including inflammation of more than one part of the eye, e.g., retinochoroiditis, iridocyclitis, iridocyclochoroiditis (also known as uveitis), keratoconjunctivitis, blepharoconjunctivitis, etc.; other COX-2 mediated retinopathies including diabetic retinopathy; ocular tumors; ocular photophobia; acute trauma of any tissue of the eye including postsurgical trauma, e.g., following cataract or corneal transplant surgery; postsurgical ocular inflammation; intraoperative miosis; corneal graft rejection; ocular, for example retinal, neovascularization including that following injury or infection; macular degeneration; cystoid macular edema; retrolental fibroplasia; neovascular glaucoma; ocular pain; and COX-2 mediated side effects from ocular prostaglandin therapy including increased iridial pigmentation, disruption of the blood aqueous barrier and cystoid macular edema.[0049]
- It is understood that certain COX-2 mediated disorders of the eye are disorders of surface tissues such as the conjunctiva, and that topical application of a selective COX-2 inhibitory drug to the eye, therefore, results in delivery of the drug directly to its site of action in the case of such disorders. Other COX-2 mediated disorders of the eye are disorders of internal tissues such as the retina, in which case the drug has to move from the locus of administration to the targeted tissue. Administration of a composition of the invention to the eye generally results in direct contact of the drug with the cornea, through which at least a portion of the administered drug passes. The term “topical” as applied herein to ocular administration of a composition of the invention will be understood to embrace administration followed by corneal absorption as well as administration directly to a targeted surface tissue of the eye such as open tissues in connection with eye surgery or postsurgical treatment.[0050]
- What constitutes a “concentration effective for treatment and/or prophylaxis of a COX-2 mediated disorder” depends, among other factors, on the particular drug being administered; the residence time provided by the particular formulation of the drug; the species, age and body weight of the subject; the particular ophthalmic condition for which treatment or prophylaxis is sought; and the severity of the condition. In the case of celecoxib, an effective concentration in a composition of the invention for topical administration to an eye will generally be found in the range from about 0.1% to about 50% weight/volume. For selective COX-2 inhibitory drugs other than celecoxib, an appropriate concentration range is one that is therapeutically equivalent to the celecoxib concentration range indicated above.[0051]
- A composition of the invention is preferably formulated as an in situ gellable aqueous liquid, and can be administered as eye drops. Typically each drop of the composition, generated by a conventional dispensing means, has a volume of about 15 to about 40 μl. From 1 to about 6 such drops typically provides a suitable dose of the selective COX-2 inhibitory drug. Where the composition is administered in a form other than eye drops, for example as an ophthalmic ointment or as a solid implant, an equivalent dose is provided. Such a dose can be administered as needed, but typically administration to the[0052]
eye 1 to about 4 times per day, inmost cases - The term “ophthalmically acceptable” with respect to a formulation, composition or ingredient herein means having no persistent detrimental effect on the treated eye or the functioning thereof, or on the general health of the subject being treated. It will be recognized that transient effects such as minor irritation or a “stinging” sensation are common with topical ophthalmic administration of drugs and the existence of such transient effects is not inconsistent with the formulation, composition or ingredient in question being “ophthalmically acceptable” as herein defined. However, preferred formulations, compositions and ingredients are those that cause no substantial detrimental effect, even of a transient nature.[0053]
- By contrast with therapeutic and prophylactic methods involving NSAIDs lacking selectivity for inhibition of COX-2, highly effective relief or prevention of COX-2 mediated ophthalmic disorders can be obtained with greatly reduced risk of the side-effects commonly associated with COX-1 inhibition. Thus the method of the present invention is particularly suitable where conventional NSAIDs are contraindicated, for example in patients with peptic ulcers, gastritis, regional enteritis, ulcerative colitis or diverticulitis, patients with a recurrent history of gastrointestinal lesions, patients with gastrointestinal bleeding, coagulation disorders including anemia such as hypothrombinemia, hemophilia and other bleeding problems, or kidney disease, patients prior to surgery, or patients taking anticoagulants.[0054]
- A particular advantage over conventional NSAIDs for topical application to eyes is the lack of effect on baseline COX-1 mediated physiological functions including wound healing following eye surgery, and intraocular pressure control.[0055]
- Further, previously disclosed ophthalmic compositions containing a selective COX-2 inhibitory drug have not been specified to be resistant to removal from a treated eye by lacrimation, and in particular an effective residence time of at least about 2 hours has not been specified. Yet, according to the present invention, such a residence time is believed to be critical in the case of at least the great majority of selective COX-2 inhibitory drugs. Without being bound by theory, it is believed that the criticality of a sufficiently long residence time arises at least in part from the following factors.[0056]
- A first factor is the extremely low solubility in water of most selective COX-2 inhibitory drugs, including for example celecoxib, deracoxib, valdecoxib, rofecoxib, etoricoxib, 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-1-one and 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3-(2H)-pyridazinone. In aqueous compositions, such drugs are typically present as dispersed particles, from which release is not instantaneous. Without the residence time provided by the present invention, an insufficient amount of the drug would be released before loss of the composition from the treated eye by lacrimal drainage.[0057]
- A second factor is the need for sustained COX-2 inhibitory action. When a selective COX-2 inhibitory drug is administered orally, it is absorbed in the alimentary tract into the bloodstream and becomes systemically distributed throughout the body. Typically such a drug has a relatively long half-life in the bloodstream and repeat administration is generally not necessary for about 12 to about 24 hours or more. By contrast, in a topical administration method as provided by the present invention, the dosage is generally insufficient to lead to a therapeutically or prophylactically effective blood serum concentration and sustained effectiveness is therefore dependent on a depot of the drug remaining in situ at the locus of application.[0058]
- The very low dose permitted by the composition and method of the invention, by comparison with normal orally administered doses of selective COX-2 inhibitory drugs, is a further advantage of the invention.[0059]
- Formulations of the invention are contemplated to be useful for any drug, of low water solubility, for which ophthalmic administration is desired.[0060]
- Other features and advantages of the invention will be in part apparent and in part pointed out hereinafter.[0061]
- FIG. 1 is a graph illustrating the pharmacokinetic results of ocular versus oral delivery for the concentration of valdecoxib in the conjunctiva plotted against time;[0062]
- FIG. 2 is a graph illustrating the valdecoxib concentration in the conjunctiva, cornea, aqueous humor and plasma four hours after oral administration of the drug; and[0063]
- FIG. 3 is a graph illustrating the valdecoxib concentration in the conjunctiva, cornea, aqueous humor and plasma four hours after ocular administration of the drug.[0064]
- As indicated above, the invention provides a pharmaceutical composition suitable for topical administration to an eye. The composition comprises a selective COX-2 inhibitory drug or a salt or prodrug thereof in a concentration effective for treatment and/or prophylaxis of a COX-2 mediated disorder in the eye, and one or more ophthalmically acceptable excipient ingredients that reduce rate of removal of the composition from the eye by lacrimation, such reduction in rate of removal including rendering the composition resistant to removal from the eye by lacrimation. By virtue at least in part of this reduced rate of removal by lacrimation, the composition has an effective residence time in the eye of about 2 to about 24 hours.[0065]
- In one embodiment, the selective COX-2 inhibitory drug is of low water solubility. Low water solubility herein is defined as water solubility of not more than about 10 mg/ml, preferably not more than about 5 mg/ml, for example not more than about 1 mg/ml.[0066]
- The selective COX-2 inhibitory drug can be any such drug known in the art, including, without limitation, compounds disclosed in the patents and publications listed below, each of which is individually incorporated herein by reference.[0067]
- U.S. Pat. No. 5,344,991 to Reitz & Li.[0068]
- U.S. Pat. No. 5,380,738 to Norman et al.[0069]
- U.S. Pat. No. 5,393,790 to Reitz et al.[0070]
- U.S. Pat. No. 5,401,765 to Lee.[0071]
- U.S. Pat. No. 5,418,254 to Huang & Reitz.[0072]
- U.S. Pat. No. 5,420,343 to Koszyk & Weier.[0073]
- U.S. Pat. No. 5,434,178 to Talley & Rogier.[0074]
- U.S. Pat. No. 5,436,265 to Black et al.[0075]
- Above-cited U.S. Pat. No. 5,466,823.[0076]
- Above-cited U.S. Pat. No. 5,474,995.[0077]
- U.S. Pat. No. 5,475,018 to Lee & Bertenshaw.[0078]
- U.S. Pat. No. 5,486,534 to Lee et al.[0079]
- U.S. Pat. No. 5,510,368 to Lau et al.[0080]
- U.S. Pat. No. 5,521,213 to Prasit et al.[0081]
- U.S. Pat. No. 5,536,752 to Ducharme et al.[0082]
- U.S. Pat. No. 5,543,297 to Cromlish et al.[0083]
- U.S. Pat. No. 5,547,975 to Talley et al.[0084]
- U.S. Pat. No. 5,550,142 to Ducharme et al.[0085]
- U.S. Pat. No. 5,552,422 to Gauthier et al.[0086]
- U.S. Pat. No. 5,585,504 to Desmond et al.[0087]
- U.S. Pat. No. 5,593,992 to Adams et al.[0088]
- U.S. Pat. No. 5,596,008 to Lee.[0089]
- U.S. Pat. No. 5,604,253 to Lau et al.[0090]
- U.S. Pat. No. 5,604,260 to Guay & Li.[0091]
- U.S. Pat. No. 5,616,458 to Lipsky et al.[0092]
- U.S. Pat. No. 5,616,601 to Khanna et al.[0093]
- U.S. Pat. No. 5,620,999 to Weier et al.[0094]
- Above-cited U.S. Pat. No. 5,633,272.[0095]
- U.S. Pat. No. 5,639,780 to Lau et al.[0096]
- U.S. Pat. No. 5,643,933 to Talley et al.[0097]
- U.S. Pat. No. 5,658,903 to Adams et al.[0098]
- U.S. Pat. No. 5,668,161 to Talley et al.[0099]
- U.S. Pat. No. 5,670,510 to Huang & Reitz.[0100]
- U.S. Pat. No. 5,677,318 to Lau.[0101]
- U.S. Pat. No. 5,681,842 to Dellaria & Gane.[0102]
- U.S. Pat. No. 5,686,460 to Nicolai et al.[0103]
- U.S. Pat. No. 5,686,470 to Weier et al.[0104]
- U.S. Pat. No. 5,696,143 to Talley et al.[0105]
- U.S. Pat. No. 5,710,140 to Ducharme et al.[0106]
- U.S. Pat. No. 5,716,955 to Adams et al.[0107]
- U.S. Pat. No. 5,723,485 to Gungor & Teulon.[0108]
- U.S. Pat. No. 5,739,166 to Reitz et al.[0109]
- U.S. Pat. No. 5,741,798 to Lazer et al.[0110]
- U.S. Pat. No. 5,756,499 to Adams et al.[0111]
- U.S. Pat. No. 5,756,529 to Isakson & Talley.[0112]
- U.S. Pat. No. 5,776,967 to Kreft et al.[0113]
- U.S. Pat. No. 5,783,597 to Beers & Wachter.[0114]
- U.S. Pat. No. 5,789,413 to Black et al.[0115]
- U.S. Pat. No. 5,807,873 to Nicolai & Teulon.[0116]
- U.S. Pat. No. 5,817,700 to Dube et al.[0117]
- U.S. Pat. No. 5,8301911 to Failli et al.[0118]
- U.S. Pat. No. 5,849,943 to Atkinson & Wang.[0119]
- U.S. Pat. No. 5,859,036 to Sartori et al.[0120]
- Above-cited U.S. Pat. No. 5,861,419.[0121]
- U.S. Pat. No. 5,866,596 to Sartori & Teulon.[0122]
- U.S. Pat. No. 5,869,524 to Failli.[0123]
- U.S. Pat. No. 5,869,660 to Adams et al.[0124]
- U.S. Pat. No. 5,883,267 to Rossen et al.[0125]
- U.S. Pat. No. 5,892,053 to Zhi et al.[0126]
- U.S. Pat. No. 5,922,742 to Black et al.[0127]
- U.S. Pat. No. 5,929,076 to Adams & Garigipati.[0128]
- Above-cited U.S. Pat. No. 5,932,598.[0129]
- U.S. Pat. No. 5,935,990 to Khanna et al.[0130]
- U.S. Pat. No. 5,945,539 to Haruta et al.[0131]
- U.S. Pat. No. 5,958,978 to Yamazaki et al.[0132]
- U.S. Pat. No. 5,968,958 to Guay et al.[0133]
- U.S. Pat. No. 5,972,950 to Nicolai & Teulon.[0134]
- U.S. Pat. No. 5,973,191 to Marnett & Kalgutkar.[0135]
- Above-cited U.S. Pat. No. 5,981,576.[0136]
- U.S. Pat. No. 5,994,381 to Haruta et al.[0137]
- U.S. Pat. No. 6,002,014 to Haruta et al.[0138]
- U.S. Pat. No. 6,004,960 to Li et al.[0139]
- U.S. Pat. No. 6,005,000 to Hopper et al.[0140]
- U.S. Pat. No. 6,020,343 to Belley et al.[0141]
- U.S. Pat. No. 6,020,347 to DeLaszlo & Hagmann.[0142]
- Above-cited U.S. Pat. No. 6,034,256.[0143]
- U.S. Pat. No. 6,040,319 to Corley et al.[0144]
- U.S. Pat. No. 6,040,450 to Davies et al.[0145]
- U.S. Pat. No. 6,046,208 to Adams et al.[0146]
- U.S. Pat. No. 6,046,217 to Friesen et al.[0147]
- U.S. Pat. No. 6,057,319 to Black et al.[0148]
- U.S. Pat. No. 6,063,804 to De Nanteuil et al.[0149]
- U.S. Pat. No. 6,063,807 to Chabrier de Lassauniere & Broquet.[0150]
- U.S. Pat. No. 6,071,954 to LeBlanc et al.[0151]
- U.S. Pat. No. 6,077,868 to Cook et al.[0152]
- U.S. Pat. No. 6,077,869 to Sui & Wachter.[0153]
- U.S. Pat. No. 6,083,969 to Ferro et al.[0154]
- U.S. Pat. No. 6,096,753 to Spohr et al.[0155]
- U.S. Pat. No. 6,133,292 to Wang et al.[0156]
- International Patent Publication No. WO 94/15932.[0157]
- International Patent Publication No. WO 96/19469.[0158]
- International Patent Publication No. WO 96/26921.[0159]
- International Patent Publication No. WO 96/31509.[0160]
- International Patent Publication No. WO 96/36623.[0161]
- International Patent Publication No. WO 96/38418.[0162]
- International Patent Publication No. WO 97/03953.[0163]
- International Patent Publication No. WO 97/10840.[0164]
- International Patent Publication No. WO 97/13755.[0165]
- International Patent Publication No. WO 97/13767.[0166]
- International Patent Publication No. WO 97/25048.[0167]
- International Patent Publication No. WO 97/30030.[0168]
- International Patent Publication No. WO 97/34882.[0169]
- International Patent Publication No. WO 97/46524.[0170]
- International Patent Publication No. WO 98/04527.[0171]
- International Patent Publication No. WO 98/06708.[0172]
- International Patent Publication No. WO 98/07425.[0173]
- International Patent Publication No. WO 98/17292.[0174]
- International Patent Publication No. WO 98/21195.[0175]
- International Patent Publication No. WO 98/22457.[0176]
- International Patent Publication No. WO 98/32732.[0177]
- International Patent Publication No. WO 98/41516.[0178]
- International Patent Publication No. WO 98/43966.[0179]
- International Patent Publication No. WO 98/45294.[0180]
- International Patent Publication No. WO 98/47871.[0181]
- International Patent Publication No. WO 99/01130.[0182]
- International Patent Publication No. WO 99/01131.[0183]
- International Patent Publication No. WO 99/01452.[0184]
- International Patent Publication No. WO 99/01455.[0185]
- International Patent Publication No. WO 99/10331.[0186]
- International Patent Publication No. WO 99/10332.[0187]
- International Patent Publication No. WO 99/11605.[0188]
- International Patent Publication No. WO 99/12930.[0189]
- International Patent Publication No. WO 99/14195.[0190]
- International Patent Publication No. WO 99/14205.[0191]
- International Patent Publication No. WO 99/15505.[0192]
- International Patent Publication No. WO 99/23087.[0193]
- International Patent Publication No. WO 99/24404.[0194]
- International Patent Publication No. WO 99/25695.[0195]
- International Patent Publication No. WO 99/35130.[0196]
- International Patent Publication No. WO 99/61016.[0197]
- International Patent Publication No. WO 99/61436.[0198]
- International Patent Publication No. WO 99/62884.[0199]
- International Patent Publication No. WO 99/64415.[0200]
- International Patent Publication No. WO 00/01380.[0201]
- International Patent Publication No. WO 00/08024.[0202]
- International Patent Publication No. WO 00/10993.[0203]
- International Patent Publication No. WO 00/13684.[0204]
- International Patent Publication No. WO 00/18741.[0205]
- International Patent Publication No. WO 00/18753.[0206]
- International Patent Publication No. WO 00/23426.[0207]
- International Patent Publication No. WO 00/24719.[0208]
- International Patent Publication No. WO 00/26216.[0209]
- International Patent Publication No. WO 00/31072.[0210]
- International Patent Publication No. WO 00/40087.[0211]
- International Patent Publication No. WO 00/56348.[0212]
- Europea n Patent Application No. 0 799 823.[0213]
- European Patent Application No. 0 846 689.[0214]
- Above-cited European Patent Application No. 0 863 134.[0215]
- European Patent Application No. 0 985 666.[0216]
- where R[0218]3is a methyl or amino group, R4is hydrogen or a C1-4alkyl or alkoxy group, X is N or CR5where R5is hydrogen or halogen, and Y and Z are independently carbon or nitrogen atoms defining adjacent atoms of a five- to six-membered ring that is unsubstituted or substituted at one or more positions with oxo, halo, methyl or halomethyl groups. Preferred such five- to six-membered rings are cyclopentenone, furanone, methylpyrazole, isoxazole and pyridine rings substituted at no more than one position. Also useful are prodrugs that provide such selective COX-2 inhibitory compounds upon administration, for example parecoxib, which is a prodrug of valdecoxib.
- Illustratively, celecoxib, deracoxib, valdecoxib, rofecoxib, etoricoxib, 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-1-one, (S)-6,8-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid and 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3-(2H)-pyridazinone, more particularly celecoxib, valdecoxib, rofecoxib and etoricoxib, still more particularly valdecoxib and etoricoxib, and most particularly valdecoxib, are useful in the method and composition of the invention.[0219]
- The invention is illustrated herein with particular reference to celecoxib, and it will be understood that any other selective COX-2 inhibitory compound can, if desired, be substituted in whole or in part for celecoxib, with appropriate adjustment in concentration and dosage ranges, in the compositions and methods herein described.[0220]
- Selective COX-2 inhibitory drugs used in the method and composition of the invention can be prepared by a process known per se, in the case of celecoxib, for example, by processes described in U.S. Pat. No. 5,466,863 to Talley et al. or in U.S. Pat. No. 5,892,053 to Zhi & Newaz, both incorporated herein by reference. Other selective COX-2 inhibitory drugs can be prepared by processes known per se, including processes set forth in patent publications disclosing such drugs; for example in the case of valdecoxib in above-cited U.S. Pat. No. 5,633,272, and in the case of rofecoxib in above-cited U.S. Pat. No. 5,474,995.[0221]
- Preferably the composition has an effective residence time in the eye of about 3 to about 24 hours, more preferably about 4 to about 24 hours and most preferably about 6 to about 24 hours.[0222]
- A composition of the invention can illustratively take the form of a liquid wherein the drug is present in solution, in suspension or both. The term “solution/suspension” herein refers to a liquid composition wherein a first portion of the drug is present in solution and a second portion of the drug is present in particulate form, in suspension in a liquid matrix. A liquid composition herein includes a gel. Preferably the liquid composition is aqueous. Alternatively, the composition can take the form of an ointment. The composition of the present invention can also be delivered by electrophoresis, electroporation or iontophoresis.[0223]
- As a further alternative, the composition can take the form of a solid article that can be inserted between the eye and eyelid or in the conjunctival sac, where it releases the drug as described, for example, in U.S. Pat. No. 3,863,633 and U.S. Pat. No. 3,868,445, both to Ryde & Ekstedt, incorporated herein by reference. Release is to the lacrimal fluid that bathes the surface of the cornea, or directly to the cornea itself, with which the solid article is generally in intimate contact. Solid articles suitable for implantation in the eye in such fashion are generally composed primarily of polymers and can be biodegradable or non-biodegradable. Biodegradable polymers that can be used in preparation of ocular implants carrying a selective COX-2 inhibitory drug in accordance with the present invention include without restriction aliphatic polyesters such as polymers and copolymers of poly(glycolide), poly(lactide), poly(c-caprolactone), poly(hydroxybutyrate) and poly(hydroxyvalerate), polyamino acids, polyorthoesters, polyanhydrides, aliphatic polycarbonates and polyether lactones. Illustrative of suitable non-biodegradable polymers are silicone elastomers.[0224]
- In a presently preferred embodiment, the composition is an aqueous solution, suspension or solution/suspension, which can be presented in the form of eye drops. By means of a suitable dispenser, a desired dosage of the drug can be metered by administration of a known number of drops into the eye. For example, for a drop volume of 25 μl, administration of 1-6 drops will deliver 25-150 μl of the composition. Aqueous compositions of the invention preferably contain from about 0.01% to about 50%, more preferably about 0.1% to about 20%, still more preferably about 0.2% to about 10%, and most preferably about 0.5% to about 5%, weight/volume of the selective COX-2 inhibitory drug. In one embodiment, a composition of the invention contains a concentration of the selective COX-2 inhibitory drug that is therapeutically or prophylactically equivalent to a celecoxib weight/volume concentration of about 0.1% to about 50%, preferably about 0.5% to about 20%, and most preferably about 1% to about 10%. In another embodiment, a composition of the invention has relatively high loading of the drug and is suitable for a relatively long residence time in a treated eye. In this embodiment the weight/volume concentration of the drug in the composition is about 1.3% to about 50%, preferably about 1.5% to about 30%, and most preferably about 2% to about 20%, for example about 2% to about 10%.[0225]
- Preferably no more than 3 drops, more preferably no more than 2 drops, and most preferably no more than 1 drop, each of about 15 to about 40 μl, preferably about 20 to about 30 μl, for example about 25 μl, should contain the desired dose of the drug for administration to an eye. Administration of a larger volume to the eye risks loss of a significant portion of the applied composition by lacrimation.[0226]
- Aqueous compositions of the invention have ophthalmically compatible pH and osmolality.[0227]
- In an aqueous suspension or solution/suspension composition of a preferred embodiment of the invention, the selective COX-2 inhibitory drug is present predominantly in the form of nanoparticles, i.e., solid particles smaller than about 1 μm in their longest dimension. A benefit of this embodiment is more rapid release of the drug, and therefore more complete release during the residence time of the composition in a treated eye, than occurs with larger particle size. Another benefit is reduced potential for eye irritation by comparison with larger particle size. Reduced eye irritation in turn leads to a reduced tendency for loss of the composition from the treated eye by lacrimation, which is stimulated by such irritation.[0228]
- In a related embodiment the drug preferably has a D[0229]90particle size of about 0.01 to about 200 μm, wherein about 25% to 100% by weight of the particles are nanoparticles. “D90” is defined as a linear measure of diameter having a value such that 90% by volume of particles in the composition, in the longest dimension of the particles, are smaller than that diameter. For practical purposes a determination of D90based on 90% by weight rather than by volume is generally suitable.
- In one embodiment substantially all of the drug particles in the composition are smaller than 1 μm, i.e., the percentage by weight of nanoparticles is 100% or close to 100%. The selective cyclooxygenase-2 inhibitory drug can be in crystalline or amorphous form in the nanoparticles. Processes for preparing nanoparticles that involve milling or grinding typically provide the drug in crystalline form, whereas processes that involve precipitation from solution typically provide the drug in amorphous form.[0230]
- Nanoparticles comprising or consisting essentially of a selective COX-2 inhibitory drug of low water solubility can be prepared according to any process previously applied to preparation of other poorly water soluble drugs in form of nanoparticles. Suitable processes, without restriction, are illustratively disclosed for such other drugs in patents and publications listed below and incorporated herein by reference.[0231]
- U.S. Pat. No. 4,826,689 to Violanto & Fischer.[0232]
- Above-cited U.S. Pat. No. 5,145,684.[0233]
- U.S. Pat. No. 5,298,262 to Na & Rajagopalan.[0234]
- U.S. Pat. No. 5,302,401 to Liversidge et al.[0235]
- U.S. Pat. No. 5,336,507 to Na & Rajagopalan.[0236]
- U.S. Pat. No. 5,340,564 to Illig & Sarpotdar.[0237]
- U.S. Pat. No. 5,346,702 to Na & Rajagopalan.[0238]
- U.S. Pat. No. 5,352,459 to Hollister et al.[0239]
- U.S. Pat. No. 5,354,560 to Lovrecich.[0240]
- Above-cited U.S. Pat. No. 5,384,124.[0241]
- U.S. Pat. No. 5,429,824 to June.[0242]
- U.S. Pat. No. 5,503,723 to Ruddy et al.[0243]
- U.S. Pat. No. 5,510,118 to Bosch et al.[0244]
- U.S. Pat. No. 5,518,187 to Bruno et al.[0245]
- U.S. Pat. No. 5,518,738 to Eickhoff et al.[0246]
- U.S. Pat. No. 5,534,270 to De Castro.[0247]
- U.S. Pat. No. 5,536,508 to Canal et al.[0248]
- U.S. Pat. No. 5,552,160 to Liversidge et al.[0249]
- U.S. Pat. No. 5,560,931 to Eickhoff et al.[0250]
- U.S. Pat. No. 5,560,932 to Bagchi et al.[0251]
- U.S. Pat. No. 5,565,188 to Wong et al.[0252]
- U.S. Pat. No. 5,569,448 to Wong et al.[0253]
- U.S. Pat. No. 5,571,536 to Eickhoff et al.[0254]
- U.S. Pat. No. 5,573,783 to Desieno & Stetsko.[0255]
- U.S. Pat. No. 5,580,579 to Ruddy et al.[0256]
- U.S. Pat. No. 5,585,108 to Ruddy et al.[0257]
- U.S. Pat. No. 5,587,143 to Wong.[0258]
- U.S. Pat. No. 5,591,456 to Franson et al.[0259]
- U.S. Pat. No. 5,622,938 to Wong.[0260]
- U.S. Pat. No. 5,662,883 to Bagchi et al.[0261]
- U.S. Pat. No. 5,665,331 to Bagchi et al.[0262]
- U.S. Pat. No. 5,718,919 to Ruddy et al.[0263]
- U.S. Pat. No. 5,747,001 to Wiedmann et al.[0264]
- Above-cited International Patent Publication No. WO 93/25190.[0265]
- International Patent Publication No. WO 96/24336.[0266]
- International Patent Publication No. WO 97/14407.[0267]
- International Patent Publication No. WO 98/35666.[0268]
- International Patent Publication No. WO 99/65469.[0269]
- International Patent Publication No. WO 00/18374.[0270]
- International Patent Publication No. WO 00/27369.[0271]
- International Patent Publication No. WO 00/30615.[0272]
- One of ordinary skill in the art will readily adapt the processes therein described to preparation of a poorly water soluble selective COX-2 inhibitory drug in form of nanoparticles.[0273]
- In one embodiment of the invention, nanoparticles of a selective COX-2 inhibitory drug are prepared by a milling process, preferably a wet milling process in presence of a surface modifying agent that inhibits aggregation and/or crystal growth of nanoparticles once created. In another embodiment of the invention, nanoparticles of a selective COX-2 inhibitory drug are prepared by a precipitation process, preferably a process of precipitation in an aqueous medium from a solution of the drug in a non-aqueous solvent. The non-aqueous solvent can be a liquefied, e.g., supercritical, gas under pressure. Illustrative examples of these and other processes for preparing nanoparticles of a selective COX-2 inhibitory drug are presented with greater particularity below.[0274]
- In one particular embodiment of the invention, nanoparticles are prepared by a process comprising the steps of (a) dispersing a selective COX-2 inhibitory drug and a surface modifying agent in a liquid dispersion medium; and (b) wet milling the resulting drug dispersion in presence of grinding media to result in crystalline nanoparticles of the drug having the surface modifying agent adsorbed on the surface thereof in an amount sufficient to maintain a weight average particle size of less than about 400 nm, substantially as disclosed in above-cited U.S. Pat. No. 5,145,684. The surface modifying agent inhibits aggregation of the nanoparticles and can be any of various polymers, low molecular weight oligomers, natural products, surfactants, etc. The nanoparticles in this and related embodiments are referred to herein as being composed of a nanocrystalline drug/surface modifier complex.[0275]
- In another embodiment of the invention, if there are relatively high amounts of an amorphous phase in the drug composition, water-soluble polymeric excipients, such as povidone and modified celluloses, may be present in order to help prevent the occurrence of nucleation/crystallization.[0276]
- In a related embodiment of the invention, a nanocrystalline drug/surface modifier complex prepared as described above comprises a purified surface modifying agent, for example a purified polymeric surfactant, to prevent particle aggregation during a subsequent sterilization step, substantially as disclosed in above-cited U.S. Pat. No. 5,352,459.[0277]
- In another related embodiment of the invention, a nanocrystalline drug/surface modifier complex prepared as described above comprises as a surface modifying agent the surfactant p-isononylphenoxypoly(glycidol), substantially as disclosed in above-cited U.S. Pat. No. 5,340,564.[0278]
- In another related embodiment of the invention, a nanocrystalline drug/surface modifier complex prepared as described above is associated with an anionic or cationic cloud point modifier to increase the cloud point of the surface modifying agent, substantially as described in above-cited U.S. Pat. No. 5,298,262 (cationic or anionic surfactant as cloud point modifier), U.S. Pat. No. 5,336,507 (charged phospholipid as cloud point modifier), or U.S. Pat. No. 5,346,702 (non-ionic cloud point modifier).[0279]
- In another related embodiment of the invention, a nanocrystalline drug/surface modifier complex prepared as described above further comprises a cryoprotectant, for example a carbohydrate or sugar alcohol, in an amount sufficient to permit the nanoparticles to be lyophilized, substantially as described in above-cited U.S. Pat. No. 5,302,401. A preferred cryoprotectant of this embodiment is sucrose. The method of making nanoparticles having a surface modifier adsorbed on the surface thereof and a cryoprotectant associated therewith comprises contacting the nanoparticles with the cryoprotectant for a time and under conditions sufficient to permit lyophilization of the nanoparticles.[0280]
- In another related embodiment of the invention, drug nanoparticles having a surface modifying agent adsorbed on the surface thereof in an amount sufficient to maintain a weight average particle size of less than about 400 nm are prepared by a process comprising the steps of (a) dispersing the drug in a liquid dispersion medium wherein the drug is insoluble; and (b) grinding the medium (e.g., in a dispersion mill) in the presence of rigid grinding media, wherein pH of the medium is maintained within a range of about 2 to about 6, substantially as disclosed in above-cited U.S. Pat. No. 5,552,160.[0281]
- In another related embodiment of the invention, nanoparticles are prepared by a process comprising the steps of (a) providing a selective COX-2 inhibitory drug substance; (b) depyrogenating rigid grinding media, for example in an oven at about 200° C. to about 300° C. for about 6 to about 20 hours; mixing the drug substance and grinding media together and autoclaving at about 100° C. to about 150° C. for about 10 to about 60 minutes); and (c) adding a surface modifying agent (e.g., selected from polymers, low molecular weight oligomers, natural products and surfactants) to the resulting autoclaved drug substance followed by wet grinding to provide and maintain a weight average particle size of less than about 400 nm, substantially as disclosed in above-cited U.S. Pat. No. 5,534,270.[0282]
- In another related embodiment of the invention, nanoparticles are prepared by a process comprising contacting a selective COX-2 inhibitory drug with a surface modifying agent (e.g., by adding the drug to a liquid medium comprising the surface modifying agent and wet grinding in a dispersion mill) for a time and under conditions sufficient to provide and maintain a weight average particle size of less than about 400 nm, substantially as described in above-cited U.S. Pat. No. 5,429,824. In this embodiment the surface modifying agent is a nonionic liquid polymer of the alkylaryl polyether alcohol type, for example tyloxapol. Optionally an additional surface modifying agent can be present.[0283]
- In another related embodiment of the invention, nanoparticles are prepared by a process comprising the steps of (a) forming a premix of a selective COX-2 inhibitory drug and a surface modifier (e.g., selected from polymers, low molecular weight oligomers, surfactants, etc.) in a liquid dispersion medium (e.g., water, salt solution, ethanol, etc.); (b) transferring the premix to a microfluidizer having an interaction chamber capable of producing shear, impact, cavitation and attrition forces; (c) subjecting the premix to these forces at a temperature not exceeding about 40° C. and a fluid pressure of about 20,000 to about 200,000 kPa by passing the premix through the interaction chamber to reduce the particle size of the drug and to obtain a homogeneous slurry thereof; (d) collecting the slurry from the interaction chamber into a receiving tank; (e) reintroducing the slurry into the interaction chamber to further reduce particle size; and (f) repeating the collection and reintroduction steps until the weight average particle size of the drug is less than about 400 nm, substantially as disclosed in above-cited U.S. Pat. No. 5,510,118.[0284]
- In another related embodiment of the invention, nanoparticles are prepared by a process comprising the steps of (a) milling (e.g., in a dispersion mill), optionally in the presence of an oil, a selective COX-2 inhibitory drug in the presence of surface modifying agents (e.g., gelatin, casein, lecithin, polyvinylpyrrolidone, tyloxapol, poloxamers, other block polymers, etc.) substantially as disclosed in above-cited U.S. Pat. No. 5,560,931. In this embodiment, the drug particles have a non-crosslinked modifier adsorbed on the surface thereof, and are suspended in an aqueous phase which is emulsified in a continuous oil phase. Weight average particle size is less than about 1000 nm. The oil phase can be oleic acid, as disclosed in above-cited U.S. Pat. No. 5,571,536.[0285]
- In another related embodiment of the invention, nanoparticles are prepared by a process comprising the steps of (a) introducing a selective COX-2 inhibitory drug, a liquid medium, grinding media and a surface modifying agent into a grinding vessel; and (b) wet grinding to reduce the weight average particle size of the drug to less than about 1000 nm, substantially as disclosed in above-cited U.S. Pat. No. 5,565,188 (block copolymer as surface modifying agent containing one or more polyoxyethylene blocks and one or more polyoxy(higher alkylene) blocks wherein at least some of the blocks are linked together by an oxymethylene linking group) and U.S. Pat. No. 5,587,143 (block copolymer of ethylene oxide and butylene oxide as surface modifying agent).[0286]
- In another related embodiment of the invention, a composition is provided comprising selective COX-2 inhibitory drug nanoparticles having a block copolymer linked to at least one anionic group as a surface modifying agent adsorbed on the surface thereof. The composition is prepared by a process comprising the steps of (a) preparing the drug in particulate form, preferably at a particle size less than about 100 μm; (b) adding the drug to a liquid medium in which it is essentially insoluble to form a premix; and (c) subjecting the premix to mechanical means to reduce the average particle size in the premix to less than about 1000 nm, substantially as disclosed in above-cited U.S. Pat. No. 5,569,448. Preferably, the surface modifying agent is present in the premix.[0287]
- In another related embodiment of the invention, nanoparticles are prepared by a process comprising the steps of (a) adding a selective COX-2 inhibitory drug and a surface modifying agent (e.g., a steric stabilizer such as gelatin, casein, lecithin, gum acacia, cholesterol, tragacanth, sorbitan esters, polyethylene glycol, polyoxyethylene alkyl esters, polyoxyethylene stearates, etc.) to a liquid in which the drug is insoluble to form a premix, and (b) subjecting the premix to mechanical means (e.g., in a dispersion mill) to reduce average particle size to less than about 400 nm, substantially as disclosed in above-cited U.S. Pat. No. 5,573,783.[0288]
- In another related embodiment of the invention, nanoparticles are prepared by a process comprising the steps of (a) dispersing a selective COX-2 inhibitory drug and a surface active agent (e.g., poloxamers having a molecular weight of about 1,000 to about 15,000 daltons, polyvinyl alcohol, polyvinylpyrrolidone, hydroxypropylmethylcellulose, and polyoxyethylene sorbitan monooleate) in a liquid dispersion medium in which the drug is poorly soluble, then applying mechanical means (e.g., in a dispersion mill) to reduce drug particle size to less than about 400 nm, substantially as disclosed in above-cited U.S. Pat. No. 5,585,108.[0289]
- In another related embodiment of the invention, nanoparticles are prepared by a process comprising the steps of (a) adding a selective COX-2 inhibitory drug and hydroxypropylcellulose as a surface modifying agent to a liquid medium in which the drug is essentially insoluble to form a premix, and employing mechanical means (e.g., in a dispersion mill) to reduce drug particle size to less than about 1000 nm, preferably less than about 400 nm, substantially as disclosed in above-cited U.S. Patent No. 5,591,456.[0290]
- In another related embodiment of the invention, nanoparticles are prepared by a process as described herein that employs a surface modifying agent, the surface modifying agent being selected such that the resulting composition has a hydrophile-lipophile balance (HLB) of about 4 to about 9, substantially as disclosed in above-cited International Patent Publication No. WO 00/30615.[0291]
- In another particular embodiment of the invention, nanoparticles are prepared by a process comprising the steps of (a) mixing a selective COX-2 inhibitory drug with a support material, preferably a crosslinked, water-swellable polymer; (b) grinding the resulting mixture in a grinding chamber which is saturated with a solvent vapor (e.g., water, ethanol, isopropanol, chloroform, methanol, etc.); (c) drying the ground mixture under vacuum; and (d) sieving the dried ground mixture to eliminate any aggregates formed, substantially as disclosed in above-cited U.S. Pat. No. 5,354,560.[0292]
- In another particular embodiment of the invention, nanoparticles are prepared by a process comprising the steps of (a) forming a paste comprising (i) nanoparticles of a selective COX-2 inhibitory drug, (ii) at least one thickening or binding agent (e.g., selected from polypeptides, high molecular weight polymers, colloids, etc.) and/or extender, (iii) one or more stabilizing agents to prevent settling and/or rising to the surface of the nanoparticles, and (iv) a suitable amount of water to adjust viscosity; and (b) lyophilizing the paste, substantially as disclosed in above-cited U.S. Pat. No. 5,384,124.[0293]
- In another particular embodiment of the invention, nanoparticles are prepared by a process comprising the steps of (a) preparing a selective COX-2 inhibitory drug in particulate form, preferably at a particle size smaller than about 100 μm; (b) adding the prepared drug to a liquid medium (preferably comprising a surface modifying agent such as a hygroscopic sugar) in which the drug is essentially insoluble to form a premix; and (c) subjecting the premix to mechanical means to reduce the average particle size in the premix to less than about 1000 nm, substantially as disclosed in above-cited U.S. Pat. No. 5,518,738. Preferably, polyvinylpyrrolidone and/or a wetting agent, e.g., sodium lauryl sulfate, are also present in the premix. Compositions prepared by this process preferably have a film adsorbed on the surface of the nanoparticles comprising a polyvinylpyrrolidone, a hygroscopic sugar and sodium lauryl sulfate.[0294]
- In another particular embodiment of the invention, nanoparticles are prepared by a process comprising the steps of (a) co-solubilizing one or more polymeric constituents including, for example, a biodegradable polymer (e.g., polylactic acid, polyglycolic acid or co-polymers thereof, polyhydroxybutyric acid, polycaprolactone, polyorthoesters, etc.), a polysaccharide jellifying and/or bioadhesive polymer, and/or an amphiphilic polymer (e.g. polyethylene glycol, polyvinylpyrrolidone or polyvinyl alcohol) together with an agent modifying interface properties to form a polymer mixture, optionally in the presence of one or more solvents; (b) dissolving or suspending a selective COX-2 inhibitory drug in the polymer mixture; and (c) forming particles consisting of the polymers, the agent modifying the interface properties and the drug by a technique of emulsion, extrusion, spray drying or spray congealing, substantially as disclosed in above-cited U.S. Pat. No. 5,536,508. Nanoparticles prepared by this process preferably have a weight average particle size of about 0.1 μm to about 150 μm.[0295]
- In another particular embodiment of the invention, nanoparticles are prepared by a process comprising the steps of (a) preparing a solution of a selective COX-2 inhibitory drug in a water-miscible organic solvent; (b) infusing an aqueous precipitating liquid (e.g., water, solution of mineral salt, or surfactant solution) into the solution to produce a suspension of precipitated, amorphous, solid drug in the form of non-aggregated particles; and (c) separating the particles from the precipitating liquid and washing in an aqueous washing liquid, substantially as disclosed in above-cited U.S. Pat. No. 4,826,689.[0296]
- In another particular embodiment of the invention, nanoparticles are prepared by a process comprising the steps of (a) dissolving a selective COX-2 inhibitory drug in an aqueous base (e.g., NaOH, KOH, CsOH, etc.) with stirring to form a solution; (b) adding a surface modifier (e.g., various polymers, surfactants, low molecular weight oligomers, etc.) to form a clear solution; and (c) neutralizing the clear solution with stirring and with an appropriate acid solution (e.g., HCl, HNQ[0297]3, HClO4, H2SO4, formic acid, propionic acid, acetic acid, butyric acid, etc.), substantially as disclosed in above-cited U.S. Pat. Nos. 5,560,932 and No. 5,580,579.
- In another related embodiment of the invention, nanoparticles are prepared by a process comprising the steps of (a) dissolving a selective COX-2 inhibitory drug in a liquid medium base (e.g., NaOH, KOH, CsOH, trialkylamines, pyridine, etc.) comprising a non-toxic solvent in which the drug is poorly soluble to form a solution; (b) adding an aqueous solution of one or more surface modifying agents (e.g., anionic or nonionic surfactants, polymeric or oligomeric substances); and (c) neutralizing the resulting alkaline solution with an acid (e.g., HCl, HNO[0298]3, HC104, H2SO4, formic acid, propionic acid, acetic acid, butyric acid, etc.), to form a dispersion, preferably having a Z-average particle diameter of less than about 100 nm as measured by photon correlation spectroscopy, substantially as disclosed in above-cited U.S. Pat. No. 5,662,883.
- In another related embodiment of the invention, nanoparticles are prepared by a process comprising the steps of (a) dissolving a selective COX-2 inhibitory drug and a crystal growth modifier (i.e., a compound that is substantially isostructural to the drug) in an aqueous base (e.g., NaOH, KOH, CsOH, trialkylamines, pyridine, etc.) to form a solution; (b) adding an aqueous solution of one or more surface modifying agents (e.g., a mixture of anionic surfactant, nonionic surfactant, polymeric substance and oligomeric substance); and neutralizing the resulting alkaline solution with an acid (e.g., HCl, HNO[0299]3, HCl04, H2SO4, formic acid, propionic acid, acetic acid, butyric acid, etc.), to form a dispersion, preferably wherein the drug particles have a Z-average particle diameter of less than about 400 nm as measured by photon correlation spectroscopy, substantially as disclosed in above-cited U.S. Pat. No. 5,665,331.
- In another particular embodiment of the invention, nanoparticles having a weight average particle size of less than about 400 nm are prepared from a dispersion comprising a first particle distribution of a selective COX-2 inhibitory drug together with a surface modifying agent such as polysulfated tyloxapol by a process comprising the steps of (a) placing the dispersion between a first electrode and a second electrode; and (b) removing a portion of the dispersion at a position between the first electrode and the second electrode, this portion of the dispersion having a second particle size distribution that is smaller than the first particle distribution, substantially as disclosed in above-cited U.S. Pat. No. 5,503,723.[0300]
- In another particular embodiment of the invention, nanoparticles having a weight average particle size of up to about 300 nm are prepared by a process comprising the steps of (a) dissolving a selective COX-2 inhibitory drug in a solvent to form a solution; and (b) spraying the solution into a liquefied gas or supercritical fluid in presence of a surface modifying agent dispersed or dissolved in an aqueous phase, substantially as disclosed in above-cited International Patent Publication No. WO 97/14407.[0301]
- In another related embodiment of the invention, nanoparticles having a weight average particle size of up to about 300 nm are prepared by a process comprising the steps of (a) dissolving a selective COX-2 inhibitory drug in a liquefied gas or supercritical fluid to form a solution; (b) preparing an aqueous phase containing a surface modifying agent; and (c) spraying the solution into the aqueous phase, substantially as disclosed in the same above-cited International Patent Publication No. Wo 97/14407.[0302]
- Patent and other literature relating to drug nanoparticle compositions teaches that, in general, the smaller the drug particle size, the greater is the advantage in speed of onset of therapeutic effect, or other pharmacodynamic benefit, obtained upon oral administration. For example, at least the following patents propose reduction of particle size to about 400 nm or smaller.[0303]
- Above-cited U.S. Pat. No. 5,145,684.[0304]
- Above-cited U.S. Pat. No. 5,298,262.[0305]
- Above-cited U.S. Pat. No. 5,302,401.[0306]
- Above-cited U.S. Pat. No. 5,336,507.[0307]
- Above-cited U.S. Pat. No. 5,340,564.[0308]
- Above-cited U.S. Pat. No. 5,346,702.[0309]
- Above-cited U.S. Pat. No. 5,352,459.[0310]
- Above-cited U.S. Pat. No. 5,429,824.[0311]
- Above-cited U.S. Pat. No. 5,503,723.[0312]
- Above-cited U.S. Pat. No. 5,510,118.[0313]
- Above-cited U.S. Pat. No. 5,534,270.[0314]
- Above-cited U.S. Pat. No. 5,552,160.[0315]
- Above-cited U.S. Pat. No. 5,573,783.[0316]
- Above-cited U.S. Pat. No. 5,585,108.[0317]
- Above-cited U.S. Pat. No. 5,591,456.[0318]
- Above-cited U.S. Pat. No. 5,662,883.[0319]
- Above-cited U.S. Pat. No. 5,665,331.[0320]
- In general, however, the smaller the drug particle size, the more grinding or milling time, energy and labor is required to produce the particles and consequently, the more costly and less efficient is the process. Thus, smaller nano-sized drug particles are generally significantly more expensive and labor-intensive to produce in quantity than larger nano-sized drug particles.[0321]
- Surprisingly, we discovered that a selective COX-2 inhibitory drug composition having a weight average particle size of about 450 nm to about 1000 nm (referred to herein as a “sub-micron” formulation and particle size) exhibits onset time and bioavailability substantially equal to that of a comparative composition having a weight average particle size of about 200 to about 400 nm, as measured in vitro and in vivo. The sub-micron formulation requires less milling time and energy than the formulation comprising smaller nanoparticles with a weight average particle size in the 200-400 nm range.[0322]
- It is further contemplated that certain advantages in addition to cost saving are obtainable with sub-micron as opposed to smaller particle sizes. For example, in situations where ultra-fine particles tend to agglomerate or fail to disperse in the body fluid, the slightly larger sub-micron particles can exhibit enhanced dispersion.[0323]
- Accordingly, in a particularly preferred embodiment of the present invention, there is provided a pharmaceutical composition comprising a selective COX-2 inhibitory drug of low water solubility in a therapeutically effective amount, wherein the drug is present in solid particles having a D[0324]25particle size of about 450 nm to about 1000 nm, and more preferably about 500 nm to about 900 nm, the composition providing at least a substantially similar Cmaxand/or at most a substantially similar Tmaxby comparison with an otherwise similar composition having a D25particle size of less than 400 nm, and/or providing a substantially greater Cmaxand/or a substantially shorter Tmaxby comparison with an otherwise similar composition having a D25particle size larger than 1000 nm.
- There is also provided a pharmaceutical composition comprising a selective COX-2 inhibitory drug of low water solubility in a therapeutically effective amount, wherein the drug is present in solid particles, about 25% to 100% by weight of which have a particle size of about 450 nm to about 1000 nm, more preferably about 500 nm to about 900 nm.[0325]
- There is also provided a pharmaceutical composition comprising a selective COX-2 inhibitory drug of low water solubility in a therapeutically effective amount, wherein the drug is present in solid particles having a weight average particle size of about 450 nm to about 1000 nm, and more preferably about 500 nm to about 900 nm, the composition providing at least a substantially similar C[0326]maxand/or at most a substantially similar Tmaxby comparison with an otherwise similar composition having a weight average particle size of less than 400 nm, and/or providing a substantially greater Cmaxand/or a substantially shorter Tmaxby comparison with an otherwise similar composition having a weight average particle size larger than 1000 nm. For purposes of this description, “weight average particle size” can be considered synonymous with D50particle size.
- One of ordinary skill in the art will readily adapt the processes therein described to the preparation of a poorly water soluble selective cyclooxygenase-2 inhibitory drug, for example celecoxib, deracoxib, valdecoxib, rofecoxib, etoricoxib, 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-1-one and 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3-(2H)-pyridazinone in form of nanoparticles.[0327]
- In a particular illustrative embodiment of the present invention, the ophthalmic composition comprises an aqueous suspension of a selective COX-2 inhibitory drug of low water solubility, wherein preferably the drug is present predominantly or substantially entirely in form of nanoparticles Without being bound by theory, it is believed that release of the drug from nanoparticles is significantly faster than from a typical “micronized” composition having a D[0328]90particle size of, for example, about 10 μm or greater.
- An aqueous suspension composition of the invention can comprise a first portion of the drug in form of nanoparticles, to promote relatively rapid release, and a second portion of the drug having a D[0329]90particle size of about 10 μm or greater, that can provide a depot or reservoir of the drug in the treated eye for release over a period of time, for example about 2 to about 24 hours, more typically about 2 to about 12 hours, to promote sustained therapeutic effect and permit a reduced frequency of administration.
- An aqueous suspension can contain one or more polymers as suspending agents. Useful polymers include water-soluble polymers such as cellulosic polymers, e.g., hydroxypropyl methylcellulose, and water-insoluble polymers such as cross-linked carboxyl-containing polymers.[0330]
- In a particular embodiment the composition is an in situ gellable aqueous solution, suspension or solution/suspension having excipients substantially as disclosed in above-cited U.S. Pat. No. 5,192,535, comprising about 0.1% to about 6.5%, preferably about 0.5% to about 4.5%, by weight, based on the total weight of the composition, of one or more cross-linked carboxyl-containing polymers. Such an aqueous suspension is preferably sterile and has an osmolality of about 10 to about 400 mOsM, preferably about 100 to about 250 mOsM, a pH of about 3 to about 6.5, preferably about 4 to about 6, and an initial viscosity, when administered to the eye, of about 1000 to about 30,000 cPs, as measured at 25° C. using a Brookfield Digital LVT viscometer with #25 spindle and 13R small sample adapter at 12 rpm. More typically the initial viscosity is about 5000 to about 20,000 cPs. The polymer component has an average particle size not greater than about 50 μm, preferably not greater than about 30 μm, more preferably not greater than about 20 μm, and most preferably about 1 μm to about 5 μm, in equivalent spherical diameter, and is lightly cross-linked to a degree such that, upon contact with tear fluid in the eye, which has a typical pH of about 7.2 to about 7.4, the viscosity of the suspension rapidly increases, to form a gel. This formation of a gel enables the composition to remain in the eye for a prolonged period without loss by lacrimal drainage.[0331]
- Preferred carboxyl-containing polymers for use in this embodiment are prepared from one or more carboxyl-containing monoethylenically unsaturated monomers such as acrylic, methacrylic, ethacrylic, crotonic, angelic, tiglic, α-butylcrotonic, α-phenylacrylic, α-benzylacrylic, α-cyclohexylacrylic, cinnamic, coumaric and umbellic acids, most preferably acrylic acid. The polymers are cross-linked by using less than about 5%, preferably about 0.1% to about 5%, more preferably about 0.2% to about 1%, by weight of one or more polyfunctional cross-linking agents such as non-polyalkenyl polyether difunctional cross-linking monomers, e.g., divinyl glycol. Other suitable cross-linking agents illustratively include 2,3-dihydroxyhexa-1,5-diene, 2,5-dimethylhexa-1,5-diene, divinylbenzene, N,N-diallylacrylamide and N,N-diallylmethacrylamide. Divinyl glycol is preferred. Polyacrylic acid cross-linked with divinyl glycol is called polycarbophil. A polymer system containing polycarbophil is commercially available under the trademark DuraSite® of InSite Vision Inc., Alameda, Calif., as a sustained-release topical ophthalmic delivery system.[0332]
- A composition of this embodiment can be prepared by a procedure substantially as disclosed in above-cited U.S. Pat. No. 5,192,535. One of skill in the art will readily modify such procedure as appropriate for incorporation of a selective COX-2 inhibitory drug in accordance with the present invention.[0333]
- In another particular embodiment the composition is an in situ gellable aqueous solution, suspension or solution/suspension having excipients substantially as disclosed in above-cited U.S. Pat. No. 4,861,760, comprising about 0.1% to about 2% by weight of a polysaccharide that gels when it contacts an aqueous medium having the ionic strength of tear fluid. A preferred polysaccharide is gellan gum. A composition of this embodiment can be prepared by a procedure substantially as disclosed in above-cited U.S. Pat. No. 4,861,760. One of skill in the art will readily modify such procedure as appropriate for incorporation of a selective COX-2 inhibitory drug in accordance with the present invention.[0334]
- In another particular embodiment the composition is an in situ gellable aqueous solution, suspension or solution/suspension having excipients substantially as disclosed in above-cited U.S. Pat. No. 5,587,175, comprising about 0.2% to about 3%, preferably about 0.5% to about 1%, by weight of a gelling polysaccharide, preferably selected from gellan gum, alginate gum and chitosan, and about 1% to about 50% of a water-soluble film-forming polymer, preferably selected from alkylcelluloses (e.g., methylcellulose, ethylcellulose), hydroxyalkylcelluloses (e.g., hydroxyethylcellulose, hydroxypropyl methylcellulose), hyaluronic acid and salts thereof, chondroitin sulfate and salts thereof, polymers of acrylamide, acrylic acid and polycyanoacrylates, polymers of methyl methacrylate and 2-hydroxyethyl methacrylate, polydextrose, cyclodextrins, polydextrin, maltodextrin, dextran, polydextrose, gelatin, collagen, natural gums (e.g., xanthan, locust bean, acacia, tragacanth and carrageenan gums and agar), polygalacturonic acid derivatives (e.g., pectin), polyvinyl alcohol, polyvinylpyrrolidone and polyethylene glycol. The composition can optionally contain a gel-promoting counterion such as calcium in latent form, for example encapsulated in gelatin. A composition of this embodiment can be prepared by a procedure substantially as disclosed in above-cited U.S. Pat. No. 5,587,175. One of skill in the art will readily modify such procedure as appropriate for incorporation of a selective COX-2 inhibitory drug in accordance with the present invention.[0335]
- In another particular embodiment the composition is an in situ gellable aqueous solution, suspension or solution/suspension having excipients substantially as disclosed in European Patent No. 0 424 043, comprising about 0.1% to about 5% of a carrageenan gum. Carrageenans are sulfated polysaccharides; in this embodiment a carrageenan having no more than 2 sulfate groups per repeating disaccharide unit is preferred, including kappa-carrageenan, having 18-25% ester sulfate by weight, iota-carrageenan, having 25-34% ester sulfate by weight, and mixtures thereof. A composition of this embodiment can be prepared by a procedure substantially as disclosed in above-cited European Patent No. 0 424 043. One of skill in the art will readily modify such procedure as appropriate for incorporation of a selective COX-2 inhibitory drug in accordance with the present invention.[0336]
- An exemplary formulation of the invention is an ophthalmic suspension of nanoparticles of valdecoxib comprising from about 0.01% to about 50% of valdecoxib, more preferably from about 0.1% to about 20% of valdecoxib, for example from about 0.1% to about 5% of valdecoxib; from about 0.05% to about 10% of carrageenan, preferably from about 0.1% to about 10% of carrageenan, for example from about 0.25% to about 8% of carrageenan and from about 0.5% to about 20% of hydroxypropyl γ-cyclodextrin, preferably from about 1% to about 10% g of hydroxypropyl β-cyclodextrin, for example from about 2% to about 6% of hydroxypropyl β-cyclodextrin (amounts are expressed as % by weight). In another particular embodiment of the invention the composition comprises xanthan gum substantially as disclosed in U.S. Pat. No. 6,174,524.[0337]
- In another particular embodiment the composition comprises an ophthalmically acceptable mucoadhesive polymer, selected for example from carboxymethylcellulose, carbomer (acrylic acid polymer), poly(methylmethacrylate), polyacrylamide, polycarbophil, acrylic acid/butyl acrylate copolymer, sodium alginate and dextran.[0338]
- In another embodiment of the invention, the selective COX-2 inhibitory drug is solubilized at least in part by an ophthalmically acceptable solubilizing agent. The term “solubilizing agent” herein includes agents that result in formation of a micellar solution or a true solution of the drug. Certain ophthalmically acceptable nonionic surfactants, for[0339]
example polysorbate 80, can be useful as solubilizing agents, as can ophthalmically acceptable glycols, polyglycols, e.g., polyethylene glycol 400, and glycol ethers. - A class of solubilizing agents having particular utility in solution and solution/suspension compositions of the invention is the cyclodextrins. Suitable cyclodextrins can be selected from α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, alkylcyclodextrins (e.g., methyl-β-cyclodextrin, dimethyl-β-cyclodextrin, diethyl-β-cyclodextrin), hydroxyalkylcyclodextrins (e.g., hydroxyethyl-β-cyclodextrin, hydroxypropyl-β-cyclodextrin), carboxyalkylcyclodextrins (e.g., carboxymethyl-β-cyclodextrin), sulfoalkylether cyclodextrins (e.g., sulfobutylether-β-cyclodextrin), and the like. Ophthalmic applications of cyclodextrins have been reviewed by Rajewski & Stella (1996),[0340]Journal of Pharmaceutical Sciences,85, 1154, at pages 1155-1159. If desired, complexation of a selective COX-2 inhibitory drug by a cyclodextrin can be increased by addition of a water-soluble polymer such as carboxymethylcellulose, hydroxypropyl methylcellulose or polyvinylpyrrolidone, as described by Loftsson (1998),Pharmazie,53, 733-740.
- One or more ophthalmically acceptable pH adjusting agents and/or buffering agents can be included in a composition of the invention, including acids such as acetic, boric, citric, lactic, phosphoric and hydrochloric acids; bases such as sodium hydroxide, sodium phosphate, sodium borate, sodium citrate, sodium acetate, sodium lactate and tris-hydroxymethylaminomethane; and buffers such as citrate/dextrose, sodium bicarbonate and ammonium chloride. Such acids, bases and buffers are included in an amount required to maintain pH of the composition in an ophthalmically acceptable range.[0341]
- The composition of the present invention preferably includes at least one ophthalmically acceptable salt, sugar and/or sugar alcohol in an amount required to bring osmolality of the composition into an ophthalmically acceptable range. Salts suitable for use in the composition include those having sodium, potassium or ammonium cations and chloride, citrate, ascorbate, borate, phosphate, bicarbonate, sulfate, thiosulfate or bisulfite anions; particularly preferred salts include sodium chloride, potassium chloride, sodium thiosulfate, sodium bisulfite and ammonium sulfate, with sodium chloride being especially preferred. Sugars and sugar alcohols suitable for use in the composition include mannitol, dextrose and lactose, glycerol, sorbitol and mannitol; preferred sugars and sugar alcohols include mannitol and dextrose.[0342]
- The composition optionally includes at least one ophthalmically acceptable acid having at least two dissociable hydrogen as interactive agents to retard release of the drug through inhibition of erosion of the polymer, as disclosed in above-cited International Patent Publication No. WO 95/03784. Acids useful as interactive agents include boric, lactic, orthophosphoric, citric, oxalic, succinic, tartaric and formic glycerophosphoric acids.[0343]
- The composition optionally includes an ophthalmically acceptable xanthine derivative such as caffeine, theobromine or theophylline, substantially as disclosed in above-cited U.S. Pat. No. 4,559,343, to reduce ocular discomfort associated with administration of the composition.[0344]
- Optionally, one or more ophthalmically acceptable preservatives are included in the composition to inhibit microbial activity. Suitable preservatives include mercury-containing substances such as merfen and thiomersal; stabilized chlorine dioxide; and quaternary ammonium compounds such as benzalkonium chloride, cetyltrimethylammonium bromide and cetylpyridinium chloride.[0345]
- Optionally, one or more ophthalmically acceptable surfactants, preferably nonionic surfactants are included in the composition to enhance physical stability or for other purposes. Suitable nonionic surfactants include polyoxyethylene fatty acid glycerides and vegetable oils, e.g., polyoxyethylene (60) hydrogenated castor oil; and polyoxyethylene alkylethers and alkylphenyl ethers, e.g.,[0346]
octoxynol 10,octoxynol 40. - Optionally, one or more antioxidants are included in the composition to enhance chemical stability where required. Suitable antioxidants include ascorbic acid and sodium metabisulfite.[0347]
- One or more ophthalmic lubricating agents are optionally included in the composition to promote lacrimation or as a “dry eye” medication. Such agents include polyvinyl alcohol, methylcellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, etc.[0348]
- Compositions of the invention are preferably used in co-therapy with one or more drugs other than selective COX-2 inhibitory drugs. Such drugs other than COX-2 inhibitory drugs can be co-administered topically to the eye together with a composition of the invention. A composition of the invention preferably further comprises, in co-formulation with a first drug that is a selective COX-2 inhibitory drug as described herein, a therapeutically and/or prophylactically effective amount of a second drug that is other than a selective COX-2 inhibitory drug. This second drug cooperates with the first drug in treating and/or preventing a COX-2 mediated ophthalmic condition, or it can be used to treat a related or unrelated condition simultaneously affecting the eye.[0349]
- Any drug having utility as a topical ophthalmic application can be used in co-therapy, co-administration or co-formulation with a composition of the invention as described immediately above. Such drugs include without limitation demulcents; antibiotics, antivirals and other anti-infectives; steroids, NSAIDs and other anti-inflammatory agents; acetylcholine blocking agents; antiglaucoma agents including beta-adrenergic receptor blocking agents, carbonic anhydrase inhibitors and prostaglandins; antihypertensives; antihistamines; anticataract agents; and topical and regional anesthetics. Illustrative specific drugs include acebutolol, aceclidine, acetylsalicylic acid (aspirin), N[0350]4acetylsulfisoxazole, alclofenac, alprenolol, amfenac, amiloride, aminocaproic acid, p-aminoclonidine, aminozolamide, anisindione, apafant, atenolol, bacitracin, benoxaprofen, benoxinate, benzofenac, bepafant, betamethasone, betaxolol, bethanechol, bimatoprost brimonidine, bromfenac, bromhexine, bucloxic acid, bupivacaine, butibufen, carbachol, carprofen, cephalexin, chloramphenicol, chlordiazepoxide, chlorprocaine, chlorpropamide, chlortetracycline, cicloprofen, cinmetacin, ciprofloxacin, clidanac, clindamycin, clonidine, clonixin, clopirac, cocaine, cromolyn, cyclopentolate, cyproheptadine, demecarium, dexamethasone, dibucaine, diclofenac, diflusinal, dipivefrin, dorzolamide, enoxacin, eperezolid, epinephrine, erythromycin, eserine, estradiol, ethacrynic acid, etidocaine, etodolac, fenbufen, fenclofenac, fenclorac, fenoprofen, fentiazac, flufenamic acid, flufenisal, flunoxaprofen, fluorocinolone, fluorometholone, flurbiprofen and esters thereof, fluticasone propionate, furaprofen, furobufen, furofenac, furosemide, gancyclovir, gentamycin, gramicidin, hexylcaine, homatropine, hydrocortisone, ibufenac, ibuprofen and esters thereof, idoxuridine, indomethacin, indoprofen, interferons, isobutylmethylxanthine, isofluorophate, isoproterenol, isoxepac, ketoprofen, ketorolac, labetolol, lactorolac, latanoprost, levobunolol, lidocaine, linezolid, lonazolac, loteprednol, meclofenamate, medrysone, mefenamic acid, mepivacaine, metaproterenol, methanamine, methylprednisolone, metiazinic, metoprolol, metronidazole, minopafant, miroprofen, modipafant, nabumetome, nadolol, namoxyrate, naphazoline, naproxen and esters thereof, neomycin, nepafenac, nitroglycerin, norepinephrine, norfloxacin, nupafant, olfloxacin, olopatadine, oxaprozin, oxepinac, oxyphenbutazone, oxyprenolol, oxytetracycline, penicillins, perfloxacin, phenacetin, phenazopyridine, pheniramine, phenylbutazone, phenylephrine, phenylpropanolamine, phospholine, pilocarpine, pindolol, pirazolac, piroxicam, pirprofen, polymyxin, polymyxin B, prednisolone, prilocaine, probenecid, procaine, proparacaine, protizinic acid, rimexolone, salbutamol, scopolamine, sotalol, sulfacetamide, sulfanilic acid, sulindac, suprofen, tenoxicam, terbutaline, tetracaine, tetracycline, theophyllamine, timolol, tobramycin, tolmetin, travoprost, triamcinolone, trimethoprim, trospectomycin, isopropyl unoprostone, vancomycin, vidarabine, vitamin A, warfarin, zomepirac and pharmaceutically acceptable salts thereof.
- In an especially preferred embodiment, a composition of the invention is administered in co-therapy or co-formulation with a prostaglandin capable of reducing the intraocular pressure and/or treating glaucoma. Preferably, the prostaglandin is a derivative of native prostaglandin F[0351]2α modified in its omega chain to reduce side effects such a ocular irritation and hyperemia and modified in its alpha chain to improve topical delivery to the cornea. Useful such prostaglandins are described in the patents listed below, each of which is individually incorporated herein by reference.
- U.S. Pat. No. 5,422,368.[0352]
- U.S. Pat. No. 5,001,153.[0353]
- U.S. Pat. No. 5,515,444.[0354]
- U.S. Pat. No. 5,510,383.[0355]
- U.S. Pat. No. 5,665,773.[0356]
- U.S. Pat. No. 5,889,052.[0357]
- U.S. Pat. No. 5,352,708.[0358]
- U.S. Pat. No. 5,607,978.[0359]
- U.S. Pat. No. 5,658,897.[0360]
- U.S. Pat. No. 5,688,819.[0361]
- U.S. Pat. No. 5,834,498.[0362]
- U.S. Pat. No. 5,972,991.[0363]
- U.S. Pat. No. 6,037,364.[0364]
- U.S. Pat. No. 6,124,344.[0365]
- U.S. Pat. No. 6,160,129.[0366]
- U.S. Pat. No. 6,204,287.[0367]
- For example, intraocular pressure reducing prostaglandin derivatives such as latanoprost, travoprost, isopropyl unoprostone and bimatoprost are especially useful. The co-therapy or co-formulation has utility for any of the COX-2 mediated disorders outlined above, in conjunction with glaucoma and/or intraocular hypertension treatment associated with prostaglandins. In addition, co-therapy or co-administration of a selective cyclooxygenase-2 inhibitory drug with a prostaglandin has use in reducing or eliminating side effects that may appear from ocular prostaglandin therapy including, but not limited to, increased iridial pigmentation, disruption of the blood aqueous barrier and cystoid macular edema. Further, the co-therapy or co-administration of a selective cyclooxygenase-2 inhibitory drug and a prostaglandin is of advantage by enabling the extension of a glaucoma or intraocular hypertension prostaglandin treatment to patients suffering from a COX-2 mediated complication during which prostaglandin therapy would otherwise be set out or conducted in conjunction with steroids. Co-therapy or co-administration of a selective cyclooxygenase-2 inhibitory drug and a prostaglandin is also useful in surgical adjunct therapy in connection with eye surgery, e.g., cataract or corneal transplant surgery. This enables or improves glaucoma treatment also in eyes suffering from inflammatory process or trauma, such as cataract surgery, see K Miyake et al Arch. Ophthalmol. 1999, Vol. 117, pages 34-40. The mentioned co-therapy or co-administration is also useful for potentiating the delivery of selective cyclooxygenase-2 inhibitory drugs to exert their activity in the posterior parts of the eye including the region of the optical nerve head. Such delivery enhancing effects of prostagladins have been reported for verapamil in U.S. Pat. No. 5,952,378.[0368]
- Compositions of the present invention can be prepared by methods known in the art and described in patents and publications cited herein and incorporated herein by reference.[0369]
- Aqueous suspension compositions of the invention can be packaged in single-dose non-reclosable containers. Such containers can maintain the composition in a sterile condition and thereby eliminate need for preservatives such as mercury-containing preservatives, which can sometimes cause irritation and sensitization of the eye. Alternatively, multiple-dose reclosable containers can be used, in which case it is preferred to include a preservative in the composition.[0370]
- Formulations of the invention are contemplated to be useful for any drug, of low water solubility, for which ophthalmic administration is desired. Hence, nanoparticle compositions, of any drug of low water solubility, can be formulated substantially as described for selective cyclooxygenase-2 inhibitory drugs herein above. Accordingly, the present invention provides a pharmaceutical composition suitable for topical administration to an eye, the composition comprising nanoparticles of a drug of low water solubility in a concentration effective for treatment and/or prophylaxis of a disorder in the eye, and one or more ophthalmically acceptable excipients that reduce rate of removal of the composition from the eye by lacrimation such that the composition has an effective residence time in the eye of about 2 to about 24 hours.[0371]
- The present invention, while not limited thereto, will be further illustrated by the following example.[0372]
- Oral and ophthalmic suspensions of valdecoxib nanoparticles were prepared. The oral nanoparticle suspension formulation contained unlabeled valdecoxib in a concentration of 0.5 mg/g and 2% povidone and 0.15% sodium dodecyl sulfate as vehicle components. The ophthalmic oral nanoparticle suspension formulation contained labeled [[0373]13C6] valdecoxib in a concentration of 2.15 mg/g and 1.2% glycerin, 0.8% EDTA.2Na.2H2O, 4.0% hydroxypropyl β-cyclodextrin (HPBCD), 0.4% carrageenan (Gelcarin™ GP-379NF,FMC Biopolymer, USA), 0.21% carrageenan (SeaSpen™ PF, FMC Biopolymer, USA) and 0.8% povidone. The formulations are shown in Table 1 below. The two carrageenan excipients are both ι-carrageenans with slightly different chemical and physical properties.
TABLE 1 Vehicle Assay Formulation Components (mg/g ± SD) 0.5 mg/ g 2% Povidone 0.477 ± 0.009 Valdecoxib 0.15% Sodium Dodecyl Sulfate 2.5 mg/g [13C6] 1.2% Glycerin 2.15 ± 0.03 Valdecoxib 0.8% EDTA.2Na.2H2O 4.0% HPBCD 0.4% Gelcarin ™ 0.21% Seaspen ™ 0.8% Povidone - Eighteen male New Zealand white rabbits weighing from 1.8-2.5 kg were provided as test animals and divided into three lots containing six rabbits each. Each of the animals received a single bolus oral dose of unlabeled valdecoxib, in an amount of 0.5 mg/kg of body weight, in the form of the oral unlabeled formulation via gastric intubation. Each of the rabbits also received about 0.1 mg of valdecoxib by applying a single ocular dose of 25 μL of the labeled ophthalmic formulation to each eye of the animal using a 0.5 cc syringe with an attached feeding tube.[0374]
- A first lot of rabbits was sacrificed 0.5 hours after the administration of the oral and ophthalmic formulations of the valdecoxib, a second lot of rabbits was sacrificed two hours after the drug administration and a third lot of rabbits was sacrificed four hours after the drug administration. Selected eye tissues, aqueous humor, bulbar conjunctiva, cornea, eyelids, vitreous humor and sclera, were excised at the time of sacrifice, weighed directly into tared vials, solubilized and/or diluted as necessary, and analyzed by HPLC-MS. Just prior to sacrifice, 0.5 mL of a blood sample was collected from the ear central artery via a syringe, placed into a K[0375]2-EDTA vacutainer, mixed gently and stored on ice up to one hour prior to centrifuging to separate the plasma. The plasma was stored at −10° C. or colder until analysis.
- The plasma and eye tissue samples were analyzed by LC-MS and the results are shown in FIGS.[0376]1-3. FIG. 1 is a graph illustrating the pharmacokinetic results of ocular and oral delivery of the valdecoxib formulations plotted as the concentration of the drug in the conjunctiva versus time. As illustrated in FIG. 1, the ocular delivery of the drug achieved a much higher initial concentration of valdecoxib and maintained this higher concentration over time.
- FIG. 2 is a graph illustrating the valdecoxib concentration in the conjunctiva, cornea, aqueous humor and plasma four hours after oral administration and FIG. 3 is a graph illustrating the valdecoxib concentration in the conjunctiva, cornea, aqueous humor and plasma four hours after ocular administration of valdecoxib.[0377]
- As shown in FIGS. 2 and 3, ocular administration of the valdecoxib is much more effective in delivering the drug to the eye than oral administration and yet avoids the high systemic (plasma) concentration of the drug that accompanies oral delivery.[0378]
Claims (40)
1. A pharmaceutical composition suitable for topical administration to an eye, the composition comprising a selective COX-2 inhibitory drug or a salt or prodrug thereof in a concentration effective for treatment and/or prophylaxis of a COX-2 mediated disorder in the eye, and at least one ophthalmically acceptable excipient ingredient that reduce rate of removal of the composition from the eye by lacrimation such that the composition has an effective residence time in the eye of about 2 to about 24 hours.
2. The composition ofclaim 1 wherein the selective COX-2 inhibitory drug is of low water solubility.
3. The composition ofclaim 1 wherein the selective COX-2 inhibitory drug is a compound having the formula:
where R3 is a methyl, amino or imide group, R4 is hydrogen or a C1-4 alkyl or alkoxy group, X is N or CR5 where R5 is hydrogen or halogen, and Y and Z are independently carbon or nitrogen atoms defining adjacent atoms of a five- to six-membered ring that is unsubstituted or substituted at one or more positions with oxo, halo, methyl or halomethyl groups; or a prodrug of such a compound.
4. The composition ofclaim 3 wherein the five- to six-membered ring is a ring selected from the group consisting of: cyclopentenone, furanone, methylpyrazole, isoxazole, and a pyridine ring substituted at no more than one position.
5. The composition ofclaim 1 wherein the selective COX-2 inhibitory drug is selected from the group consisting of: celecoxib; deracoxib; valdecoxib; rofecoxib; etoricoxib; 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-1-one; (S)-6,8-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid; and 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3-(2H)-pyridazinone.
6. The composition ofclaim 1 that is in a form selected from the group consisting of: solutions; suspensions and solution/suspensions that are gellable in situ upon placement in the eye; ointments; and solid articles suitable for ocular implant.
7. The composition ofclaim 1 that is an in situ gellable solution, suspension or solution/suspension having ophthalmically compatible pH and osmolality.
8. The composition ofclaim 7 that comprises about 0.01% to about 50% weight/volume of the selective COX-2 inhibitory drug.
9. The composition ofclaim 7 that comprises about 0.1% to about 20% weight/volume of the selective COX-2 inhibitory drug.
10. The composition ofclaim 7 that is a suspension or solution/suspension wherein the selective COX-2 inhibitory drug is present predominantly as nanoparticles.
11. The composition ofclaim 10 wherein average particle size of the drug is about 500 to about 900 nm.
12. The composition ofclaim 7 that (a) comprises about 0.1% to about 6.5% by weight of one or more lightly cross-linked carboxyl-containing polymers, (b) has a pH of about 3 to about 6.5 and an initial viscosity, when administered to the eye, of about 1000 to about 30,000 cPs, and (c) gels on contact with tear fluid having a pH of about 7.2 to about 7.4.
13. The composition ofclaim 12 wherein the carboxyl-containing polymer is polycarbophil.
14. The composition ofclaim 7 that comprises about 0.1% to about 2% by weight of a polysaccharide that gels when it contacts an aqueous medium having the ionic strength of tear fluid.
15. The composition ofclaim 14 wherein the polysaccharide is gellan gum.
16. The composition ofclaim 7 that comprises about 0.2% to about 3% by weight of a polysaccharide that gels on contact with calcium ions, and about 1% to about 50% of a water-soluble film-forming polymer.
17. The composition ofclaim 16 wherein the polysaccharide is selected from gellan gum, alginate gum, xanthan gum and chitosan.
18. The composition ofclaim 7 that comprises an ophthalmically acceptable mucoadhesive polymer.
19. The composition ofclaim 7 that is a solution or solution/suspension wherein the selective COX-2 inhibitory drug is solubilized at least in part by an ophthalmically acceptable solubilizing agent.
20. The composition ofclaim 19 wherein the solubilizing agent is a cyclodextrin.
21. The composition ofclaim 19 wherein the solubilizing agent is polyethylene glycol.
22. The composition ofclaim 10 comprising from about 0.01% to about 50% by weight of valdecoxib, from about 0.05% to about 10% by weight of carrageenan, and from about 0.5% to about 20% by weight of hydroxypropyl β-cyclodextrin.
23. A method of treating and/or preventing a COX-2 mediated disorder in an eye of a mammalian subject, the method comprising administering in each of one or more topical applications to the eye a therapeutically or prophylactically effective amount of a composition comprising a selective COX-2 inhibitory drug or a salt or prodrug thereof and one or more ophthalmically acceptable excipient ingredients that reduce rate of removal of the composition from the eye by lacrimation such that the composition has an effective residence time in the eye of about 2 to about 24 hours.
24. The method ofclaim 23 wherein the mammalian subject is a human subject.
25. The method ofclaim 24 wherein the selective COX-2 inhibitory drug is a compound having the formula:
where R3 is a methyl or amino group, R4 is hydrogen or a C1-4 alkyl or alkoxy group, X is N or CR5 where R5 is hydrogen or halogen, and Y and Z are independently carbon or nitrogen atoms defining adjacent atoms of a five- to six-membered ring that is unsubstituted or substituted at one or more positions with oxo, halo, methyl or halomethyl groups; or a prodrug of such a compound.
26. The method ofclaim 25 wherein the five- to six-membered ring is selected from the group consisting of: cyclopentenone, furanone, methylpyrazole, isoxazole and pyridine rings substituted at no more than one position.
27. The method ofclaim 24 wherein the selective COX-2 inhibitory drug is selected from the group consisting of: celecoxib, deracoxib, valdecoxib, rofecoxib, etoricoxib, 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-1-one, (S)-6,8-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid and 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3-(2H)-pyridazinone.
28. The method ofclaim 24 that further comprises topical administration to the eye, in co-therapy, co-administration and/or co-formulation with the selective COX-2 inhibitory drug, a second drug.
29. The method ofclaim 28 wherein the second drug is selected from acebutolol, aceclidine, acetylsalicylic acid, N4 acetylsulfisoxazole, alclofenac, alprenolol, amfenac, amiloride, aminocaproic acid, p-aminoclonidine, aminozolamide, anisindione, apafant, atenolol, bacitracin, benoxaprofen, benoxinate, benzofenac, bepafant, betamethasone, betaxolol, bethanechol, bimatoprost, brimonidine, bromfenac, bromhexine, bucloxic acid, bupivacaine, butibufen, carbachol, carprofen, cephalexin, chloramphenicol, chlordiazepoxide, chlorprocaine, chlorpropamide, chlortetracycline, cicloprofen, cinmetacin, ciprofloxacin, clidanac, clindamycin, clonidine, clonixin, clopirac, cocaine, cromolyn, cyclopentolate, cyproheptadine, demecarium, dexamethasone, dibucaine, diclofenac, diflusinal, dipivefrin, dorzolamide, enoxacin, eperezolid, epinephrine, erythromycin, eserine, estradiol, ethacrynic acid, etidocaine, etodolac, fenbufen, fenclofenac, fenclorac, fenoprofen, fentiazac, flufenamic acid, flufenisal, flunoxaprofen, fluorocinolone, fluorometholone, flurbiprofen and esters thereof, fluticasone propionate, furaprofen, furobufen, furofenac, furosemide, gancyclovir, gentamycin, gramicidin, hexylcaine, homatropine, hydrocortisone, ibufenac, ibuprofen and esters thereof, idoxuridine, indomethacin, indoprofen, interferons, isobutylmethylxanthine, isofluorophate, isoproterenol, isoxepac, ketoprofen, ketorolac, labetolol, lactorolac, latanoprost, levobunolol, lidocaine, linezolid, lonazolac, loteprednol, meclofenamate, medrysone, mefenamic acid, mepivacaine, metaproterenol, methanamine, methylprednisolone, metiazinic, metoprolol, metronidazole, minopafant, miroprofen, modipafant, nabumetome, nadolol, namoxyrate, naphazoline, naproxen and esters thereof, neomycin, nepafenac, nitroglycerin, norepinephrine, norfloxacin, nupafant, olfloxacin, olopatadine, oxaprozin, oxepinac, oxyphenbutazone, oxyprenolol, oxytetracycline, penicillins, perfloxacin, phenacetin, phenazopyridine, pheniramine, phenylbutazone, phenylephrine, phenylpropanolamine, phospholine, pilocarpine, pindolol, pirazolac, piroxicam, pirprofen, polymyxin, polymyxin B, prednisolone, prilocaine, probenecid, procaine, proparacaine, protizinic acid, rimexolone, salbutamol, scopolamine, sotalol, sulfacetamide, sulfanilic acid, sulindac, suprofen, tenoxicam, terbutaline, tetracaine, tetracycline, theophyllamine, timolol, tobramycin, tolmetin, travoprost, triamcinolone, trimethoprim, trospectomycin, isopropyl unoprostone, vancomycin, vidarabine, vitamin A, warfarin, zomepirac and pharmaceutically acceptable salts thereof.
30. The method ofclaim 28 wherein the second drug is a prostaglandin.
31. The method ofclaim 30 where iridial pigmentation after administration to an eye is reduced by comparison with treatment with the prostaglandin alone.
32. The method ofclaim 30 where the drugs are administrated as surgical adjunct therapy in connection with eye surgery.
33. The method ofclaim 30 wherein the prostaglandin is selected from latanoprost, bimatoprost travoprost and isopropyl unoprostone.
34. The method ofclaim 24 wherein the composition is an in situ gellable solution, suspension or solution/suspension having ophthalmically compatible pH and osmolality.
35. The method ofclaim 24 wherein the selective COX-2 inhibitory drug is present predominantly as nanoparticles.
36. The method ofclaim 35 wherein average particle size of the drug is about 500 to 900 nm.
37. A method of manufacturing a medicament for topically treating or preventing a COX-2 mediated disorder in an eye, comprising a step of utilizing a composition comprising a selective COX-2 inhibitory drug or a salt or prodrug thereof and one or more ophthalmically acceptable excipient ingredients that reduce rate of removal of the composition from the eye by lacrimation such that the composition has an effective residence time in the eye of about 2 to about 24 hours in the medicament.
38. The method ofclaim 23 wherein the drug is administered by electroosmosis, electroporation or by iontophoresis.
39. A pharmaceutical composition suitable for topical administration to an eye, the composition comprising nanoparticles of a drug of low water solubility in a concentration effective for treatment and/or prophylaxis of a disorder in the eye, and one or more ophthalmically acceptable excipients that reduce rate of removal of the composition from the eye by lacrimation such that the composition has an effective residence time in the eye of about 2 to about 24 hours.
40. A method of treating and/or preventing a disorder in an eye of a mammalian subject, the method comprising administering in each of one or more topical applications to the eye a therapeutically or prophylactically effective amount of a composition comprising nanoparticles of a drug of low water solubility and one or more ophthalmically acceptable excipients that reduce rate of removal of the composition from the eye by lacrimation such that the composition has an effective residence time in the eye of about 2 to about 24 hours.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/904,098US20020035264A1 (en) | 2000-07-13 | 2001-07-12 | Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21810100P | 2000-07-13 | 2000-07-13 | |
| US27928501P | 2001-03-28 | 2001-03-28 | |
| US29483801P | 2001-05-31 | 2001-05-31 | |
| US29638801P | 2001-06-06 | 2001-06-06 | |
| US09/904,098US20020035264A1 (en) | 2000-07-13 | 2001-07-12 | Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20020035264A1true US20020035264A1 (en) | 2002-03-21 |
Family
ID=27499099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/904,098AbandonedUS20020035264A1 (en) | 2000-07-13 | 2001-07-12 | Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20020035264A1 (en) |
| EP (1) | EP1303271A4 (en) |
| JP (1) | JP2004528267A (en) |
| AR (1) | AR033382A1 (en) |
| AU (1) | AU2001275908A1 (en) |
| CA (1) | CA2414780A1 (en) |
| MX (1) | MXPA03000407A (en) |
| PE (1) | PE20020146A1 (en) |
| WO (1) | WO2002005815A1 (en) |
Cited By (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6551584B2 (en)* | 2000-10-10 | 2003-04-22 | Pharmacia & Upjohn Company | Topical antibiotic composition for treatment of eye infection |
| US6566347B1 (en)* | 2001-08-22 | 2003-05-20 | Duquesne University Of The Holy Ghost | Controlled release pharmaceutical |
| US20030100594A1 (en)* | 2001-08-10 | 2003-05-29 | Pharmacia Corporation | Carbonic anhydrase inhibitor |
| US6646001B2 (en) | 1997-12-19 | 2003-11-11 | Alcon Manufacturing, Ltd. | Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension |
| US20030220376A1 (en)* | 2001-08-10 | 2003-11-27 | Pharmacia Corporation | Methods for treating carbonic anhydrase mediated disorders |
| US20040033938A1 (en)* | 2000-09-12 | 2004-02-19 | Britten Nancy J. | Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis |
| US20040067992A1 (en)* | 2001-08-10 | 2004-04-08 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia |
| US20040175435A1 (en)* | 1998-09-02 | 2004-09-09 | Allergan Sales, Inc. | Preserved cyclodextrin-containing compositions |
| US20040229038A1 (en)* | 2003-03-03 | 2004-11-18 | Elan Pharma International Ltd. | Nanoparticulate meloxicam formulations |
| US20050002970A1 (en)* | 2001-12-21 | 2005-01-06 | Ketelson Howard Allen | Inorganic nanopartices to modify the viscosity and physical properties of ophthalmic and otic compositions |
| US20050004074A1 (en)* | 2003-07-01 | 2005-01-06 | Allergan, Inc. | Inhibition of irritating side effects associated with use of a topical ophthalmic medication |
| US20050003014A1 (en)* | 2001-12-21 | 2005-01-06 | Ketelson Howard Allen | Use of synthetic inorganic nanoparticles as carriers for ophthalmic and otic drugs |
| US20050008676A1 (en)* | 2002-12-19 | 2005-01-13 | Yongxing Qiu | Medical devices having antimicrobial coatings thereon |
| US20050038103A1 (en)* | 2003-08-13 | 2005-02-17 | Amarjit Singh | Uses of dorzolamide |
| US20050228048A1 (en)* | 2002-08-23 | 2005-10-13 | Santen Pharmaceutical Co., Ltd. | Stable eye drops containing latanoprost as the active ingredient |
| US20050234018A1 (en)* | 2004-04-15 | 2005-10-20 | Allergan, Inc. | Drug delivery to the back of the eye |
| US20050276867A1 (en)* | 2004-06-09 | 2005-12-15 | Allergan, Inc. | Stabilized compositions comprising a therapeutically active agent and an oxidizing preservative |
| US20060246145A1 (en)* | 2004-04-30 | 2006-11-02 | Allergan, Inc. | Methods for treating ocular conditions with cyclic lipid containing microparticles |
| US20070020298A1 (en)* | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid |
| US20070232567A1 (en)* | 2006-03-28 | 2007-10-04 | Curtis Wright | Formulations Of Low Dose Non-Steroidal Anti-Inflammatory Drugs And Beta-Cyclodextrin |
| US20070232566A1 (en)* | 2006-03-28 | 2007-10-04 | Curtis Wright | Formulations Of Low Dose Diclofenac And Beta-Cyclodextrin |
| US20070238789A1 (en)* | 2006-03-31 | 2007-10-11 | Chin-Ming Chang | Prednisolone acetate compositions |
| US20080033351A1 (en)* | 2006-08-04 | 2008-02-07 | Allergan, Inc. | Ocular implant delivery assemblies with distal caps |
| US20080102121A1 (en)* | 1998-11-02 | 2008-05-01 | Elan Pharma International Limited | Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone |
| US20080131484A1 (en)* | 2006-12-01 | 2008-06-05 | Allergan, Inc. | Intraocular drug delivery systems |
| US20080145430A1 (en)* | 2004-12-08 | 2008-06-19 | Santipharp Panmai | Ophthalmic Nanoparticulate Formulation Of A Cyclooxygenase-2 Selective Inhibitor |
| US20080145403A1 (en)* | 2006-12-19 | 2008-06-19 | Allergan, Inc. | Low temperature processes for making cyclic lipid implants for intraocular use |
| US20080153894A1 (en)* | 2002-12-19 | 2008-06-26 | Pharmacia Corporation | Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis |
| WO2008077712A1 (en)* | 2006-12-22 | 2008-07-03 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Gel useful for the delivery of ophthalmic drugs |
| US20080166414A1 (en)* | 2004-01-28 | 2008-07-10 | Johns Hopkins University | Drugs And Gene Carrier Particles That Rapidly Move Through Mucous Barriers |
| US20080299166A1 (en)* | 2002-04-19 | 2008-12-04 | Lajos Szente | Novel biomaterials, their preparation and use |
| US20090312724A1 (en)* | 2007-06-28 | 2009-12-17 | Cydex Pharmaceuticals, Inc. | Nasal and Ophthalmic Delivery of Aqueous Corticosteroid Solutions |
| US20100076045A1 (en)* | 2008-09-19 | 2010-03-25 | Castillo Ernesto J | Stabilized pharmaceutical sub-micron suspensions and methods of forming same |
| US20100215580A1 (en)* | 2006-09-08 | 2010-08-26 | The Johns Hopkins University | Compositions and methods for enhancing transport through mucus |
| US20100247606A1 (en)* | 2009-03-25 | 2010-09-30 | Allergan, Inc. | Intraocular sustained release drug delivery systems and methods for treating ocular conditions |
| US20100278898A1 (en)* | 2004-04-30 | 2010-11-04 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
| US20100297252A1 (en)* | 2003-03-03 | 2010-11-25 | Elan Pharma International Ltd. | Nanoparticulate meloxicam formulations |
| US20110034568A1 (en)* | 2000-12-19 | 2011-02-10 | The Board Of Regents Of The University Of Texas System | Compositions comprising lecithin oils and NSAIDS for protecting the gastrointestinal tract and providing enhanced therapeutic activity |
| US7915312B2 (en) | 2000-09-22 | 2011-03-29 | Nolan Gerard M | Physiological method of improving vision |
| US20110091520A1 (en)* | 2004-04-30 | 2011-04-21 | Allergan, Inc. | Sustained Release Intraocular Implants and Methods for Treating Ocular Neuropathies |
| US20110117189A1 (en)* | 2008-07-08 | 2011-05-19 | S.I.F.I. Societa' Industria Farmaceutica Italiana S.P.A. | Ophthalmic compositions for treating pathologies of the posterior segment of the eye |
| US20110275711A1 (en)* | 2010-04-12 | 2011-11-10 | R-Tech Ueno, Ltd. | Method for treating macular edema |
| US20120022149A1 (en)* | 2010-07-21 | 2012-01-26 | Chowhan Masood A | Pharmaceutical composition with enhanced solubility characteristics |
| WO2012033811A1 (en)* | 2010-09-09 | 2012-03-15 | Sawaya Assad S | Compositions for a topical ophthalmic clear colloidal liquid which undergoes a liquid-gel phase transition in the eye |
| US20120070401A1 (en)* | 2010-09-21 | 2012-03-22 | Jinzhong Zhang | Composition and Method for Promoting Wound Healing |
| US8637068B2 (en) | 2004-04-30 | 2014-01-28 | Allergan, Inc. | Hypotensive prostamide-containing biodegradable intraocular implants and related methods |
| US8647659B2 (en) | 2010-01-22 | 2014-02-11 | Allergan, Inc. | Intracameral sustained release therapeutic agent implants |
| US8715713B2 (en) | 2011-04-29 | 2014-05-06 | Allergan, Inc. | Solvent cast film sustained release latanoprost implant |
| US8771745B2 (en) | 2008-10-27 | 2014-07-08 | Allergan, Inc. | Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof |
| US8871733B2 (en)* | 2006-04-28 | 2014-10-28 | Mayo Foundation For Medical Education And Research | Treating glaucoma, cardiovascular diseases, and renal diseases |
| US9216150B2 (en) | 2011-09-29 | 2015-12-22 | Plx Pharma Inc. | pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same |
| US9301933B2 (en) | 2011-09-20 | 2016-04-05 | Allergan, Inc. | Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism |
| US9326949B2 (en) | 2004-04-30 | 2016-05-03 | Allergan, Inc. | Method of making oil-in-oil emulsified polymeric implants containing a hypotensive lipid |
| US9393212B2 (en) | 2012-05-03 | 2016-07-19 | Kala Pharmaceuticals, Inc. | Nanocrystals, compositions, and methods that aid particle transport in mucus |
| US9492316B2 (en) | 2013-10-31 | 2016-11-15 | Allergan, Inc. | Prostamide-containing intraocular implants and methods of use thereof |
| US20160338951A1 (en)* | 2015-05-20 | 2016-11-24 | Gavis Pharmaceuticals | Process of preparing aqueous ophthalmic solution of olopatadine |
| US9566242B2 (en) | 2010-02-25 | 2017-02-14 | The Johns Hopkins University | Sustained delivery of therapeutic agents to an eye compartment |
| US9630909B2 (en) | 2013-06-27 | 2017-04-25 | Mylan Laboratories Ltd | Process for the preparation of nepafenac |
| US9775846B2 (en) | 2004-04-30 | 2017-10-03 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related implants |
| US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| US9827225B2 (en)* | 2016-01-25 | 2017-11-28 | Jenivision Inc. | Use of prostacyclin antagonists for treating ocular surface nociception |
| US9827324B2 (en) | 2003-12-31 | 2017-11-28 | Cydex Pharmaceuticals, Inc. | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| US9867810B1 (en) | 2016-08-19 | 2018-01-16 | Orasis Pharmaceuticals Ltd. | Ophthalmic pharmaceutical compositions and uses relating thereto |
| US9889208B2 (en) | 2012-05-04 | 2018-02-13 | The Johns Hopkins University | Lipid-based drug carriers for rapid penetration through mucus linings |
| US9950072B2 (en) | 2012-03-16 | 2018-04-24 | The Johns Hopkins University | Controlled release formulations for the delivery of HIF-1 inhibitors |
| CN108627598A (en)* | 2018-05-23 | 2018-10-09 | 山东鲁抗舍里乐药业有限公司 | A method of measuring SC 59046 content |
| WO2018204905A1 (en)* | 2017-05-05 | 2018-11-08 | Pamel Gregory J | Composition containing chlorine dioxide and methods for using same |
| US10159743B2 (en) | 2012-03-16 | 2018-12-25 | The Johns Hopkins University | Non-linear multiblock copolymer-drug conjugates for the delivery of active agents |
| US10307372B2 (en) | 2010-09-10 | 2019-06-04 | The Johns Hopkins University | Rapid diffusion of large polymeric nanoparticles in the mammalian brain |
| CN110831585A (en)* | 2017-06-16 | 2020-02-21 | 凯乌维·科恩 | Bromhexine for the treatment of pain |
| US10568975B2 (en) | 2013-02-05 | 2020-02-25 | The Johns Hopkins University | Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof |
| US10610518B2 (en) | 2018-04-24 | 2020-04-07 | Allergan, Inc. | Presbyopia treatments |
| US10617763B2 (en)* | 2013-08-28 | 2020-04-14 | Presbyopia Therapies, LLC | Compositions and methods for the treatment of presbyopia |
| US10688041B2 (en) | 2012-05-03 | 2020-06-23 | Kala Pharmaceuticals, Inc. | Compositions and methods utilizing poly(vinyl alcohol) and/or other polymers that aid particle transport in mucus |
| US10864219B2 (en) | 2012-05-03 | 2020-12-15 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| US11071724B2 (en) | 2019-05-17 | 2021-07-27 | Ocular Science, Inc. | Compositions and methods for treating presbyopia |
| US11219597B2 (en) | 2012-05-03 | 2022-01-11 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| WO2022093978A1 (en)* | 2020-10-28 | 2022-05-05 | Tremeau Pharmaceuticals, Inc. | Aqueous formulations of water insoluble cox-2 inhibitors |
| US11395825B2 (en) | 2017-05-04 | 2022-07-26 | Ocular Science, Inc. | Compositions and methods for treating eyes and methods of preparation |
| WO2022173923A1 (en)* | 2021-02-10 | 2022-08-18 | Iolyx Therapeutics, Inc. | Methods for ophthalmic delivery of roflumilast |
| US11484580B2 (en)* | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
| US11633350B2 (en) | 2014-02-23 | 2023-04-25 | The Johns Hopkins University | Hypotonic microbicidal formulations and methods of use |
| US11648257B2 (en) | 2020-03-26 | 2023-05-16 | Plx Opco Inc. | Pharmaceutical carriers capable of pH dependent reconstitution and methods for making and using same |
| US12128036B2 (en) | 2018-10-10 | 2024-10-29 | Lenz Therapeutics Operations, Inc. | Compositions and methods for storage stable ophthalmic drugs |
| US12180206B2 (en) | 2021-11-17 | 2024-12-31 | Lenz Therapeutics Operations, Inc. | Aceclidine derivatives, compositions thereof and methods of use thereof |
| US12263160B2 (en) | 2021-09-22 | 2025-04-01 | Iolyx Therapeutics, Inc. | Methods of treating ocular inflammatory diseases |
| US12370352B2 (en) | 2007-06-28 | 2025-07-29 | Cydex Pharmaceuticals, Inc. | Nasal and ophthalmic delivery of aqueous corticosteroid solutions |
| US12414942B1 (en) | 2024-03-15 | 2025-09-16 | Lenz Therapeutics Operations, Inc. | Compositions, methods, and systems for treating presbyopia |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA01013257A (en)* | 2001-12-18 | 2003-06-25 | Arturo Jimenez Bayardo | Rofecoxib ophthalmic suspension for the treatment of ocular inflammation and pain. |
| TW200403072A (en)* | 2002-01-23 | 2004-03-01 | Upjohn Co | Combination therapy for the treatment of bacterial infections |
| JP2005521691A (en)* | 2002-02-22 | 2005-07-21 | ファルマシア・コーポレーション | Ophthalmic antibacterial drug formulation containing cyclodextrin compound and cetylpyridinium chloride |
| JP2006504661A (en) | 2002-07-30 | 2006-02-09 | オメロス コーポレイション | Ophthalmological cleaning solution and ophthalmological cleaning method |
| CA2505106A1 (en)* | 2002-11-27 | 2004-06-17 | Pharmacia Corporation | Concentrated liquid valdecoxib composition |
| JP2006512367A (en)* | 2002-12-19 | 2006-04-13 | ファルマシア・コーポレーション | Method and composition for the treatment of herpes virus infections using a cyclooxygenase-2 selective inhibitor or a cyclooxygenase-2 inhibitor in combination with an antiviral agent |
| US20070224278A1 (en) | 2003-11-12 | 2007-09-27 | Lyons Robert T | Low immunogenicity corticosteroid compositions |
| US20050101582A1 (en) | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
| ES2318453T3 (en) | 2004-01-20 | 2009-05-01 | Allergan, Inc. | COMPOSITIONS FOR LOCALIZED EYE THERAPY, WHICH INCLUDE, PREFERENCE, ACETONID TRIAMCINOLONE AND HIALURONIC ACID. |
| AU2013200020B2 (en)* | 2004-01-20 | 2014-07-17 | Allergan, Inc. | Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid |
| US8119154B2 (en) | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
| WO2006040839A1 (en)* | 2004-10-15 | 2006-04-20 | Advanced Medicine Research Institute | Eye drops and kit for treatment of eye disease |
| MX2007001172A (en)* | 2004-11-05 | 2007-03-12 | Senju Pharma Co | Aqueous eye drops with accelerated intraocular migration. |
| JP5112669B2 (en)* | 2005-09-30 | 2013-01-09 | 富山化学工業株式会社 | Aqueous suspension containing nanoparticle of poorly soluble drug |
| WO2008015695A2 (en)* | 2006-05-15 | 2008-02-07 | Sun Pharmaceutical Industries Limited | Inclusion complex of olopatadine and cyclodextrin |
| EP2231169B1 (en)* | 2007-12-06 | 2016-05-04 | Bend Research, Inc. | Pharmaceutical compositions comprising nanoparticles and a resuspending material |
| JP5709523B2 (en)* | 2008-11-06 | 2015-04-30 | 国立大学法人大阪大学 | Eye drops and fluorescent imaging agents with high intraocular transferability and methods for producing them |
| DE102008059201A1 (en)* | 2008-11-27 | 2010-06-02 | GÖPFERICH, Achim, Prof. Dr. | In situ precipitating drug solutions |
| US20100158980A1 (en)* | 2008-12-18 | 2010-06-24 | Casey Kopczynski | Drug delivery devices for delivery of therapeutic agents |
| RU2012124216A (en)* | 2009-11-11 | 2013-12-20 | Микро Лабс Лимитед | PHARMACEUTICAL COMBINATION OF PROSTAGLANDINE AND NSAID COMPOUNDS FOR TREATMENT OF GLAUCOMA AND EYE HYPERTENSION |
| US8921337B2 (en) | 2009-12-03 | 2014-12-30 | Alcon Research, Ltd. | Carboxyvinyl polymer-containing nanoparticle suspensions |
| CA2798084A1 (en) | 2010-05-17 | 2011-11-24 | Aerie Pharmaceuticals, Inc. | Drug delivery devices for delivery of ocular therapeutic agents |
| CN103384514A (en)* | 2011-01-12 | 2013-11-06 | 索夫特意大利公司 | Corneal delivery of cross-linking agents by iontophoresis for the treatment of keratoconus and ophthalmic compositions related thereto |
| AU2013201465B2 (en) | 2012-10-24 | 2016-03-03 | Rayner Intraocular Lenses Limited | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
| ES2686675T3 (en)* | 2013-03-29 | 2018-10-19 | Askat Inc. | Therapeutic agent for eye disease |
| MY193694A (en)* | 2014-05-01 | 2022-10-25 | Integral Biosystems Llc | Membrane-adherent self-assembled systems for treatment of ocular disorders |
| TWI705812B (en) | 2014-12-01 | 2020-10-01 | 奥默羅斯公司 | Anti-inflammatory and mydriatic intracameral solutions for inhibition of postoperative ocular inflammatory conditions |
| US11707430B2 (en) | 2016-08-09 | 2023-07-25 | The University Of Liverpool | Ophthalmic compositions |
| CN109917036B (en)* | 2019-03-26 | 2022-04-01 | 广西壮族自治区食品药品检验所 | HPLC-ELSD detection method for content of gentamicin C component in gentamicin procaine vitamin B12 capsule |
| CN111929394B (en)* | 2020-08-25 | 2022-11-08 | 北京和合医学诊断技术股份有限公司 | Warfarin detection method |
Citations (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3863633A (en)* | 1971-06-04 | 1975-02-04 | Pharmacia Ab | Composition containing a substance showing a topical effect on the eye, and a method of preparing the same |
| US3868445A (en)* | 1972-11-30 | 1975-02-25 | Pharmacia Ab | Dosage unit containing a substance showing a topical effect on the eye, and a method of preparing same |
| US4281654A (en)* | 1980-04-07 | 1981-08-04 | Alza Corporation | Drug delivery system for controlled ocular therapy |
| US4826689A (en)* | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
| US4829088A (en)* | 1986-04-14 | 1989-05-09 | Dispersa Ag | Medicament for the treatment of inflammations of the eye |
| US4829083A (en)* | 1986-04-14 | 1989-05-09 | Dispersa Ag | Stabilization of mercury-containing preservatives in ophthalmic medicaments |
| US4861760A (en)* | 1985-10-03 | 1989-08-29 | Merck & Co., Inc. | Ophthalmological composition of the type which undergoes liquid-gel phase transition |
| US4913903A (en)* | 1987-02-04 | 1990-04-03 | Alza Corporation | Post-surgical applications for bioerodible polymers |
| US5001153A (en)* | 1987-09-18 | 1991-03-19 | K.K. Ueno Seiyaku Oyo Kenkyujo | Ocular hypotensive agents |
| US5110493A (en)* | 1987-09-11 | 1992-05-05 | Syntex (U.S.A.) Inc. | Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant |
| US5298262A (en)* | 1992-12-04 | 1994-03-29 | Sterling Winthrop Inc. | Use of ionic cloud point modifiers to prevent particle aggregation during sterilization |
| US5302401A (en)* | 1992-12-09 | 1994-04-12 | Sterling Winthrop Inc. | Method to reduce particle size growth during lyophilization |
| US5336507A (en)* | 1992-12-11 | 1994-08-09 | Sterling Winthrop Inc. | Use of charged phospholipids to reduce nanoparticle aggregation |
| US5340564A (en)* | 1992-12-10 | 1994-08-23 | Sterling Winthrop Inc. | Formulations comprising olin 10-G to prevent particle aggregation and increase stability |
| US5380738A (en)* | 1993-05-21 | 1995-01-10 | Monsanto Company | 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents |
| US5384124A (en)* | 1988-07-21 | 1995-01-24 | Farmalyoc | Solid porous unitary form comprising micro-particles and/or nano-particles, and its preparation |
| US5393790A (en)* | 1994-02-10 | 1995-02-28 | G.D. Searle & Co. | Substituted spiro compounds for the treatment of inflammation |
| US5401765A (en)* | 1993-11-30 | 1995-03-28 | G. D. Searle | 1,4,5-triphenyl pyrazolyl compounds for the treatment of inflammation and inflammation-related disorders |
| US5418254A (en)* | 1994-05-04 | 1995-05-23 | G. D. Searle & Co. | Substituted cyclopentadienyl compounds for the treatment of inflammation |
| US5420343A (en)* | 1994-08-31 | 1995-05-30 | G. D. Searle & Co. | Derivatives of aromatic cyclic alkylethers |
| US5422368A (en)* | 1988-09-06 | 1995-06-06 | Kabi Pharmacia Ab | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| US5429824A (en)* | 1992-12-15 | 1995-07-04 | Eastman Kodak Company | Use of tyloxapole as a nanoparticle stabilizer and dispersant |
| US5434178A (en)* | 1993-11-30 | 1995-07-18 | G.D. Searle & Co. | 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation |
| US5436265A (en)* | 1993-11-12 | 1995-07-25 | Merck Frosst Canada, Inc. | 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents |
| US5443505A (en)* | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| US5486534A (en)* | 1994-07-21 | 1996-01-23 | G. D. Searle & Co. | 3,4-substituted pyrazoles for the treatment of inflammation |
| US5503723A (en)* | 1995-02-08 | 1996-04-02 | Eastman Kodak Company | Isolation of ultra small particles |
| US5510368A (en)* | 1995-05-22 | 1996-04-23 | Merck Frosst Canada, Inc. | N-benzyl-3-indoleacetic acids as antiinflammatory drugs |
| US5510383A (en)* | 1993-08-03 | 1996-04-23 | Alcon Laboratories, Inc. | Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension |
| US5510118A (en)* | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
| US5515444A (en)* | 1992-10-21 | 1996-05-07 | Virginia Polytechnic Institute And State University | Active control of aircraft engine inlet noise using compact sound sources and distributed error sensors |
| US5518738A (en)* | 1995-02-09 | 1996-05-21 | Nanosystem L.L.C. | Nanoparticulate nsaid compositions |
| US5518187A (en)* | 1992-11-25 | 1996-05-21 | Nano Systems L.L.C. | Method of grinding pharmaceutical substances |
| US5521213A (en)* | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
| US5534270A (en)* | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
| US5536752A (en)* | 1993-06-24 | 1996-07-16 | Merck Frosst Canada Inc. | Phenyl heterocycles as COX-2 inhibitors |
| US5536508A (en)* | 1990-11-22 | 1996-07-16 | Vectorpharma International S.P.A. | Pharmaceutical compositions in the form of particles suitable for the controlled release of pharmacologically active substances and process for preparing the same compositions |
| US5543297A (en)* | 1992-12-22 | 1996-08-06 | Merck Frosst Canada, Inc. | Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity |
| US5547975A (en)* | 1994-09-20 | 1996-08-20 | Talley; John J. | Benzopyranopyrazolyl derivatives for the treatment of inflammation |
| US5560931A (en)* | 1995-02-14 | 1996-10-01 | Nawosystems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
| US5560932A (en)* | 1995-01-10 | 1996-10-01 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents |
| US5565188A (en)* | 1995-02-24 | 1996-10-15 | Nanosystems L.L.C. | Polyalkylene block copolymers as surface modifiers for nanoparticles |
| US5569448A (en)* | 1995-01-24 | 1996-10-29 | Nano Systems L.L.C. | Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
| US5591456A (en)* | 1995-02-10 | 1997-01-07 | Nanosystems L.L.C. | Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer |
| US5593992A (en)* | 1993-07-16 | 1997-01-14 | Smithkline Beecham Corporation | Compounds |
| US5596008A (en)* | 1995-02-10 | 1997-01-21 | G. D. Searle & Co. | 3,4-Diaryl substituted pyridines for the treatment of inflammation |
| US5604260A (en)* | 1992-12-11 | 1997-02-18 | Merck Frosst Canada Inc. | 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 |
| US5604253A (en)* | 1995-05-22 | 1997-02-18 | Merck Frosst Canada, Inc. | N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors |
| US5607978A (en)* | 1992-09-21 | 1997-03-04 | Allergan | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
| US5616601A (en)* | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
| US5616458A (en)* | 1990-03-14 | 1997-04-01 | Board Of Regents, University Of Tx System | Tripterygium wilfordii hook F extracts and components, and uses thereof |
| US5620999A (en)* | 1994-07-28 | 1997-04-15 | Weier; Richard M. | Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation |
| US5622938A (en)* | 1995-02-09 | 1997-04-22 | Nano Systems L.L.C. | Sugar base surfactant for nanocrystals |
| US5632984A (en)* | 1993-07-22 | 1997-05-27 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
| US5633272A (en)* | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
| US5639780A (en)* | 1995-05-22 | 1997-06-17 | Merck Frosst Canada, Inc. | N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors |
| US5643933A (en)* | 1995-06-02 | 1997-07-01 | G. D. Searle & Co. | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
| US5716955A (en)* | 1996-01-11 | 1998-02-10 | Smithkline Beecham Corporation | Substituted imidazole compounds |
| US5718919A (en)* | 1995-02-24 | 1998-02-17 | Nanosystems L.L.C. | Nanoparticles containing the R(-)enantiomer of ibuprofen |
| US5723485A (en)* | 1996-08-01 | 1998-03-03 | Laboratories Upsa | 1,2-Diarylindole derivatives, processes for their preparation and their uses in therapeutics |
| US5739166A (en)* | 1994-11-29 | 1998-04-14 | G.D. Searle & Co. | Substituted terphenyl compounds for the treatment of inflammation |
| US5741798A (en)* | 1996-06-03 | 1998-04-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | 2-benzyl-4-sulfonyl-4H-isoquinolin-1,3-diones and their use as antiinflammatory agents |
| US5747001A (en)* | 1995-02-24 | 1998-05-05 | Nanosystems, L.L.C. | Aerosols containing beclomethazone nanoparticle dispersions |
| US5756499A (en)* | 1996-01-11 | 1998-05-26 | Smithkline Beecham Corporation | Substituted imidazole compounds |
| US5756529A (en)* | 1995-09-29 | 1998-05-26 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies |
| US5760068A (en)* | 1993-11-30 | 1998-06-02 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation |
| US5767153A (en)* | 1995-06-07 | 1998-06-16 | Insite Vision Incorporated | Sustained release emulsions |
| US5776967A (en)* | 1996-07-26 | 1998-07-07 | American Home Products Corporation | Pyranoindole inhibitors of COX--2 |
| US5783597A (en)* | 1997-03-04 | 1998-07-21 | Ortho Pharmaceutical Corporation | 2,5-disubstituted thiophenes: inhibitors of 5-lipoxygenase and inducible cyclooxygenase (COX-2) enzymes, composition and use |
| US5859036A (en)* | 1997-10-07 | 1999-01-12 | Laboratories Upsa | 3,4-diarylthiazolin-2-one or -2-thione derivatives, their methods of preparation and their uses in their methods of preparation and their uses in therapeutics |
| US5861419A (en)* | 1996-07-18 | 1999-01-19 | Merck Frosst Canad, Inc. | Substituted pyridines as selective cyclooxygenase-2 inhibitors |
| US5866596A (en)* | 1996-09-13 | 1999-02-02 | Laboratories Upsa | 3,4-diaryloxazolone derivatives, their methods of preparation and their uses in therapeutics |
| US5869660A (en)* | 1995-06-07 | 1999-02-09 | Smithkline Beecham Corporation | Process of preparing imidazole compounds |
| US5869524A (en)* | 1996-11-12 | 1999-02-09 | American Home Products Corporation | Indene inhibitors of COX-2 |
| US5869079A (en)* | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| US5883267A (en)* | 1996-05-31 | 1999-03-16 | Merck & Co., Inc. | Process for making phenyl heterocycles useful as cox-2 inhibitors |
| US5892053A (en)* | 1995-05-25 | 1999-04-06 | G. D. Searle & Co. | Process for preparing 3-haloalkyl-1H-pyrazoles |
| US5922742A (en)* | 1996-04-23 | 1999-07-13 | Merck Frosst Canada | Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors |
| US5929076A (en)* | 1997-01-10 | 1999-07-27 | Smithkline Beecham Corporation | Cycloalkyl substituted imidazoles |
| US6020343A (en)* | 1995-10-13 | 2000-02-01 | Merck Frosst Canada, Inc. | (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors |
| US6020347A (en)* | 1997-11-18 | 2000-02-01 | Merck & Co., Inc. | 4-substituted-4-piperidine carboxamide derivatives |
| US6034256A (en)* | 1997-04-21 | 2000-03-07 | G.D. Searle & Co. | Substituted benzopyran derivatives for the treatment of inflammation |
| US6037364A (en)* | 1992-09-21 | 2000-03-14 | Allergan Sales, Inc. | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| US6040450A (en)* | 1997-09-25 | 2000-03-21 | Merck & Co., Inc. | Process for making diaryl pyridines useful as cox-2-inhibitors |
| US6040319A (en)* | 1998-04-24 | 2000-03-21 | Merck & Co., Inc. | Process for synthesizing COX-2 inhibitors |
| US6046217A (en)* | 1997-09-12 | 2000-04-04 | Merck Frosst Canada & Co. | 2,3,5-trisubstituted pyridines as inhibitors of cyclooxygenase-2 |
| US6046208A (en)* | 1996-01-11 | 2000-04-04 | Smithkline Beecham Corporation | Substituted imidazole compounds |
| US6057319A (en)* | 1995-10-30 | 2000-05-02 | Merck Frosst Canada & Co. | 3,4-Diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors |
| US6063804A (en)* | 1997-11-26 | 2000-05-16 | Adir Et Compagnie | Pyrrole compounds |
| US6063807A (en)* | 1995-07-15 | 2000-05-16 | Societe De Conseils De Recherches D'applications Scientifiques (S.C.R.A.S.) | Cyclo-oxygenase inhibitor and amidine derivatives salts, preparation method therefor, use thereof as drugs, and pharmaceutical compositions containing said salts |
| US6071954A (en)* | 1997-03-14 | 2000-06-06 | Merk Frosst Canada, Inc. | (methylsulfonyl)phenyl-2-(5H)-furanones with oxygen link as COX-2 inhibitors |
| US6075066A (en)* | 1994-03-14 | 2000-06-13 | Seikagaku Kogyo Kabushiki Kaisha | Material to be worn on the eyeball |
| US6077869A (en)* | 1998-10-29 | 2000-06-20 | Ortho-Mcneil Pharmaceutical, Inc. | Aryl phenylhydrazides as selective COX-2 inhibitors for treatment of inflammation |
| US6077868A (en)* | 1999-07-20 | 2000-06-20 | Wisconsin Alumni Research Foundation | Selective inhibition of cyclooxygenase-2 |
| US6083969A (en)* | 1999-10-20 | 2000-07-04 | Ortho-Mcneil Pharaceutical, Inc. | 1,3- and 2,3-diarylcycloalkano and cycloalkeno pyrazoles as selective inhibitors of cyclooxygenase-2 and antiinflammatory agents |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4474751A (en)* | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Ophthalmic drug delivery system utilizing thermosetting gels |
| US5192535A (en)* | 1988-02-08 | 1993-03-09 | Insite Vision Incorporated | Ophthalmic suspensions |
| US5318780A (en)* | 1991-10-30 | 1994-06-07 | Mediventures Inc. | Medical uses of in situ formed gels |
| IT1273742B (en)* | 1994-08-01 | 1997-07-09 | Lifegroup Spa | HIGH BIO ADHESIVE AND MUCO ADHESIVE COMPOSITIONS USEFUL FOR THE TREATMENT OF EPITALS AND MUCOSES |
| AU5276696A (en)* | 1995-04-04 | 1996-10-23 | Glaxo Group Limited | Imidazo{1,2-a}pyridine derivatives |
| US6174524B1 (en)* | 1999-03-26 | 2001-01-16 | Alcon Laboratories, Inc. | Gelling ophthalmic compositions containing xanthan gum |
| AU754064B2 (en)* | 1998-05-15 | 2002-11-07 | Wakamoto Pharmaceutical Co., Ltd. | Anti-inflammatory eye drops |
| AR020660A1 (en)* | 1998-09-30 | 2002-05-22 | Alcon Lab Inc | ANTIBIOTIC COMPOSITIONS FOR THE TREATMENT OF EYES, EARS AND NOSE |
| SE9803761D0 (en)* | 1998-11-04 | 1998-11-04 | Synphora Ab | Method to avoid increased iridial pigmentation during prostaglandin treatment |
| AU6917400A (en)* | 1999-08-31 | 2001-03-26 | Alcon Laboratories, Inc. | Use of 5-ht1b/1d agonists to treat otic pain |
- 2001
- 2001-07-11PEPE2001000686Apatent/PE20020146A1/ennot_activeApplication Discontinuation
- 2001-07-12MXMXPA03000407Apatent/MXPA03000407A/enunknown
- 2001-07-12CACA002414780Apatent/CA2414780A1/ennot_activeAbandoned
- 2001-07-12JPJP2002511747Apatent/JP2004528267A/enactivePending
- 2001-07-12USUS09/904,098patent/US20020035264A1/ennot_activeAbandoned
- 2001-07-12EPEP01953462Apatent/EP1303271A4/ennot_activeWithdrawn
- 2001-07-12WOPCT/US2001/022061patent/WO2002005815A1/ennot_activeApplication Discontinuation
- 2001-07-12ARARP010103304Apatent/AR033382A1/enunknown
- 2001-07-12AUAU2001275908Apatent/AU2001275908A1/ennot_activeAbandoned
Patent Citations (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3863633A (en)* | 1971-06-04 | 1975-02-04 | Pharmacia Ab | Composition containing a substance showing a topical effect on the eye, and a method of preparing the same |
| US3868445A (en)* | 1972-11-30 | 1975-02-25 | Pharmacia Ab | Dosage unit containing a substance showing a topical effect on the eye, and a method of preparing same |
| US4281654A (en)* | 1980-04-07 | 1981-08-04 | Alza Corporation | Drug delivery system for controlled ocular therapy |
| US4826689A (en)* | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
| US4861760A (en)* | 1985-10-03 | 1989-08-29 | Merck & Co., Inc. | Ophthalmological composition of the type which undergoes liquid-gel phase transition |
| US4829088A (en)* | 1986-04-14 | 1989-05-09 | Dispersa Ag | Medicament for the treatment of inflammations of the eye |
| US4829083A (en)* | 1986-04-14 | 1989-05-09 | Dispersa Ag | Stabilization of mercury-containing preservatives in ophthalmic medicaments |
| US4913903A (en)* | 1987-02-04 | 1990-04-03 | Alza Corporation | Post-surgical applications for bioerodible polymers |
| US5110493A (en)* | 1987-09-11 | 1992-05-05 | Syntex (U.S.A.) Inc. | Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant |
| US5001153A (en)* | 1987-09-18 | 1991-03-19 | K.K. Ueno Seiyaku Oyo Kenkyujo | Ocular hypotensive agents |
| US5384124A (en)* | 1988-07-21 | 1995-01-24 | Farmalyoc | Solid porous unitary form comprising micro-particles and/or nano-particles, and its preparation |
| US5422368A (en)* | 1988-09-06 | 1995-06-06 | Kabi Pharmacia Ab | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| US5616458A (en)* | 1990-03-14 | 1997-04-01 | Board Of Regents, University Of Tx System | Tripterygium wilfordii hook F extracts and components, and uses thereof |
| US5536508A (en)* | 1990-11-22 | 1996-07-16 | Vectorpharma International S.P.A. | Pharmaceutical compositions in the form of particles suitable for the controlled release of pharmacologically active substances and process for preparing the same compositions |
| US6204287B1 (en)* | 1992-09-21 | 2001-03-20 | Allergan Sales, Inc. | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| US6037364A (en)* | 1992-09-21 | 2000-03-14 | Allergan Sales, Inc. | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| US5607978A (en)* | 1992-09-21 | 1997-03-04 | Allergan | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
| US5515444A (en)* | 1992-10-21 | 1996-05-07 | Virginia Polytechnic Institute And State University | Active control of aircraft engine inlet noise using compact sound sources and distributed error sensors |
| US5518187A (en)* | 1992-11-25 | 1996-05-21 | Nano Systems L.L.C. | Method of grinding pharmaceutical substances |
| US5298262A (en)* | 1992-12-04 | 1994-03-29 | Sterling Winthrop Inc. | Use of ionic cloud point modifiers to prevent particle aggregation during sterilization |
| US5302401A (en)* | 1992-12-09 | 1994-04-12 | Sterling Winthrop Inc. | Method to reduce particle size growth during lyophilization |
| US5340564A (en)* | 1992-12-10 | 1994-08-23 | Sterling Winthrop Inc. | Formulations comprising olin 10-G to prevent particle aggregation and increase stability |
| US5336507A (en)* | 1992-12-11 | 1994-08-09 | Sterling Winthrop Inc. | Use of charged phospholipids to reduce nanoparticle aggregation |
| US5604260A (en)* | 1992-12-11 | 1997-02-18 | Merck Frosst Canada Inc. | 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 |
| US5429824A (en)* | 1992-12-15 | 1995-07-04 | Eastman Kodak Company | Use of tyloxapole as a nanoparticle stabilizer and dispersant |
| US5543297A (en)* | 1992-12-22 | 1996-08-06 | Merck Frosst Canada, Inc. | Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity |
| US5380738A (en)* | 1993-05-21 | 1995-01-10 | Monsanto Company | 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents |
| US5536752A (en)* | 1993-06-24 | 1996-07-16 | Merck Frosst Canada Inc. | Phenyl heterocycles as COX-2 inhibitors |
| US5710140A (en)* | 1993-06-24 | 1998-01-20 | Merck Frosst Canada, Inc. | Phenyl heterocycles as COX-2 inhibitors |
| US5550142A (en)* | 1993-06-24 | 1996-08-27 | Merck Frosst Canada Inc. | Phenyl heterocycles as cox-2 inhibitors |
| US5593992A (en)* | 1993-07-16 | 1997-01-14 | Smithkline Beecham Corporation | Compounds |
| US5632984A (en)* | 1993-07-22 | 1997-05-27 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
| US5510383A (en)* | 1993-08-03 | 1996-04-23 | Alcon Laboratories, Inc. | Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension |
| US5889052A (en)* | 1993-08-03 | 1999-03-30 | Alcon Laboraties, Inc. | Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension |
| US5436265A (en)* | 1993-11-12 | 1995-07-25 | Merck Frosst Canada, Inc. | 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents |
| US5443505A (en)* | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| US5760068A (en)* | 1993-11-30 | 1998-06-02 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation |
| US5401765A (en)* | 1993-11-30 | 1995-03-28 | G. D. Searle | 1,4,5-triphenyl pyrazolyl compounds for the treatment of inflammation and inflammation-related disorders |
| US5434178A (en)* | 1993-11-30 | 1995-07-18 | G.D. Searle & Co. | 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation |
| US5393790A (en)* | 1994-02-10 | 1995-02-28 | G.D. Searle & Co. | Substituted spiro compounds for the treatment of inflammation |
| US6075066A (en)* | 1994-03-14 | 2000-06-13 | Seikagaku Kogyo Kabushiki Kaisha | Material to be worn on the eyeball |
| US5418254A (en)* | 1994-05-04 | 1995-05-23 | G. D. Searle & Co. | Substituted cyclopentadienyl compounds for the treatment of inflammation |
| US5486534A (en)* | 1994-07-21 | 1996-01-23 | G. D. Searle & Co. | 3,4-substituted pyrazoles for the treatment of inflammation |
| US5616601A (en)* | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
| US5620999A (en)* | 1994-07-28 | 1997-04-15 | Weier; Richard M. | Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation |
| US5521213A (en)* | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
| US5420343A (en)* | 1994-08-31 | 1995-05-30 | G. D. Searle & Co. | Derivatives of aromatic cyclic alkylethers |
| US5547975A (en)* | 1994-09-20 | 1996-08-20 | Talley; John J. | Benzopyranopyrazolyl derivatives for the treatment of inflammation |
| US5739166A (en)* | 1994-11-29 | 1998-04-14 | G.D. Searle & Co. | Substituted terphenyl compounds for the treatment of inflammation |
| US5560932A (en)* | 1995-01-10 | 1996-10-01 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents |
| US5569448A (en)* | 1995-01-24 | 1996-10-29 | Nano Systems L.L.C. | Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
| US5503723A (en)* | 1995-02-08 | 1996-04-02 | Eastman Kodak Company | Isolation of ultra small particles |
| US5534270A (en)* | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
| US5622938A (en)* | 1995-02-09 | 1997-04-22 | Nano Systems L.L.C. | Sugar base surfactant for nanocrystals |
| US5518738A (en)* | 1995-02-09 | 1996-05-21 | Nanosystem L.L.C. | Nanoparticulate nsaid compositions |
| US5596008A (en)* | 1995-02-10 | 1997-01-21 | G. D. Searle & Co. | 3,4-Diaryl substituted pyridines for the treatment of inflammation |
| US5591456A (en)* | 1995-02-10 | 1997-01-07 | Nanosystems L.L.C. | Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer |
| US5633272A (en)* | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
| US5510118A (en)* | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
| US5560931A (en)* | 1995-02-14 | 1996-10-01 | Nawosystems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
| US5747001A (en)* | 1995-02-24 | 1998-05-05 | Nanosystems, L.L.C. | Aerosols containing beclomethazone nanoparticle dispersions |
| US5718919A (en)* | 1995-02-24 | 1998-02-17 | Nanosystems L.L.C. | Nanoparticles containing the R(-)enantiomer of ibuprofen |
| US5565188A (en)* | 1995-02-24 | 1996-10-15 | Nanosystems L.L.C. | Polyalkylene block copolymers as surface modifiers for nanoparticles |
| US5510368A (en)* | 1995-05-22 | 1996-04-23 | Merck Frosst Canada, Inc. | N-benzyl-3-indoleacetic acids as antiinflammatory drugs |
| US5604253A (en)* | 1995-05-22 | 1997-02-18 | Merck Frosst Canada, Inc. | N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors |
| US5639780A (en)* | 1995-05-22 | 1997-06-17 | Merck Frosst Canada, Inc. | N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors |
| US5892053A (en)* | 1995-05-25 | 1999-04-06 | G. D. Searle & Co. | Process for preparing 3-haloalkyl-1H-pyrazoles |
| US5643933A (en)* | 1995-06-02 | 1997-07-01 | G. D. Searle & Co. | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
| US5869079A (en)* | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| US5869660A (en)* | 1995-06-07 | 1999-02-09 | Smithkline Beecham Corporation | Process of preparing imidazole compounds |
| US5767153A (en)* | 1995-06-07 | 1998-06-16 | Insite Vision Incorporated | Sustained release emulsions |
| US6063807A (en)* | 1995-07-15 | 2000-05-16 | Societe De Conseils De Recherches D'applications Scientifiques (S.C.R.A.S.) | Cyclo-oxygenase inhibitor and amidine derivatives salts, preparation method therefor, use thereof as drugs, and pharmaceutical compositions containing said salts |
| US5756529A (en)* | 1995-09-29 | 1998-05-26 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies |
| US6020343A (en)* | 1995-10-13 | 2000-02-01 | Merck Frosst Canada, Inc. | (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors |
| US6057319A (en)* | 1995-10-30 | 2000-05-02 | Merck Frosst Canada & Co. | 3,4-Diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors |
| US5716955A (en)* | 1996-01-11 | 1998-02-10 | Smithkline Beecham Corporation | Substituted imidazole compounds |
| US6046208A (en)* | 1996-01-11 | 2000-04-04 | Smithkline Beecham Corporation | Substituted imidazole compounds |
| US5756499A (en)* | 1996-01-11 | 1998-05-26 | Smithkline Beecham Corporation | Substituted imidazole compounds |
| US5922742A (en)* | 1996-04-23 | 1999-07-13 | Merck Frosst Canada | Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors |
| US5883267A (en)* | 1996-05-31 | 1999-03-16 | Merck & Co., Inc. | Process for making phenyl heterocycles useful as cox-2 inhibitors |
| US5741798A (en)* | 1996-06-03 | 1998-04-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | 2-benzyl-4-sulfonyl-4H-isoquinolin-1,3-diones and their use as antiinflammatory agents |
| US5861419A (en)* | 1996-07-18 | 1999-01-19 | Merck Frosst Canad, Inc. | Substituted pyridines as selective cyclooxygenase-2 inhibitors |
| US5776967A (en)* | 1996-07-26 | 1998-07-07 | American Home Products Corporation | Pyranoindole inhibitors of COX--2 |
| US5723485A (en)* | 1996-08-01 | 1998-03-03 | Laboratories Upsa | 1,2-Diarylindole derivatives, processes for their preparation and their uses in therapeutics |
| US5866596A (en)* | 1996-09-13 | 1999-02-02 | Laboratories Upsa | 3,4-diaryloxazolone derivatives, their methods of preparation and their uses in therapeutics |
| US5869524A (en)* | 1996-11-12 | 1999-02-09 | American Home Products Corporation | Indene inhibitors of COX-2 |
| US5929076A (en)* | 1997-01-10 | 1999-07-27 | Smithkline Beecham Corporation | Cycloalkyl substituted imidazoles |
| US5783597A (en)* | 1997-03-04 | 1998-07-21 | Ortho Pharmaceutical Corporation | 2,5-disubstituted thiophenes: inhibitors of 5-lipoxygenase and inducible cyclooxygenase (COX-2) enzymes, composition and use |
| US6071954A (en)* | 1997-03-14 | 2000-06-06 | Merk Frosst Canada, Inc. | (methylsulfonyl)phenyl-2-(5H)-furanones with oxygen link as COX-2 inhibitors |
| US6034256A (en)* | 1997-04-21 | 2000-03-07 | G.D. Searle & Co. | Substituted benzopyran derivatives for the treatment of inflammation |
| US6046217A (en)* | 1997-09-12 | 2000-04-04 | Merck Frosst Canada & Co. | 2,3,5-trisubstituted pyridines as inhibitors of cyclooxygenase-2 |
| US6040450A (en)* | 1997-09-25 | 2000-03-21 | Merck & Co., Inc. | Process for making diaryl pyridines useful as cox-2-inhibitors |
| US5859036A (en)* | 1997-10-07 | 1999-01-12 | Laboratories Upsa | 3,4-diarylthiazolin-2-one or -2-thione derivatives, their methods of preparation and their uses in their methods of preparation and their uses in therapeutics |
| US6020347A (en)* | 1997-11-18 | 2000-02-01 | Merck & Co., Inc. | 4-substituted-4-piperidine carboxamide derivatives |
| US6063804A (en)* | 1997-11-26 | 2000-05-16 | Adir Et Compagnie | Pyrrole compounds |
| US6040319A (en)* | 1998-04-24 | 2000-03-21 | Merck & Co., Inc. | Process for synthesizing COX-2 inhibitors |
| US6077869A (en)* | 1998-10-29 | 2000-06-20 | Ortho-Mcneil Pharmaceutical, Inc. | Aryl phenylhydrazides as selective COX-2 inhibitors for treatment of inflammation |
| US6077868A (en)* | 1999-07-20 | 2000-06-20 | Wisconsin Alumni Research Foundation | Selective inhibition of cyclooxygenase-2 |
| US6083969A (en)* | 1999-10-20 | 2000-07-04 | Ortho-Mcneil Pharaceutical, Inc. | 1,3- and 2,3-diarylcycloalkano and cycloalkeno pyrazoles as selective inhibitors of cyclooxygenase-2 and antiinflammatory agents |
Cited By (190)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6646001B2 (en) | 1997-12-19 | 2003-11-11 | Alcon Manufacturing, Ltd. | Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension |
| US20040175435A1 (en)* | 1998-09-02 | 2004-09-09 | Allergan Sales, Inc. | Preserved cyclodextrin-containing compositions |
| US20080102121A1 (en)* | 1998-11-02 | 2008-05-01 | Elan Pharma International Limited | Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone |
| US20040033938A1 (en)* | 2000-09-12 | 2004-02-19 | Britten Nancy J. | Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis |
| US7915312B2 (en) | 2000-09-22 | 2011-03-29 | Nolan Gerard M | Physiological method of improving vision |
| US6551584B2 (en)* | 2000-10-10 | 2003-04-22 | Pharmacia & Upjohn Company | Topical antibiotic composition for treatment of eye infection |
| US20110034568A1 (en)* | 2000-12-19 | 2011-02-10 | The Board Of Regents Of The University Of Texas System | Compositions comprising lecithin oils and NSAIDS for protecting the gastrointestinal tract and providing enhanced therapeutic activity |
| US9687551B2 (en) | 2000-12-19 | 2017-06-27 | The Board Of Regents Of The University Of Texas System | Compositions comprising lecithin oils and NSAIDs for protecting the gastrointestinal tract and providing enhanced therapeutic activity |
| US9351984B2 (en) | 2000-12-19 | 2016-05-31 | The Board Of Regents Of The University Of Texas System | Compositions comprising lecithin oils and NSAIDs for protecting the gastrointestinal tract and providing enhanced therapeutic activity |
| US9101637B2 (en) | 2000-12-19 | 2015-08-11 | The Board Of Regents Of The University Of Texas System | Methods of treating inflammation with compositions comprising lecithin oils and NSAIDS for protecting the gastrointestinal tract and providing enhanced therapeutic activity |
| US8911752B2 (en) | 2000-12-19 | 2014-12-16 | The Board Of Regents Of The University Of Texas System | Methods of making compositions comprising lecithin oils and NSAIDS for protecting the gastrointestinal tract and providing enhanced therapeutic activity |
| US8865187B2 (en) | 2000-12-19 | 2014-10-21 | The Board Of Regents Of The University Of Texas System | Compositions comprising lecithin oils and NSAIDs for protecting the gastrointestinal tract and providing enhanced therapeutic activity |
| US20110065677A1 (en)* | 2000-12-19 | 2011-03-17 | The Board Of Regents Of The University Of Texas System | Methods of Treating Inflammation with Compositions Comprising Lecithin Oils and NSAIDS for Protecting the Gastrointestinal Tract and Providing Enhanced Therapeutic Activity |
| US20040198781A1 (en)* | 2001-08-10 | 2004-10-07 | Pharmacia Corporation | Carbonic anhydrase inhibitor |
| US20030220376A1 (en)* | 2001-08-10 | 2003-11-27 | Pharmacia Corporation | Methods for treating carbonic anhydrase mediated disorders |
| US20030100594A1 (en)* | 2001-08-10 | 2003-05-29 | Pharmacia Corporation | Carbonic anhydrase inhibitor |
| US20040067992A1 (en)* | 2001-08-10 | 2004-04-08 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia |
| US6566347B1 (en)* | 2001-08-22 | 2003-05-20 | Duquesne University Of The Holy Ghost | Controlled release pharmaceutical |
| US20050003014A1 (en)* | 2001-12-21 | 2005-01-06 | Ketelson Howard Allen | Use of synthetic inorganic nanoparticles as carriers for ophthalmic and otic drugs |
| US20050002970A1 (en)* | 2001-12-21 | 2005-01-06 | Ketelson Howard Allen | Inorganic nanopartices to modify the viscosity and physical properties of ophthalmic and otic compositions |
| US8257745B2 (en) | 2001-12-21 | 2012-09-04 | Novartis Ag | Use of synthetic inorganic nanoparticles as carriers for ophthalmic and otic drugs |
| US20080299166A1 (en)* | 2002-04-19 | 2008-12-04 | Lajos Szente | Novel biomaterials, their preparation and use |
| WO2004014430A1 (en)* | 2002-08-07 | 2004-02-19 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia |
| US20050228048A1 (en)* | 2002-08-23 | 2005-10-13 | Santen Pharmaceutical Co., Ltd. | Stable eye drops containing latanoprost as the active ingredient |
| US20110118348A1 (en)* | 2002-08-23 | 2011-05-19 | Santen Pharmaceutical Co., Ltd. | Methods of stabilizing latanoprost in an aqueous solution |
| US20080153894A1 (en)* | 2002-12-19 | 2008-06-26 | Pharmacia Corporation | Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis |
| US8309117B2 (en) | 2002-12-19 | 2012-11-13 | Novartis, Ag | Method for making medical devices having antimicrobial coatings thereon |
| US20050008676A1 (en)* | 2002-12-19 | 2005-01-13 | Yongxing Qiu | Medical devices having antimicrobial coatings thereon |
| US8637071B2 (en) | 2002-12-19 | 2014-01-28 | Novartis Ag | Method for making medical devices having antimicrobial coatings thereon |
| US20050058844A1 (en)* | 2002-12-19 | 2005-03-17 | Rubner Michael F. | Method for making medical devices having antimicrobial coatings thereon |
| US10709713B2 (en) | 2003-03-03 | 2020-07-14 | Baudax Bio, Inc. | Nanoparticulate meloxicam formulations |
| EP3090731A1 (en) | 2003-03-03 | 2016-11-09 | DV Technology LLC | Formulations comprising nanoparticulate meloxicam |
| US10463673B2 (en) | 2003-03-03 | 2019-11-05 | Recro Pharma, Inc. | Nanoparticulate meloxicam formulations |
| US20100297252A1 (en)* | 2003-03-03 | 2010-11-25 | Elan Pharma International Ltd. | Nanoparticulate meloxicam formulations |
| US10471067B2 (en) | 2003-03-03 | 2019-11-12 | Recro Pharma, Inc. | Nanoparticulate meloxicam formulations |
| US8512727B2 (en) | 2003-03-03 | 2013-08-20 | Alkermes Pharma Ireland Limited | Nanoparticulate meloxicam formulations |
| US20040229038A1 (en)* | 2003-03-03 | 2004-11-18 | Elan Pharma International Ltd. | Nanoparticulate meloxicam formulations |
| EP3434261A1 (en) | 2003-03-03 | 2019-01-30 | Recro Pharma, Inc. | Formulations comprising nanoparticulate meloxicam |
| US20050004074A1 (en)* | 2003-07-01 | 2005-01-06 | Allergan, Inc. | Inhibition of irritating side effects associated with use of a topical ophthalmic medication |
| US6933289B2 (en)* | 2003-07-01 | 2005-08-23 | Allergan, Inc. | Inhibition of irritating side effects associated with use of a topical ophthalmic medication |
| US20050038103A1 (en)* | 2003-08-13 | 2005-02-17 | Amarjit Singh | Uses of dorzolamide |
| US20070020298A1 (en)* | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid |
| US10207008B2 (en) | 2003-12-31 | 2019-02-19 | Cydex Pharmaceuticals, Inc. | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| US10159752B2 (en) | 2003-12-31 | 2018-12-25 | Cydex Pharmaceuticals, Inc. | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| US10799599B2 (en) | 2003-12-31 | 2020-10-13 | Cydex Pharmaceuticals, Inc. | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| US9827324B2 (en) | 2003-12-31 | 2017-11-28 | Cydex Pharmaceuticals, Inc. | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| US20080166414A1 (en)* | 2004-01-28 | 2008-07-10 | Johns Hopkins University | Drugs And Gene Carrier Particles That Rapidly Move Through Mucous Barriers |
| US8957034B2 (en) | 2004-01-28 | 2015-02-17 | Johns Hopkins University | Drugs and gene carrier particles that rapidly move through mucous barriers |
| US20060258617A1 (en)* | 2004-04-15 | 2006-11-16 | Allergan, Inc. | Drug delivery to the back of the eye |
| US20050234018A1 (en)* | 2004-04-15 | 2005-10-20 | Allergan, Inc. | Drug delivery to the back of the eye |
| US9326949B2 (en) | 2004-04-30 | 2016-05-03 | Allergan, Inc. | Method of making oil-in-oil emulsified polymeric implants containing a hypotensive lipid |
| US8715709B2 (en) | 2004-04-30 | 2014-05-06 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular neuropathies |
| US9393223B2 (en) | 2004-04-30 | 2016-07-19 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| US10864218B2 (en) | 2004-04-30 | 2020-12-15 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| US10064872B2 (en) | 2004-04-30 | 2018-09-04 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
| US9101583B2 (en) | 2004-04-30 | 2015-08-11 | Allergan, Inc. | Microparticles manufactured in an oil-in-water process comprising a prostamide |
| US20060246145A1 (en)* | 2004-04-30 | 2006-11-02 | Allergan, Inc. | Methods for treating ocular conditions with cyclic lipid containing microparticles |
| US10328086B2 (en) | 2004-04-30 | 2019-06-25 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| US8911767B2 (en) | 2004-04-30 | 2014-12-16 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| US20110091520A1 (en)* | 2004-04-30 | 2011-04-21 | Allergan, Inc. | Sustained Release Intraocular Implants and Methods for Treating Ocular Neuropathies |
| US8900622B1 (en) | 2004-04-30 | 2014-12-02 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| US10398707B2 (en) | 2004-04-30 | 2019-09-03 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related implants |
| US10406168B2 (en) | 2004-04-30 | 2019-09-10 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
| US20100278898A1 (en)* | 2004-04-30 | 2010-11-04 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
| US9775846B2 (en) | 2004-04-30 | 2017-10-03 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related implants |
| US9669039B2 (en) | 2004-04-30 | 2017-06-06 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
| US8637068B2 (en) | 2004-04-30 | 2014-01-28 | Allergan, Inc. | Hypotensive prostamide-containing biodegradable intraocular implants and related methods |
| US9750751B2 (en) | 2004-04-30 | 2017-09-05 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| US8722097B2 (en) | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
| US8673341B2 (en) | 2004-04-30 | 2014-03-18 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
| US9707238B2 (en) | 2004-04-30 | 2017-07-18 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
| AU2005253931B2 (en)* | 2004-06-09 | 2011-05-19 | Allergan, Inc. | Stabilized compositions comprising a therapeutically active agent, citric acid or a conjugated base and chlorine dioxide |
| US8691802B2 (en) | 2004-06-09 | 2014-04-08 | Allergan, Inc. | Stabilized compositions comprising a therapeutically active agent and an oxidizing preservative |
| JP2008502723A (en)* | 2004-06-09 | 2008-01-31 | アラーガン、インコーポレイテッド | A stabilized composition comprising a therapeutically active agent, citric acid or a conjugate base, and chlorine dioxide |
| US20050276867A1 (en)* | 2004-06-09 | 2005-12-15 | Allergan, Inc. | Stabilized compositions comprising a therapeutically active agent and an oxidizing preservative |
| US8343949B2 (en) | 2004-06-09 | 2013-01-01 | Allergan, Inc. | Stabilized compositions comprising a therapeutically active agent, and an oxidizing preservative |
| US20080300315A1 (en)* | 2004-06-09 | 2008-12-04 | Lyons Robert T | Stabilized Compositions Comprising a Therapeutically Active Agent, and an Oxidizing Preservative |
| US20080145430A1 (en)* | 2004-12-08 | 2008-06-19 | Santipharp Panmai | Ophthalmic Nanoparticulate Formulation Of A Cyclooxygenase-2 Selective Inhibitor |
| US20110218247A1 (en)* | 2006-03-28 | 2011-09-08 | Curtis Wright | Formulations of low dose diclofenac and beta-cyclodextrin |
| US8580954B2 (en) | 2006-03-28 | 2013-11-12 | Hospira, Inc. | Formulations of low dose diclofenac and beta-cyclodextrin |
| US20070232566A1 (en)* | 2006-03-28 | 2007-10-04 | Curtis Wright | Formulations Of Low Dose Diclofenac And Beta-Cyclodextrin |
| US8946292B2 (en) | 2006-03-28 | 2015-02-03 | Javelin Pharmaceuticals, Inc. | Formulations of low dose diclofenac and beta-cyclodextrin |
| US20070232567A1 (en)* | 2006-03-28 | 2007-10-04 | Curtis Wright | Formulations Of Low Dose Non-Steroidal Anti-Inflammatory Drugs And Beta-Cyclodextrin |
| US20070238789A1 (en)* | 2006-03-31 | 2007-10-11 | Chin-Ming Chang | Prednisolone acetate compositions |
| US10058597B2 (en) | 2006-04-28 | 2018-08-28 | Mayo Foundation For Medical Education And Research | Treating glaucoma, cardiovascular diseases, and renal diseases |
| US9393322B2 (en) | 2006-04-28 | 2016-07-19 | Mayo Foundation For Medical Education And Research | Treating glaucoma, cardiovascular diseases, and renal diseases |
| US8871733B2 (en)* | 2006-04-28 | 2014-10-28 | Mayo Foundation For Medical Education And Research | Treating glaucoma, cardiovascular diseases, and renal diseases |
| US10456480B2 (en) | 2006-04-28 | 2019-10-29 | Mayo Foundation For Medical Education And Research | Treating glaucoma, cardiovascular diseases, and renal diseases |
| US9039761B2 (en)* | 2006-08-04 | 2015-05-26 | Allergan, Inc. | Ocular implant delivery assemblies with distal caps |
| US20080033351A1 (en)* | 2006-08-04 | 2008-02-07 | Allergan, Inc. | Ocular implant delivery assemblies with distal caps |
| US20100215580A1 (en)* | 2006-09-08 | 2010-08-26 | The Johns Hopkins University | Compositions and methods for enhancing transport through mucus |
| US8969415B2 (en) | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
| US20080131484A1 (en)* | 2006-12-01 | 2008-06-05 | Allergan, Inc. | Intraocular drug delivery systems |
| US9149428B2 (en) | 2006-12-19 | 2015-10-06 | Allergan, Inc. | Processes for making cyclic lipid implants for intraocular use |
| US20080145403A1 (en)* | 2006-12-19 | 2008-06-19 | Allergan, Inc. | Low temperature processes for making cyclic lipid implants for intraocular use |
| US10441543B2 (en) | 2006-12-19 | 2019-10-15 | Allergan, Inc. | Processes for making cyclic lipid implants for intraocular use |
| US8846073B2 (en) | 2006-12-19 | 2014-09-30 | Allergan, Inc. | Low temperature processes for making cyclic lipid implants for intraocular use |
| AU2007338210B2 (en)* | 2006-12-22 | 2013-01-31 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Gel useful for the delivery of ophthalmic drugs |
| EA016795B1 (en)* | 2006-12-22 | 2012-07-30 | Сигма-Тау Индустрие Фармасьютике Риуните С.П.А. | Gel useful for the delivery of ophthalmic drugs |
| US20100069482A1 (en)* | 2006-12-22 | 2010-03-18 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Gel useful for the delivery of ophthalmic drugs |
| WO2008077712A1 (en)* | 2006-12-22 | 2008-07-03 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Gel useful for the delivery of ophthalmic drugs |
| US8389014B2 (en) | 2006-12-22 | 2013-03-05 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Gel useful for the delivery of ophthalmic drugs |
| US20090312724A1 (en)* | 2007-06-28 | 2009-12-17 | Cydex Pharmaceuticals, Inc. | Nasal and Ophthalmic Delivery of Aqueous Corticosteroid Solutions |
| US12370352B2 (en) | 2007-06-28 | 2025-07-29 | Cydex Pharmaceuticals, Inc. | Nasal and ophthalmic delivery of aqueous corticosteroid solutions |
| US20110117189A1 (en)* | 2008-07-08 | 2011-05-19 | S.I.F.I. Societa' Industria Farmaceutica Italiana S.P.A. | Ophthalmic compositions for treating pathologies of the posterior segment of the eye |
| US20100076045A1 (en)* | 2008-09-19 | 2010-03-25 | Castillo Ernesto J | Stabilized pharmaceutical sub-micron suspensions and methods of forming same |
| US10463772B2 (en) | 2008-10-27 | 2019-11-05 | Allergan, Inc. | Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof |
| US8771745B2 (en) | 2008-10-27 | 2014-07-08 | Allergan, Inc. | Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof |
| US20100247606A1 (en)* | 2009-03-25 | 2010-09-30 | Allergan, Inc. | Intraocular sustained release drug delivery systems and methods for treating ocular conditions |
| US8647659B2 (en) | 2010-01-22 | 2014-02-11 | Allergan, Inc. | Intracameral sustained release therapeutic agent implants |
| US10278919B2 (en) | 2010-01-22 | 2019-05-07 | Allergan, Inc. | Intracameral sustained release therapeutic agent implants |
| US9504696B2 (en) | 2010-01-22 | 2016-11-29 | Allergan, Inc. | Intracameral sustained release therapeutic agent implants |
| US9937130B2 (en) | 2010-02-25 | 2018-04-10 | The Johns Hopkins University | Sustained delivery of therapeutic agents to an eye compartment |
| US9566242B2 (en) | 2010-02-25 | 2017-02-14 | The Johns Hopkins University | Sustained delivery of therapeutic agents to an eye compartment |
| US20110275711A1 (en)* | 2010-04-12 | 2011-11-10 | R-Tech Ueno, Ltd. | Method for treating macular edema |
| US20120022149A1 (en)* | 2010-07-21 | 2012-01-26 | Chowhan Masood A | Pharmaceutical composition with enhanced solubility characteristics |
| US8530449B2 (en) | 2010-09-09 | 2013-09-10 | Assad S. Sawaya | Composition for a topical ophthalmic clear colloidal liquid which undergoes a liquid-gel phase transition in the eye |
| US9006214B2 (en) | 2010-09-09 | 2015-04-14 | Altaire Pharmaceutical, Inc. | Composition for a topical ophthalmic clear colloidal liquid which undergoes a liquid-gel phase transition in the eye |
| WO2012033811A1 (en)* | 2010-09-09 | 2012-03-15 | Sawaya Assad S | Compositions for a topical ophthalmic clear colloidal liquid which undergoes a liquid-gel phase transition in the eye |
| US10307372B2 (en) | 2010-09-10 | 2019-06-04 | The Johns Hopkins University | Rapid diffusion of large polymeric nanoparticles in the mammalian brain |
| US20120070401A1 (en)* | 2010-09-21 | 2012-03-22 | Jinzhong Zhang | Composition and Method for Promoting Wound Healing |
| US9161929B2 (en) | 2011-04-29 | 2015-10-20 | Allergan, Inc. | Solvent cast film sustained release latanoprost implant |
| US8715713B2 (en) | 2011-04-29 | 2014-05-06 | Allergan, Inc. | Solvent cast film sustained release latanoprost implant |
| US9579308B2 (en) | 2011-09-20 | 2017-02-28 | Allergan, Inc. | Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism |
| US9301933B2 (en) | 2011-09-20 | 2016-04-05 | Allergan, Inc. | Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism |
| US10786444B2 (en) | 2011-09-29 | 2020-09-29 | Plx Opco Inc. | PH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same |
| US9730884B2 (en) | 2011-09-29 | 2017-08-15 | Plx Opco Inc. | pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same |
| US10179104B2 (en) | 2011-09-29 | 2019-01-15 | Plx Opco Inc. | PH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same |
| US9216150B2 (en) | 2011-09-29 | 2015-12-22 | Plx Pharma Inc. | pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same |
| US9226892B2 (en) | 2011-09-29 | 2016-01-05 | Plx Pharma Inc. | pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same |
| US10646431B2 (en) | 2011-09-29 | 2020-05-12 | Plx Opco Inc. | PH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same |
| US10159743B2 (en) | 2012-03-16 | 2018-12-25 | The Johns Hopkins University | Non-linear multiblock copolymer-drug conjugates for the delivery of active agents |
| US9950072B2 (en) | 2012-03-16 | 2018-04-24 | The Johns Hopkins University | Controlled release formulations for the delivery of HIF-1 inhibitors |
| US11660349B2 (en) | 2012-03-16 | 2023-05-30 | The Johns Hopkins University | Non-linear multiblock copolymer-drug conjugates for the delivery of active agents |
| US11642317B2 (en) | 2012-05-03 | 2023-05-09 | The Johns Hopkins University | Nanocrystals, compositions, and methods that aid particle transport in mucus |
| US11219597B2 (en) | 2012-05-03 | 2022-01-11 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| US9737491B2 (en) | 2012-05-03 | 2017-08-22 | The Johns Hopkins University | Nanocrystals, compositions, and methods that aid particle transport in mucus |
| US11878072B2 (en) | 2012-05-03 | 2024-01-23 | Alcon Inc. | Compositions and methods utilizing poly(vinyl alcohol) and/or other polymers that aid particle transport in mucus |
| US11872318B2 (en) | 2012-05-03 | 2024-01-16 | The Johns Hopkins University | Nanocrystals, compositions, and methods that aid particle transport in mucus |
| US9532955B2 (en) | 2012-05-03 | 2017-01-03 | Kala Pharmaceuticals, Inc. | Nanocrystals, compositions, and methods that aid particle transport in mucus |
| US12115246B2 (en) | 2012-05-03 | 2024-10-15 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| US12178920B2 (en) | 2012-05-03 | 2024-12-31 | The Johns Hopkins University | Nanocrystals, compositions, and methods that aid particle transport in mucus |
| US10864219B2 (en) | 2012-05-03 | 2020-12-15 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| US11318088B2 (en) | 2012-05-03 | 2022-05-03 | Kala Pharmaceuticals, Inc. | Compositions and methods utilizing poly(vinyl alcohol) and/or other polymers that aid particle transport in mucus |
| US11219596B2 (en) | 2012-05-03 | 2022-01-11 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| US10993908B2 (en) | 2012-05-03 | 2021-05-04 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| US10646437B2 (en) | 2012-05-03 | 2020-05-12 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| US10857096B2 (en) | 2012-05-03 | 2020-12-08 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| US10646436B2 (en) | 2012-05-03 | 2020-05-12 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| US10688045B2 (en) | 2012-05-03 | 2020-06-23 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| US10688041B2 (en) | 2012-05-03 | 2020-06-23 | Kala Pharmaceuticals, Inc. | Compositions and methods utilizing poly(vinyl alcohol) and/or other polymers that aid particle transport in mucus |
| US10945948B2 (en) | 2012-05-03 | 2021-03-16 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| US10736854B2 (en) | 2012-05-03 | 2020-08-11 | The Johns Hopkins University | Nanocrystals, compositions, and methods that aid particle transport in mucus |
| US9393213B2 (en) | 2012-05-03 | 2016-07-19 | Kala Pharmaceuticals, Inc. | Nanocrystals, compositions, and methods that aid particle transport in mucus |
| US9393212B2 (en) | 2012-05-03 | 2016-07-19 | Kala Pharmaceuticals, Inc. | Nanocrystals, compositions, and methods that aid particle transport in mucus |
| US9889208B2 (en) | 2012-05-04 | 2018-02-13 | The Johns Hopkins University | Lipid-based drug carriers for rapid penetration through mucus linings |
| US10556017B2 (en) | 2012-05-04 | 2020-02-11 | The Johns Hopkins University | Lipid-based drug carriers for rapid penetration through mucus linings |
| US10568975B2 (en) | 2013-02-05 | 2020-02-25 | The Johns Hopkins University | Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof |
| US9630909B2 (en) | 2013-06-27 | 2017-04-25 | Mylan Laboratories Ltd | Process for the preparation of nepafenac |
| US10617763B2 (en)* | 2013-08-28 | 2020-04-14 | Presbyopia Therapies, LLC | Compositions and methods for the treatment of presbyopia |
| US9492316B2 (en) | 2013-10-31 | 2016-11-15 | Allergan, Inc. | Prostamide-containing intraocular implants and methods of use thereof |
| US9980974B2 (en) | 2013-10-31 | 2018-05-29 | Allergan, Inc. | Prostamide-containing intraocular implants and methods of use thereof |
| US11633350B2 (en) | 2014-02-23 | 2023-04-25 | The Johns Hopkins University | Hypotonic microbicidal formulations and methods of use |
| US11484580B2 (en)* | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
| US20160338951A1 (en)* | 2015-05-20 | 2016-11-24 | Gavis Pharmaceuticals | Process of preparing aqueous ophthalmic solution of olopatadine |
| US9827225B2 (en)* | 2016-01-25 | 2017-11-28 | Jenivision Inc. | Use of prostacyclin antagonists for treating ocular surface nociception |
| US20210212993A1 (en)* | 2016-01-25 | 2021-07-15 | Jenivision Inc. | Use of prostacyclin antagonists for treating ocular surface nociception |
| US11857537B2 (en)* | 2016-01-25 | 2024-01-02 | Jenivision Inc. | Use of prostacyclin antagonists for treating ocular surface nociception |
| US11129812B2 (en) | 2016-08-19 | 2021-09-28 | Orasis Pharmaceuticals Ltd. | Ophthalmic pharmaceutical compositions and uses relating thereto |
| US11974986B2 (en) | 2016-08-19 | 2024-05-07 | Orasis Pharmaceuticals Ltd. | Ophthalmic pharmaceutical compositions and uses relating thereto |
| US9867810B1 (en) | 2016-08-19 | 2018-01-16 | Orasis Pharmaceuticals Ltd. | Ophthalmic pharmaceutical compositions and uses relating thereto |
| US10639297B2 (en) | 2016-08-19 | 2020-05-05 | Orasis Pharmaceuticals Ltd. | Ophthalmic pharmaceutical compositions and uses relating thereto |
| US11395825B2 (en) | 2017-05-04 | 2022-07-26 | Ocular Science, Inc. | Compositions and methods for treating eyes and methods of preparation |
| US10925894B2 (en) | 2017-05-05 | 2021-02-23 | Gregory J. PAMEL | Composition containing chlorine dioxide and methods for using same |
| WO2018204905A1 (en)* | 2017-05-05 | 2018-11-08 | Pamel Gregory J | Composition containing chlorine dioxide and methods for using same |
| CN110831585A (en)* | 2017-06-16 | 2020-02-21 | 凯乌维·科恩 | Bromhexine for the treatment of pain |
| US11285134B2 (en) | 2018-04-24 | 2022-03-29 | Allergan, Inc. | Presbyopia treatments |
| US10610518B2 (en) | 2018-04-24 | 2020-04-07 | Allergan, Inc. | Presbyopia treatments |
| CN108627598A (en)* | 2018-05-23 | 2018-10-09 | 山东鲁抗舍里乐药业有限公司 | A method of measuring SC 59046 content |
| US12128036B2 (en) | 2018-10-10 | 2024-10-29 | Lenz Therapeutics Operations, Inc. | Compositions and methods for storage stable ophthalmic drugs |
| US11071724B2 (en) | 2019-05-17 | 2021-07-27 | Ocular Science, Inc. | Compositions and methods for treating presbyopia |
| US11771708B2 (en) | 2020-03-26 | 2023-10-03 | Greenwood Brands, Llc | Pharmaceutical carriers capable of pH dependent reconstitution and methods for making and using same |
| US11648257B2 (en) | 2020-03-26 | 2023-05-16 | Plx Opco Inc. | Pharmaceutical carriers capable of pH dependent reconstitution and methods for making and using same |
| WO2022093978A1 (en)* | 2020-10-28 | 2022-05-05 | Tremeau Pharmaceuticals, Inc. | Aqueous formulations of water insoluble cox-2 inhibitors |
| US12102622B2 (en) | 2021-02-10 | 2024-10-01 | Iolyx Therapeutics, Inc. | Methods for ophthalmic delivery of roflumilast |
| WO2022173923A1 (en)* | 2021-02-10 | 2022-08-18 | Iolyx Therapeutics, Inc. | Methods for ophthalmic delivery of roflumilast |
| US12263160B2 (en) | 2021-09-22 | 2025-04-01 | Iolyx Therapeutics, Inc. | Methods of treating ocular inflammatory diseases |
| US12180206B2 (en) | 2021-11-17 | 2024-12-31 | Lenz Therapeutics Operations, Inc. | Aceclidine derivatives, compositions thereof and methods of use thereof |
| US12414942B1 (en) | 2024-03-15 | 2025-09-16 | Lenz Therapeutics Operations, Inc. | Compositions, methods, and systems for treating presbyopia |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002005815A1 (en) | 2002-01-24 |
| CA2414780A1 (en) | 2002-01-24 |
| PE20020146A1 (en) | 2002-03-31 |
| MXPA03000407A (en) | 2004-12-03 |
| EP1303271A1 (en) | 2003-04-23 |
| AR033382A1 (en) | 2003-12-17 |
| JP2004528267A (en) | 2004-09-16 |
| EP1303271A4 (en) | 2004-09-01 |
| AU2001275908A1 (en) | 2002-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20020035264A1 (en) | Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug | |
| KR102525438B1 (en) | Preparation of Solid Cyclodextrin Complex for Ophthalmic Active Pharmaceutical Ingredient Delivery | |
| EP3513809B9 (en) | Medicinal composition comprising tivozanib | |
| Loftsson et al. | Aqueous eye drops containing drug/cyclodextrin nanoparticles deliver therapeutic drug concentrations to both anterior and posterior segment | |
| CA2424444A1 (en) | Topical antibiotic composition for treatment of eye infection | |
| TW200303749A (en) | Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride | |
| WO2003072081A1 (en) | Ophthalmic formulation with gum system | |
| KR20150006869A (en) | Pharmaceutical nanoparticles showing improved mucosal transport | |
| US20190328772A1 (en) | Ophthalmic compositions comprising a cyclodextrin as sole active agent | |
| JP2012533562A (en) | Treatment | |
| US20020128267A1 (en) | Method of using COX-2 inhibitors in the treatment and prevention of ocular COX-2 mediated disorders | |
| US20200206137A1 (en) | Microparticle formulations for delivery of active agents | |
| TW202345853A (en) | Preservative-free ophthalmic pharmaceutical emulsion and its application | |
| JP2005524642A (en) | Stabilized pharmaceutical compositions of halofuginone and other quinazolinone derivatives | |
| US20040058926A1 (en) | Method of using cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders | |
| CN116474105A (en) | Pharmaceutical composition for preventing, relieving or treating eye diseases, preparation method and application thereof | |
| KR101869741B1 (en) | Pharmaceutical Composition for Preventing or Treating Vascular Permeability Disease Comprising Masitinib or Pharmaceutically Acceptable Salts thereof as an Active Ingredient | |
| Genov et al. | Innovative drug delivery in ophthalmology | |
| WO2025184656A1 (en) | Linsitinib nanosuspensions for local administration | |
| HK40007038B (en) | Medicinal composition comprising tivozanib | |
| KR20150051491A (en) | Pharmaceutical Composition for Preventing or Treating Vascular Permeability Disease Comprising Dasatinib or Pharmaceutically Acceptable Salts thereof as an Active Ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment | Owner name:PHARMACIA & UPJOHN COMPANY, MICHIGAN Free format text:ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KARARLI, TUGRUL T.;BANDYOPADHYAY, REBANTA;SINGH, SATISH K.;AND OTHERS;REEL/FRAME:012195/0516;SIGNING DATES FROM 20010725 TO 20010820 | |
| STCB | Information on status: application discontinuation | Free format text:ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |